var title_f5_37_5712="Coalescing urticarial les";
var content_f5_37_5712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urticaria lesions are erythematous and irregular. Urticaria may be a manifestation of a more generalized anaphylaxis, but when the pathology is limited to the skin, the patients appear otherwise well.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, MD, Ludwig S, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5712=[""].join("\n");
var outline_f5_37_5712=null;
var title_f5_37_5713="TempTest stim time";
var content_f5_37_5713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Temp",
"    <em>",
"     Test",
"    </em>",
"    &reg; can be used to determine stimulation time thresholds in patients with cold urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 198px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADGAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5btLZ7qUpGVDAZ5q4dHuAPvxH2yf8KNA/4/W/3D/MV7b8HPh9pfjCHUbzxPfXNhp0csVnavCyqZLmU4C/MDnHHHH3hz1rSMVa7OWpUmqnLE8R/si47NGfxP8AhSDSZz0aP6ZP+FdVrenXGjateadepsuLWZ4JB23KSD/KqahSMHvzn0quRGP1iZgHS5gMl4/zP+FLHpM7kgPEOM8k/wCFbsiDJwTSLGE+YkngjjtRyIPrMzB/sybON0f5/wD1qT+zZhnlOPc/4VssQTQcY7A9PrRyIr6xMxTp0w7p+Z/wo/s+X+8n5n/CtVuxpOcc9fYUuVDVeZlCwlPRk/M/4Uv9ny4zuT8zWluPv14oBwfxoUUP20zMNjIActH+dAsZT/En5n/CtJjx0AHamZyFHc+lLlQ1WkZ5sZR/En50n2KT+8n51oM2epP4VHuzgg/QUcqGqsin9jk/vJ+dH2KTONyZ+tXWb19aCSQM+v50cqH7SRS+xSeqfnS/YJd2AUJ+tXwTlMHJBH+NWreLzDIoUlc88446/wD1vxqZOK3D2kzIOnyhQd0ZBOOCevp0pyabKwJLxgA4OSePyFdAtsyokQ2tPI27C9FXB6etW4dNlliRHRwjE5zkkH349KwnVjFXNIc8nY5dNInfHzxDnHJIx79OlPTQr12AVVPJHUgcfhXfaTocbERxiV95HD8DjNbEWnfvMyRhE2bVJO7nPb8sVyTxtvhR2Qw0n8TPNB4U1AuFDW+ef4zxjr2qeLwXqUrEJJakjqN7f4V61HorIqSKpQSLuQD06f4Vo2VgFnhVmUMAQ5bA46Efr1rL63VN/q8DxyPwBq0hwstmecA725P/AHzUn/Cu9Y+UiWz2s2zO58D6/LXtljo4EhaERlAd2xjyRnpn1FaL2Zj3cM2dyqR0yeR9cU1i6nUr6tA8P/4VVr+3c01gvylsNI4wB/wGnx/CXXpJNiXOmnIBBEr4P/jle4yxtBZR+XseVVGcjLNjsB9D6VatI96psEu4DIKcn360fW6mw1hYdTwhfhD4hZWKz6a23niRzn6fJSf8Ki8QZ/4+NNIxnIlfH/oFfRfkvb5LoRE3Dk4zn6fnUhhiW0LxoHBXaSpzzTWKqsf1amfGEVu8qllK496f9kf1X86saeAUUEnlsV758Q/hH4e0Cy8XjS5dTa60SO3lhLX9vdNOsgBcyQRoskKqD95jg9RxXq2R5DlK7Pnr7K/qtL9kf1T86u/xfLRg+1FifaMpfZJPVfzpwspD0ZPzNXPc/gaeCRxRYPaMz/sUnqn50pspPVOvqav9+eppV/pRZB7RmeLGU90/Oj7DL6p+daI696XIH0osHtGZosZScBk/Oj7DL6p+daR4JI/Kgcn09qLBzszvsEvqn50n2CX1T860xzg5zScYBXFFh87M37DL6p+dAsZSQMpk+9aPf1GKbnDEjoKVg52Z5spB/En50CykPAK5/GtE4ZmGenQ03PJwSP6mnYOdmf8AZJPVfzo+ySeq/nV4kMBngdzTc4znP0osPnZT+xyYzlcfWkNq47r+dXHbHBphJBznrSsCkyqbdvVaDbuOpX86tEjHFN46U7D5mVjAw7ikMTeoqZm4Oc5qSytLnULkQWFvLcTHosakmk7IpXZT2H2p8FvNcTLFbxPLK33URSxP4CvTPDXwsurkLNrcxiQ8+RCQW+jN0H616noXhnTtEiVbGzjgJ4+X5nf3J61zVMTCOi1OunhJz1eh4XYfDrX7tFZ4obYtyEnchvyAOK0k+EniFlLeZYAD1kfn/wAdr6AgsnQKV8tTn5wBk4q1FbLvdVj2hmyT/erleLn0OxYKmfPf/CnfEIVS13pQz6zPx/45WL4v8A6p4V06K91G4sZIpJRCqwSMzZIJzgqOPlNfUa2YSYsyqpHcDOQa8v8A2hYEi8H2DA5Y3ygH28uSrpYicpJMzq4anCDaPn2iiiu88409B/4/W/3D29xXpunfEPxBpHhi10LRbn+zLe3uWu2nsmeOaZzxiRt2GAGBtwBwM5rzPw9n7a+Dj92efxFbpXP9Mda2gvdPPxEmqmhseNfElx4r8Q3Ws3lta215c7fNFsrKhKqBnDMeSAM89aw8lV9O2KewJUjHoKjJ2ttII7fSrML33JCc5J2j696Y7FV5JK+lMkIwRkkdORTGYkdO3NA0gbuMDHXGaaxySAM9aTq3UhaQH5ssOfSlfQoGU8Z6etRk4OSOQec0pOTnOf8ACmMeevU0ikhT1ODj0pDj60jdPf19aYSRnOaRSQuRngdaaxxj3PFMyAThjj0ppyemcE8cdaGy1Ec3Q9qQnIzn2pvzYG7uTzUsNtJNKUReNuWJOBUSkktS1EYpJbgdecAdanSBnbK5wOvHAqza2UhkxBtkx95wePoPatRNICyeU0rSIcY29/U1y1cRFG1OjKb0RlwRP91YXfe20snLdMk5FbulaNJcxuSfKR/TGVAwcE+9X7fRgF3Qx8YyFjOc9gc10OnWzPKFDfKPlI9DjgY9MjNcU8S27RO2OES1lqY9tYw28rOmx5Co5I5DY561qQxRrAjTNtLghgevXoPbFaX2dRC4ZOd4ZWBAPfNaUVpG8TxxBSI/nDAZ2nHzf0/WuZ3k7s64xUVoirY2rjmElYNqsGA6gVpC1SK4by1HkqVLLgktn69OtWbWORo7fzAhQsQSAMkdQT2GPSrSwvcNGrhXjBZi4+UtzwP8+lI0SvoU3ihh2ibd5SkqB3yTxj2FXtOiZpEQKofachsfNk8YHSkS0zLLFJ5kbIMhDzjJ6flV9LIx+SLZjH5i7SSeVx7+lO6sacitruTW8O5U+5CY2IHHO79ePxqxFukky0iM7NhkTgj6L1zUltI8d2C8bGJifMdMYJ/veoH4VLamN23INpU9SuQ3vRuPlRnzWzx3MYLGRcHO7+ea0I7KQztMWKc5G3BJB9fQVLLJGhUmN3ix9Nozj0/SpoVVS/z8AjKHOSeO9VbuJ6kE4CSpIpcq3y4QA4/Cq87ggwuoVOWYA9c9OatuhMgVZAmTyo/+tTrlYgx8qPDAHA71SFy9j4zsTiNSOcNmvTfEPxc1nWX124Gl6PYX+twLbX15apN5ksSgLsAkkZVBAAO1QeOteY2fMWO+asJwwz06c17Z85J2bCM7WBYZHv0oYqTlRgHsKJBtYjsKaeaZI4dv1oOduelJ0ODRngUDHAg45OMU8HgjPeo/w4p/QgfnQIBxjGaUck8ik/PrR0BwOvTigY7OTjPA604Y980wE7hRnuD0NADj1+tIxwxx/wDqpuSCMk8UrEgEkD8KQeYZOfam8ZyR3pSeDxSck9yB0oGLEfnGcAd81GQcc9R7Uv480St+8c470AIvOTk/40wk855p6Ebx83Xjioe/P50DFJ4JqMt3PSkdwvrnvWloXh3WNfkI0uyllQfelb5UX6seKHJRV2aRg27IzGYYIzVvSdK1HWLgQ6ZaS3DE9VHyr9T0Feq+GfhVaQmObWbg3so5MMJKxj2J6n9K9N0jTILOFYLW3jghQcRRJgLXHUxcVpHU7aWBlLWWh5L4f+FBVo5vENypzyIIG/m3+H516ho2hWel2vk6baRQRkgZROT7kkc/jW7HZRIwBRV5/iHI/P3rStrRlTOAuegUnJriqVpTerPQhRhTWiMmG0ZQgRnb1LjJ+vtVuOzCp7gfe6n6VowxxG5aEkiQjJDkkH6CkW1SMMkePL3Z9cGs0akEVsuwv5X7x+DhjnP0q00IVVO4716gjk/XPSkSaRflkDnrlhjaKc+DhTuw3J9frQkDTIlZSiYyP4gOoFeVftIqB4QsMEH/AE9OnP8Ayzkr1o4LOGA4GARxmvJP2jlP/CGaexCgG/QYU/8ATOSt6Gk0Y4j+HI+dKKKK9Q8Y1/DX/H84OMeWev1FbzYI+UDBGTiuf8O/8f7cZ/dn+YrpZEBTcSM56f5+lbw+E87E/GQAk5UDgc8d6jbD8t0PepApALdQueM4qNyTIO/PAA4qjBERXkjmmGPpzU8pBy2OQOtQHpjPGaRSY184xgdvzqJsjjPFKWy2fzpDzz0HUfSkaJWI89Tj6UwnJzx+VPILA8dOTxSBS/yqy+3PSpbstTSKvsNkYHhT7c01QxYhRk+p6VKsZ3AgF8jipIImlLozx4bhR1JPYcflWUqqWxooFYMBgsQM9Ohx702beFjGNpf5sd/xq3FYzXGWWNZSzYIOVwP61svoam5jmlWR8nGFXuMZH+fWsJ4lR3N4YeUtkYFvAzYKqXIPzhB37V0UWmMWJcYGA+NwLe+eK1NP05Yg6xoU3JjOO/PP061qRQ+apaMKEQfOpGSD05PpXDVxDlsd1PCJaso2lkERVLgyH51XHBP9elbFnaQNMvALEARsowAD1FSQaf8ANbSwYeHlT7EHkfrWpZWdst1JHEWnmh2v5artCjPXP5cVhrc7FBJaFWG3iUv5KrC3PyKDmprNGZmkdMgybM4Odvfn1rVHkFi2NkiZJx2b1PtUzQkHbGgKZGxAOD7fXmk4jaRQt1bbLHKdwxmN/XBwQP1q5ZymfcUZWjHyqoTbgf4//qqVbZXlxHj51zhlzsA7Yq3AF8sSPEsavgNjq2fQn86pKwtH6j7JFjtlYBCc4DLwcgdOauRxIjtDBGuNuCerIQc9u1LFZF5opPkIUfMD09Nw/DrUvlZl80SOMMWDLxnpwcdsUDuye0WV3Uuysq8dOoPpU8iOojR2jcK42hTzikti+1nIIbqScEe3NWVDCQ70ViTwTwCcckUrIpSaZCsDSSEooZkzls4X2Bq3CSty0hmQwjK4Iwc98mnOhSL5CxbvzgeuTVcunlFlSLpvUE9TTSDnLcipFErLK8gkGVXAIAxThGIiREGd3xnoNwqvHK8dsJrnG5gCc4AHA4FTpMsm5lRT8uAFOeB1Jppdy1axDJC6ozRKDt5w2MfSg5ljkVozuRCcjjB9v8aejS7IxFGETdksy5qAPMBOXYeWoyDngnHOR3NVcrQ+N7T/AFWO+anzxVa2P7vr3qcn869tHzMtxTznPNKBzjoM0ik5x14oOcUEjgeKM56UgY9uDS5wODQA7GRk98YpfbtTQTTuhz2NAg5IyKUc801uDkGlB5PIpDHDO3JFHekPp/Kk6rQMXHb37UuC3GfxprcHj0/WhjwOaAsJkDIU8UjMOMZHag4xnPvUbMBnPNA0OB5X1pjn5mOaRN88qxwo0kjEBUUZJ/Cuz8P/AA21nUysmoMmnWxxnzMNJ+C/41E5xgrtmlOlKbtFHE+ZtwCMV0eg+CNc1wo62/2S1P8Ay2uPlBHsOpr2jw94A0bRVDpaiS5A/wCPiX94w9+eF/Cu0t7EIv7s5/2m/pXHUxn8p6FPAveZ5f4Z+F+mWTo96jahLtyXlGI1/wCA/wCOa9FstNwqw7AsKgBVQDao9MCtiK0RCwbKhznGOPxq9DajYFiUoBzgHAH0rinUlPdnfClGmvdRmR2caRlAirBjaPlxzWha2oTy08sZH3cDpVnymWMADcEG5lXqfapAjuyxpjI/g9qnqXZWKyxKHQzFHkB+8RzUzq5bIBLAEgsc7TVsQpuIyu/tg0H5Xzke6kU+Um5noCsjM5KMMDK5PFTIpkUBQCpzg9iKneNcFtxDE8Z7e1MUDhckdcHNOw73IpIURCjgnd8wHXFQSQfOCwK45zuPNWbqQRYQgscc5qvcukeZJn2p2LHgU7IqKaGrDvdiwOB05ryb9pDA8F6eBkA6gpx/2zkr1nHmo8bMy9w+ec+1eS/tIEf8IbYKC3F+nX08uStqK99GGIf7uR85UUUV6Z4xqeH8/bHwcHyzz+IrpFfJKkdslu9c74cO2/b/AHCP1FdCGAbA2gDIHHU1vDY87E/xBm3JKl+ozk8UzIyAvQ9CTTmJU/MM81C4Zs8DPpTZildiM2R82Mt3J7VG0chBCISBxnOARU8cKyKGndURSTju3oBjt7026V5JWijYPu42beFHasJVtdDphR7lN/kbkMcAHgZqs0rYJCt0BzjtW7pdjcXgZydkKrjJXnPt3/8A1VsJoDqiyXCjABBEfO5R34/P8K5p4rlOqnhXLocW7Pt2gEEgFuM9+KvQ6dcyqE24JyRvPXHUf1rtxoUMdtGkqLE5wRxyR6Z7+vr0rTXSoUQx+XvLnCO6kbBxlsflXNLFt7HXHCJbnF2+js7nzCI7dwMY4wfr6Vsx+HYok3RoMgBnJOcEf/rzxXSpalZtrr5hbG1wx5H+FR3MM0wWNLQLjGHBJyM/dz071zzqyluzphh4p6IyodM3xb0Jw3OF5x+QqyluqXaxlZFw/mfdPH94g59K2lsZ0fzUmjKsnzL0IXv7fjVyOyEimS5JfCHDO2fmxwPxqHqbcrRgyRRpuaSQrvyCpHBGfX174+tOtIg0bSxtuCnj/bA71vPbqS2V5cAtlepHc+n+FWBpyKiRBDEjqDnBOGx27gVVg1RhRWsltEJsMN2A8Y756EfnWvarH5mwOFkAPOen/wBar1xYCyiGGDqVHD9Dnp+verdrAI4fM8osz7d5Q4wfr29KErFWurkK2oMglZR5TDA2Akbu9XltQsSksWQudhTgKOhzWrZeQBGJSMqCFyeT/Sp8DLpHEqjbuUjOCD/WgEY39m/uRs3MhY8Y5U88euDVi007c3mMHHy4Eefunrn35rTt2j+2m2PV49w9CoOODVkzLHMEMm3zP9XnABA6ijbcLdjHkt3hkVyxZWB+6MFD6Y71aiCqI/MPmKw5yMGtOdYooW+VWbg7euPWnQwIFLRgkS4JG7v7UdRq+5UECSr+6wpC8g9xTN6nyoRI+5iSTjoB29KS8jktZlgj2C4kG9pJGwqL0zjqeaWzt/ImVJ5FJXJBBwp44q1G2shL3ieZX2MOUbocjLNTYUjkt1AckEbiHXGKmuWWWNtgPmITsIBxnHOKbaLKyIHcMu3qwycUIT0AWkbqDIhIK4KYwD78VAEjbKW5Kxhtrhht3HHbvV9nVHGQzJtPJHT8qpRSM08wO+LDAAbOTnv+lNJhzX2JImjW1KGTdIW+UH+H2GKFJhtwqhdjKFBxS7Y45QqpyuA27qfep7uLK5mHAyeSMdKaQlM+Jbb/AFZ571Nn8Kgtj8mPepSR64969hbHhyWo4E5paapBpRzxQSOzzmlB5/pTQR06UA8Y4oAevUc9aXJHtjikB4PNCkcn8qQh+SCeRSnHAxgVGTjPHNJux1NAyVjg54GeopucZ9KjaXPOajeUDvQNJkxYD6460x37Z+lXNF0TVdekKaVZS3GOGcDCL9WPAr0rw/8ACNYws3iCaSfIH+j25wM+7dSPpWVStCG7N6WHnU2R5XaQXV/cCCxgknnbokaljXf+HfhXeXrK+tXP2ZRy0EPzyY9z0H617PoXhmy0+NY7G2S2hUfcRcEnuW7n8a6O3sF2gqh2/dDDv71xVMY3pHQ9GlgYx1nqcT4e8H6XogCWFl5bEfNKfmc/VuuPaumtrKMIoJVpFA5ZOgJ71uQWTQtI2SQ54GOgq6lp5hYlQByM9eveuOTlJ3Z3xUYqyWhnR2S+WqhXU9hjmrItW5yFXPJJOCBVt9PREReqIdwySf1qxHDmMc4LdwfShJ9Raboz1hYtkBQgXjvzUsUexArbh6D296uBPMU4+YD3qTyo12bgSepGOlUo3HoVG5jTywcgdRwKeyNgMijkEbvep1UYIQKq9+c4pmCAQ7YX+6wx+NFhWK8fzlNzMXVcbRx+NMlTfIyEAtjjPtVg/un34Yt0BIz+VLDE7hZATnqQff1q1GwO25WkHmoqsc8c0vlEqF2n5ehPYf1q1HEVDnA3DgGmSoVHcMBnHZjTtYV+xTUHcxJyv15FRiMTvtAyAQOTVsRABgOvUkVWRGySpwPT29adgbIJ4ijgg789vSvJP2k8nwXYEgD/AImCfh+6kr2F02x/NnrknNeR/tNQ+X4NsWCgA6in/oqStqUfeRz4h/u2fNVFFFd55JpaEwS7dmOAEPP4it0zZ5ETeoyOo/wrP8F6c+p6s8EThWELPknGcEcV6bpXgyS4udzh2AAYFjwc9R7H61jUxXsnyk/U5V5cyOFSGa4WVwPLhUZ3Z5yeAPr9Klt9MuLi5At45MMdisT1Occ/4V7Bp3gq0h8sttjjRA2GPIYEk59unv61oaf4bVzOqWweJWJVs/MemMH1FcdTFSlex108uUVqeV6d4Zu72eZZMxrx5i45XkjCj8cYrdg8MpBsP2UFyAh3AMQRxu616la6ZAzCSdY0Zou3Z+m4j145NXItNitIx5SRsuQMOOgPAP59jXPKcpbs64YeEdUjzu1002iqqQqIZB8xAwSO4x6datppc7glGKhiBn8z19K7HUIHiSVGChkdEj38eYTk4/MdqlisS0sUxAZ1X54ljwOoBPqeKlR0uzVR7HEwWokWGRTHIuzamVJyPUe/BrQnsmMTyJNGHUkoGPTtgV0K6PsklhjVzGsp2gcDBGSRTbhPsVjK/lCOePJCnB3A9P6HrTtraIcjsYEemi9smR1YNHhxGFC8EfN9afLbC3RAY/kiUZPJIX3HTitzDSar5cbtCIAhcqM7twJ289Bjmq0cK6rMI7yeTzMFlt4gFIHTdj396pRHy21Mu5tx56gMULpuRnxw3t68VONOkFsCsbHzQA+Pulh/Fjt0rfWyjDxtLiR1UA/Lt6dwO3Hao5LSIXtvOiNGpeRZGBwR8vBI9OKIq+gN6HOrG2+FUw8bExMx6vjnt7itm3tiLdW+d2B+ZScscdvyqxDZCaSVrTa5ik8tiRjbx1H51oRQdBIrg5Ay2V/EH1okraBvqY6xoSYWibavCFvXtg+1T29sIAQzmFiOFJwpz9fenWbS3t5Kn2ZZbT/lmzffYbsZPHHQ85pdThEGspJdxTyWMMa7WEZdIWPVmx17fStI0m3yslzS1QtjaOkEsRJkwS2WAOzjg59v6VoJGsUCKmOnB9T1zUsNtskRg7Lz0wPmHZfoeKku9IS/tjHOiBsZQluh68H2NJWb1CWhUNqJjFINqTocspbG7PVf8PpVlLcHMS/dHzMrfMQfQelV0luoLy0XUoYVjmOwtExYl8Eg8jpxWzHFvmVNpUAElCuCaJLlsEbvUzbmOeIrJGUlOOgAGT7/AEqPT8LdyRvJP56qDIr8KGPTA7cZrceJYQHVcpt+Y+grJ/sucTySfbpkSVvMWPYpA4xwevSiDVmiZRehU1WGxl86KZBPcSARhH5I9Dntjk1ohUmCIQjhARvJznjAqrplqq2hieSSYxOykuOfvZH14NXoI1MjRPIQpTcqqOBVz/l7ExXVDIbb53DIFC4I2nGfQVNFZZkXGFwCTu6c/wA6ueShiQAEMOmDjI96kVA0bgjIXkdtx9qz+RfL1ZAbcKgaQYjPOEGOfWoHLliWI8ojHK4Yn61pmNSCSxKjllK4I9qoKJ2LkIiIvC5O7cPf0qrhGKKzfKillVZM7Sduf19KgnVDCVlJYpxgD5fpV6YHOQgQZ+bGeeOlVC2Y50jXYcfLxx0oRShc+ILfGw9jmpR/nFQwfcP1p+4df1r2EeC9x/YAcUDuc0wnHWl3c80CJO9KT69qi3HIxjFJ5nYk0BYm3cUbueelVjJmp9Ps7zUrgQ2FtNcynokSFj+lJuw1BsGcAn9Kieb2rv8AQPhXrOpFW1OaLT4s/cI3yY+g4H4mvT/Dvw20XRmR1g+0XK8iWf5zn6dBXNUxUIeZ1UsHOe6seJeHvBeua+Ve3tjBbvwJp/kU/T1/CvVPDfwn0y0dX1Fm1GcYPz/LGPbb3/GvUotLdiiynce2OB9MCtaHTFgjUB2Qlsnua4qmKnLRaHoU8JCG+rMWx0qOGARwRRQxgAIsa7Rn2HStOKx3PvIbPABYYrWFursz+Xjb0J/pU9vAxACseu4HHb0rm1Z1LRFKLTyFKkhuhyMgge9W7SyCsApLAno3NWY7dPmKoysRg/1p0cDiONfMJKggbeMr/j701HqF2Iqjy9ylTj36U/abiEMreWhI6DmpVt40ZGZMMx2gjnJ+lSSRAE5wcjG3pn61SVxXRAYz5hQncDjApWjQuAUOQeo7GkCKQWByQMZ70+WVDAwH+tPfpz7VfKV5IZIqxuFJIyM4FIhLEOSMdOvepo34DOB9O2KfIhaJmVQ20jAqlElu2jI4kxlmIPPQ9TTGiGMSD5c5FV7id4rmMSBsEE5B4B9Kc9wsmxec4JLD+lNK43CW6LKRqUYIfnX2zzTWi2D5sh17D1qCOdHDx+ayc7Rj1p8DBThmJKtyC3WqSM+WS3FMhJwcn0wKe8SYBfAOcZHpVe7njT5iWXJ4zz+RqsLkB2ZkYHAxg0WK5G1dFqSFXBwc4684qtsXJRhmrEUkUmCr8sMkentTdjCUnomeAepq7Geq0ZC0KEFDlf7vFeN/tODPgbTX3ZLagmf+/cle0XO0INgYk9B7141+0+xbwLpoI5GooC3qfKkrSmveRjW/hs+Y6KKK6zzD0b4F2gvfFt3CQpBsZDg9/nSvo3T7FYozvtCrMV3/ADAnjv714d+y3Atx8Qr5GTeP7MkOMZ/5axV9Tx6fEsp2wqDx36+/sa83FL3z0cK7QMC305niUT2xJxlJUHPv61bh0zymDwuGVlHCgDbg9CK2TEFkjQMYgxOAfm2jvj8aI4PPESTnc4bAYHaSOf0+tc/LY6VIy2tx5e77MwOeSU5NZtrbzXDlLqNM+ZuRgcgj0z1B7YrqZLZ4brHmNtUkgDkY9x6019NWKArb7CrNkA8HPXjP8qTg7lRklsctqOlT6jDCDNJDJbz+arRoCxI9N3A61Y0axvFtrmG4ZZHikKRShQCyYBGccZGa0btJrmIoVlEpGC8JKkEde/Sn6Ygig2Ftkp43rliee57/AFrRX5eVlOLXvA1g8kO9wqSL3HAz04rG1XS2ntZkO4DH34/lZfUj3rp40+Uxm5lK5y2UP4dKZLDHgSJIx75YY49xUciTuhKZxFppR05L1rHddRjys7pfn7hmJP1zV9dNaK6iZvJX7KCYwgw7bhjknqOfzrWuXSGU733BzjI4HSo5hIEz5iM24DDAE4rTmew+RbkEls8uTOu1wMEZB6etQT6VJMYm86aKMZyikAyenP41eE0xnw3lnZgH5uR9DVyZmi2AN1AOwYJPWpWjuhON9GZen6UbOS7RBshkZWHz8gFcfjyKmMKSD+IAY27uMjuKtXU0quu1Pmzy4xkD2qNJUky5AdsnO4HsPyzTm3J3Y4xsjEl01bgxTtDJHcnoyyHbEN3DdcevbvVq4H2mW6tbI7XGEdyPvKR0H4VqzGMxN127QNvbNUwzQ3BWQojyLh1HOQOn061Sm3a/QVl0GGH/AEjEaPGsYAwAfTua0FEceJNzZTAB5IJ75zWdd3stogcneDgE9CKd9ohuow6HEXXJOMjp0qLalcjlvsL9khkvftDs1zMp+UsPlQHsKmnWSYshJDN3J6f/AFqdFLCqFUJdUAyxH41SnuHmK+UxKMOABim3fVi5H0JMGQlAPNhVhuy2Mn6/0pLlCu3ZuaPhi27gVDHJJHI4UtyPmUd/8+tWVuVVsEKSw2jtihIUou9iMSGWYEPtLLjdjp+FJIXMbD+Aj72Mbvagz/II41I6cHsKgkbJZQxYg4APQfSmawo2NJHL+V5mVdV2sc5Ap0kZG47n+VQV3A1kWsjI25wGwdxbPJ9q1PtAlw6F8tgndnFC1QTpuOxZQK0IUlt2d209h7VCkiqEUOrMWO1Gbk+9JFMx3AxqScqGXgY75NRCJIyGwZH/AIWGMj8adjmaepK8ZlRX3yJ823bgEn+gqmzKkcobmXGdo7VPscHBLsQvIPQGkIBikLAFlHP5f/rq9CYSep8IRnApxYj+tRA0oyThRkntXpnj2JNxpC/tXT6D4E13WArpaNbQH/lrc/u1/AdT+Vei+H/hJp0aq+p3E93J3VR5af44rKdeEd2aww857I8Ytbe4vJlhtIZJpD0VFLGu50L4W67qKiS88uwiPP7z5nP/AAEf1Ne5aH4e07TEVLG2htVzx5a8t+PU10Nvpojk/wBWSuN3rzXLUxb+yjtp4D+dnl2g/CfQraRftQlvZl5bzWwv/fI/xNekaZoEFlAiWcEdvCvSOFAgHuQK3IrZUK/MQo425q7DGBGdmMDjaTniuSVSc92dUaMKfwozLPTerEjaV+961egtjHsC8jOduMEfhWjZxLEqRQxgDrhuSasRKok3eV8x7H0qeVvcq5SSHDFjHsYfdB+vJp62wLJuOWIJHov0NWJJPKiZZMCU8HAxxVVpJHXKllQ4AyOgoSLjFyLKAKflfCqNuSamMfmj5DiQdcf1qmihht3fMOpboauW0ohQxqNynvnJJrRRCUbbCMJVmJbAU8YB+7TBMTIuwfN3GODS73MhVlwijsahcBxzgkHgjjimo2KjHuWlmHmh2Ur26Y/GrLygOqbQ24Z4OKoRK2CrdCRgMeasxqACW3Ow5ZV7e1WoEyiiEAZ2KrcsWwOwqHzEHEce4Z5J7VMFKyIVyS3GGPP4U2WPEjFc/K3PFUkXdDTuZXRc70OQM9RVmK4DwLJtO7qPpUCxHzt8fC9MHqR9aY3yn5JMKWPBGPw+tVYiVpEchaSRmcjYvAyMVC0vlKDjgN82R0zVqSQOxUctjnvUDJiMgfMxP8XIpJWZSloN8rc3y42n3oQHymJOQCcHoBT40JIUDcemAegqQ27upRVADHIORj8apLUTlbczbgsCx2Z3YxnkA+1Nbe21jww689qvPAY3KMd+OB9aqugBPOQTz/hVcpopprQZuJdHRir9OehrWgLlUZzEd3B55rJlu4Lcbbh0iVjhR1Zj7KOT+FaFxIYIfMt42kZNoVc4zk4yfoD09q0VNu2m5x1prYllRYmLhgx6ZHAH0rxf9qFifAmn52/8hNDx/wBcpa9taNSoyMnPNeKftSoi+BdO2f8AQSTI/wC2UtVBanJUleDufL1FFFbHCe1/smAn4k320Dd/ZcuCTwP3sVfWgQBgs8K71O4Mh4x7Z6V8l/smOU+Jd5gA7tMlUg9/3sVfXKSROjIwd45DyGbOMH+VcOI+K7Oui/dsR3Fqo3OFb5zzvOdo9sU+2tSGMjMsgHQHtjrirSKo2kFyD0Xdx9fpTnby0kJ7HA3DJU+nrWKWprzdBIFdNzxR743ONrLnFV74J9iZGZBuPJBLYP0PSrcU7xwqmRkAtnPT6etRXAWWLdHGu8nkZ4H171orMISfNcwjJiRPLdAx+8DzkehNV23TySLDPHhGyyr0x6ZzU0s1yZGjRptq/wDPMYA9snr9aYozIN42sA33lJB/+vWTaPQ16E2mLIN6O5G723KuB/KrM0zoCvlrHEflBPPHrVeEyyP5cI2kKMsi9u3171b++q78l+PmYfypmc46mO9uC0e2NptmCmcDFNnjEbMNw3HocdPx/CrspxlN4BHzEHt9KquySIytKxyPuqeTioOlbFC3Zg+HxjdvLHnrVm6k27RGST6hcZH/ANaoH8o7WVMbTjaD7dx3qy6M8PmYC9eDxQnoJx1TKqyFlXDszcH5utG5I9y4+ds/LnqaJGLMGQALnHTmmspiB3FSep96luxfKhISzjbJIsbAcIDnr60zP74siDfjafpU8MXmSghO2QAucn0/z6VVmR0kLhTk9dp6c03e2hGlxuxZJf3g5OQRjgcVBbBVTaV2gAgHGPwqdmXYHBDZyDjjke9EcYEOXGWbJXnJOaUUxSaQjMBEcOS3qTz+VCMYyi4CnIOfUYxSpCFkIIfjCgHuaTaRJtI2EDkkHA/Om0QpcwiTAtJklJAccAd+lJHg7RuClhjA6ZpkZiZGiDhyv3gBznrU0EUW3zCGbPGc4FUhSsivcfuyDICWxjcOlMdGyrDIA+8RzgVfNsZDuXAZAeD+mKgigJJ3RsCD0weTUtamsaysV5NjyOqtiQjOfUetXNOQ7cO25M7s+lNkgdl+ZFCn+Int6YrUtYohEd6llABKD7pq0rIyrV/dsirDKyNjOdzHjHQU1jsH3gSSCSOwq3PDlWjAYN/COmD7VXNu+MSFQR1YjFVY43Vaeoh2yIBvba/JIz2/rSSIoil3PhVGQBx+FTwRM3lsWBQc4Az0qKWOTFztd87SMgYxkUepKm9bHyR4D+H7eIrVL66uxDaMSAka7nbBwfYcj3r13QPBelaNj7FYoJB1nlG+Q/Qnp+FUvgzblvAlhIgUndKD648xq9FgtirElQQv8R/maK1WTk4m9ChTjFStq0U4LIAZlzznAPcVow267V3gAelW1gXcCMMD7VKsDpFtRFV92eO471jZnTcihiRFxHGTn0HOKuSKY4gVZgF4AB6n3FPhGxiEXJIzj1p97BuiUsq5DdulHKEXd6lLbI0+5uM9cd6ltoihBBYbTzk9akkjJUL8w9u9OhjYyAKN21STxyTVRg2zbmVjWspFk2EEbj0Xvmpy5jQbtzKzdAMkVBpxSaCC4h4SWMSDIwQCOKnWHzdoy21iRgdzWkotSae5xXi3foUr3JZGkXbg8HrUSwlZC2ArFhyTnj+lWpEcyKu0qVOME5pHVj8hUGViSFHXAqlC+x0RqJKxHgZUopYhvwx61ZiiBJMe05OQT3qFZfJeNZN4aU4VUjLMT3HHStWyiffciTcquwMQKjIGMED8QfzrSNJ2uzKpWS0RQcuHZgvyjjjmo1VEf72FcDntWytqscbtI3T5j3waLUW1wjkwgIMlg3oO9KyvbqT7dJGbHjztq5IPOdv9as6UUuLOO7hdZIZclWA/DB9KzvDWrWl9qSw6dPFN9o866kXOTGgKpGPbI5/Ouigt0t4/3YCx7idq9OTk/rXTVw/sfdlv/VzneI59jH1PybW3e8vJUgijbIkYY49PU/Sobm6htrFr26uYlstit57EBcHGDn3yK3riJpA4iETTop8rzRkKxGMkdeh7VxN3ZWa2cuia5ei6ttMa3MMit5JUMv8AGFOML2J9R9a1oYenUXvX0etu22n/AA/5ESxLWhoyNc3ElrLZeaLdZsTCSPbuQgjjvwcGtVIZFOH8qV+5x/KszwxBJDc6okd3PdaYjobSaSQyEZX50DH7wBxg89SM8VuRJljn7vr6VniIKD5F0/XXXz/4YXtXIxnjEgm2ByVz8pHf0FYunXtxqcF6LW38u+tpHhe3kkVmUjoTgng10l/eW9jdQrcJNGkhIMixlkxjoxA4/Gsa3t7GXXLCfRoEhFsspuJ4oyqyIw4Un+Jt+G74wfXmqVJODc16Ppp0+e3qW8Q09C7oJW80y1uVXY0iKzAf3iOR+BrRlIjXaowTyCvaiIK0CCMhVA6AYye9NZ8/KSBxjINc8rNtrQh1G3qQ6otzNYTLYmOO+MZ8l5RlQ3qQK5q1tr631mKCPUWvttuxuGuIVIik42Y2gck5+X0FbWv2l5qFj5Vhf/YX3jfKI9xKDqo5GM+oqtHYTwWumwxXP7uGbzZdiBN4wfl49yCSSSa7KLjGm7ta36frb7kuu5i6jvoYTwzafYyX+k6ra3upXBVFjlgUmY5+4CDuUdTxwK63btcgYUD07movs0STtcJBEsxHLqgBP49aewywIY7h2/pRXqqrbT8vu07dAjdDZsu/LZP5CvFv2pFI8DadntqSD/yFLXs8ivncm3HU14z+1KxPgXTgeP8AiZJ2/wCmUtZRVgm3yny9RRRVnMezfsq+WPiHqDSglBpcpOP+usXNfXFs8kyPLIV3g4C7eRj1Pv8A4V8k/spRvJ8Rr/ZnK6XKeOuPNir67slyGBX5tvKg5AOP/wBVcVf4zro25Rs6JMCsTlcnI2LgtjoKsIYwX3vhgmTuOBj0xUf7vBiicpLwfu4IH0qvqaKuoQSFdoZQG2jGcd/rWC25jRvXkLkFwJIiI1dsD14wT604JBLGSAQGb16++apO7x3QjEjAseGPcdetXlGBxjbx2z+VDn3LVLl1IbtA6lo48sgwAo681QktWKlsM8kfzeXng5q5K7I8jorZOM7v8/jVZb9RDIylwwzkEcmlzLc6YOW0RzzolvIojfcwBYjkgelU4mclVL78ZG7OFA9PpSRzERMEYgnncRnJHP8AhUYlDPhVIkCjcM5x3zipu2acnKWpUhuMShRIv3Qex+lZd3CvzbWABOcdPm7YrTaM79j8sucBeAKr3Co88SkdclgT8vTpSbuOE+XqQ2tqyTRtJ/eyxJ/zxVpo1eeSJQFVTuIbvz29jSiGPBQtxzkjtUCfu5MRAYCYRh94VaMZ1tdCO9ijZixk+UDOxV61SWMNKqFk8stwSe3c1qiJRaoshckjJOfmb8arxRqFdJUU4OcMOo60upKrytuQKjJOYY1JD5IwcYPenNbFosiPLA4PIzinri2jiUxgkHJGOuevFSGdmDtCoAYcFqpLqQ5Xe5nvbw+aYiCVYj5hnA/+vUy20MZQx8A8DJyatTR+XHGzxlmxnOc/nSIyY3RRqWYE4PGKaXUlzv8ACVfLzMCDmPBBx3/+vUFyHmuQFGFIwVPQg1oxt8ka7RjdyRx1prxFZCHzkcZxT0vsEb3M9rUhYtyrGwbGR1AqWOxkZsfeJyAowN31qR23Oc4BOMj19/ar6kJFlWw3XcBnFN3QSk47lZoyqqhJDKMkA8j6U+xJ3FZEYMMncepPrUwhV5GwCWwPnPPPrT4Y/LZm+8RwSO5peQnNW0I2jDBs4G1sdASagghCxggYXJbaD3z1qJ72OHWYrBVJZleVpMfKgUDqfX5qeuopJ5SiJoYpImmEkmANoxknuOCDzV+ylbYj2nmPKKqgsWLPjHPIoMIldfMflc8dqIZUu1D7JUiH3JGGPM9wOuPc1OY8DAwM4wSewqXFx0ZN1LW5TURJsEZYHdgHH60+ZQIZ/LYAlT830qTcVC/NksePQCorrebR2xzg5x06VLQ3NHjPwORv+Fe2DEALvlww6/6xutekFQsWVbDdOcV538DmA+HemfN1aYY/7aNXoke/ygMAE8DiicfffqdlN+5H0RYiX5QwQcds1NDxMSRgEdfeoIUYx/eJbG3061LDsV8hzg/dyRzQo2K5rlhflbaVzz1znH+FW4UWT5WbIHbrVJJ8qB5Z+U4OOMmraAn5VGcjI2nirUCG7CNbiMPIZAqoCSD04/pVDwrf21xNIJ71JNRfL/Z0j2bV9FJHzYHU1sPGjxiO4QMjYyrcg+xrOivLu81C1aWxktYrbczPKyZYkbQqgE4HOSTjp712UIxdOSkvnp+vfyMJzm2rM3LWIKCoACDO0ZxgVLFHtUHOCOv0qlbXSs5STg1ZeZguVjO0gls9q53Ft3ZVmtASN0ldyNxY8AGsTxJdyWt/N5UUwMVtEv2gIdimSUAjPTOFGR710MLDcPmI74x1pjBR5gO0gvuwehPbj8K3oTVKfM1czn7+hR1FLS61K6hjg1B5bYIkj2dw0bLuBIAwQCccn6irehLfLpFomrt5l6ikM5YbiMnaWI43YxnHfNOso4opbpl5kuHEkvPU7QvH4AVbjVRz19OOKudTmgqa20/LX5f8AyUXF3ZJuIQK/XPPvS+VG4IKKytkMMcEe9RtzuJJ+bB+lOjlVCV7g1jyl3uRxW6Jq8l4rIB9mS2SNVA2AMSfzyOParJcFXClgxHftTX2s+en9fenbgcg9vbpVNuW5F0tiCaztbl45ri3je4RcK54bHpkdqrJpNlBqTX1tCqTPCIXH8LKGLZI7nJ6mrfKMSWBBPWjzsvjg+verVSaXLd2M2le4zJZMMRlf4R0poDOMcr70rPjAUYJ/LFRhjn75JPHHeosNN9CJ5NmSCd4OOvWiR2cgE4/2qkKZC5BIHvUcikjux7ZPSp5bMbkMQMIsY2+1M8vOSTz3qZCGUnO5c8FeaHIPYjPFXygtdSAFFGOT70xNnmgYByOKQLggZLMByT1Nc5eeILy31OctZqunR2TXCLICJJGDAbj/dXkgDGTW1KhKq7RFKSidC6gspIxjnj+VOkw2GjJGeenJrlb3U9Q0a20vUNZvoljuJAtzbeUFSNCpJKkfNleM5zn8q2dIvrfUbP7Rah/KbBRnwCwPfGcj6cVpPCypx5t13W36AqiehosAApwCMYFeK/tTkHwHpuM4/tJP/RUtewTTBFJY4QDrjgV4x+1CSfA2m5Of+JimP8Av1LWVgnsfMVFFFBznuP7IJYfE++Kgt/xKpcgdx5sVfVeprNY3S3UEZaLlZEHvXy1+xwpb4o6hjqNIlP/AJGhr7JmjSSNtwA9h3Ga5K8bs2pvl1Rz9rG07rcEBed27u31qaa086Q7mZgQNp6/j9atnbHIF37Yum4j09aZe3fkyrHFtwepJ6HFc7ikac8pO5S1C3aaMMCcx4UEelSxBkjjJzhRtyOSM+9IkoiDxNJhQM9OOajaUM5Rpm2Dn5RjJNRoaqUmrDxEFkfLMyjjk55qjcRSrADKpMrLgnsPSprVA0hIZiWJByfqeKljnyHjlbIzt9qrRlxnKDuYZXy5CzoWO5unRhmlsd8rGYoUKjgk81NqsE8sOyyUeaG+Xc21R+ODRYPvt7eSVQVkZlcjgxvyMEenGMihQb22NpV20WWyrjAY7xnPXDD1+tQXTF0LKhMiNnn3HpV6OMiXO0k9AwIxUTx/vSUUhuVK9vwqbGS9RtsjurSBMMBgZ7VXvl226y22H8pgJFU5IXPJ9vpTbD7RZ3ciSKz+ejT8HI3g4Iz9MflSWEGxoZ7OT/QpkMkkROdpPPA659a35EtWRfUtRws0ZEjEMoHA/Q0GFpFxHhlJxz1PvViVosBypztwGx+VRtI3kuYIlZ1HyKWwCff0HvWSTKckiI22FLMBvIxx+gqvbTxy7vJVAAzKSPUcf0qKNpE1lDPIWlnhYHAOwbWHyj06555NX0RFJKhVBJOBxmtnFRMnK4krxxQK91LHEh+TlgASeg+pqhPPa2EiieZQ7ghIwPmfHoKs6hHFcabPBKRGkilMquduf4setYC2t5JrMrtG00y25gtr0xbVHPzMewPI+uOKqnSjJXkyXNx0RrRSi5hF5Ad0ZXKnBBz3yOxqxLA06kOSnTB9PpWZAs8OswWUT5sUiIBRSpG0Dl2xg5PoR+NbS7uGckMTjaDxUSjZ6DU7bsxfNSzs9QZ4NjWxGAzA789DkepqVJp7Ny10/mwhHkkSKE5UDpjufSlbTvP0++tbi686W5ZmMyxhGX+6B1HygAD6VZSAxIR587ysQGmG3zMD8MY9sVq3TWi/r+tSHKTLVvI88MbsgUONwGQcjt0prKHI+eRGbgEdveo7WCO2hMUAZYlPG5snFSiYBjkj274rB2vdBdpGReWNwzX4touUt/Jtw7Y8x25c5/ADJ71dt4XKu8yRrMyCJYx8yKg/hz39/WrCsF3Es0jMeh/hFILlWYjgLjj3+laurJqxny9ynp9gbTzkWUnzG3gYO1BgfKoOSB3/AJYq98qxAsSTnkAf1pgnJGEU7vTrmqd9fRWiB7y6t7VRyXmkC4HpzUtubuyrxRadRgbVHHINVrhoxC/BPyn7oJrldW+JHhHSwRd+IraSQdEtSZD/AOO5rh9Y+OWiRxy/2VYajdyYOHcLEv65P6U1Sm9kRKvFDvgaq/8ACuNNYkZDzYx2/etXo8af3SSRycDqa8v+CII+H+nEv8uZT06fvGr0m2mBCqx4A+9TlH3nY64zaivQtRuUjO8Z57UJ80qZy4zwSOB9KiYlwVzgdFZataeiCM87ge3Smo2NFU0uTMGYY8vLN39KuWyFVIIK46UiSRrt6njJz2qbdsUdCtaJGbmyC9lx5YJA3nGR6VT3kyHccE9wOKlu3O5SFB+bABGe3WqJd1JJIHqc4yKfKaU6iS1LsLfvWJYk45J7VaW8OBCzH5sjOD/OsuAbiUiCndyWq1AJEwWIyvHHIzRyhOtDqa4kCoCFKnAHSqoYsjZBOW7ZptxKRG0kmFijBYknAHvVa11C0fTUv/OVrN18xZGbbwfTNVGEnsjD28YmvZsScOwGemRzVgv+8IydqjpmqMUskliGCeTuX5AxDFSR3wSP1otFl+xwC5YNcqgEhAwC3c05QtuZutzO9jUDgLkEZPTNRoQSSfvA84qupxtaQ54zgc1zl9PqJ1nQ7i5zaJJetFFaK2TsMTktJjgscDgcCrpUnUb1tb/K5Dq2OobUIlv47MktM8LzDjgKpAOfxIqfz1KLx1yR71QZUMyO6K0i5VWxyoPUfQ8flTy2xANxKjiodtLBdkGp6tJZ6hplsliZ4rybyGlEoXyztLZ29SMKar61q7WLTtDZGeK2CtPIJQhUMcAKCPmP5Vh6tpUHii5jn8zUkMKMtqfmt47dj1c9C7eg6Y6962E0lxqV5PPdtcWk7xyiFkAIkRQMk914BAx1ru5KEFHn3S1Wvf17ei06mfvNs0v7St3v5rS3JnmgH74pysPoGPYn061OmTkMAAcYrDsNOWDVW1CebfeMhjcwxiJZMn7zgE7m7Anpz61r+ZsBAHJ5xXLUUE1yO/8AmbRulqV9a8qdFtpLy8tnY7lFm4WV/wBDge/H1rlLCdLrVbq21vUJLxbJVSG1RCftBbLb2C8SEDauemQa6G6sdOnu5LmaziaeRVV3Zc7wvQEdDira3G1QoAAxgDpxXRTrRpw5Ur/crPyer8iHBtnKXgubFbsaOqW97cyJK+nQoS3lhQAqsMojHkk4IH4ZrsBkKEIK8YwDuI+p71AJtqEk4HtTTddFyvHWpq1fapJr+v8AgW06+Y4rlJ9+wgHORxWLqejpe/2i811Kkl1HHEpVAfJRDuwPXLcnNXxcYIJ+8fSq8t4DnOPr60qblB3juEmnuVxpud8s15cTXskXl/aSFBRT1CKRtXOOeDUem6TY6VPczW0e2S4x5sjH5nx06cd+wpXvgDjOSR0xUL3TNn5CFHJJHArTmqNNX0ZN0abCIIWCj3rxn9qBlPgjTQn3f7RTH/fqSu51XxVpenlhqGr2FuO6yTqG/LOa8W+OPjTRPEHh+0sNJ1H7ZcR3YmYJGwQKEcdSBnlhWbhZE83Q8UooorER7f8AsjTyW/xMvpIjyNLkzxnI82HNfYyku3mHnjIz3r46/ZF/5KXqA9dJl/8ARsNfYVsQ0Q2jhOMY6VzVlqbQXukdxE7SJtk/dsPTvTIrXILFy7Ac7j6VZkZShVycL6VDI5SHcOhIyD3rBou1tGRSqAdxUo2OnrUMYTGSuQx6eh/pUks4Cjop6FTjOaoTXyxxOSyiNWyR7Z5/IUnYpJrqXEjESION4GGc1A2TK7Mp2t0I/L9cVmXt2JGAXzWTduY5xtHb8OlOa/DrtLq2PvY4I75pNX0GXrmaQxyvbxqZEQmJWOAWwcZ/KotORoLOFJUVXC5YltxJPJJ/EmsOXxFZxtK0t3FHGpBcvIEGD7npXPan8TPDVnIr/wBr2jHcMiImTjvwoPpVK/LZITnFbneTyhCqgMQOSVP6+/Sq814I2iHmDG7AwevFeP6j8aNGWTdawXt0ykrhECAg+7Gse6+NjyQmOHQmZGzhprkA/kF/rVKjNkvFU47s99e9j8sOuEC8li2BVSXUYwPlABwOBzk+gFfN938W/EcyGO1jsrSNRwFi3sfqTWFfeO/FF9IXudZul44EOI8e3ygVqsNMxljqa2Pqm61BZAiFXLs/GO3FRTanbwxpJLcQgZ2qZHC4/Ovju61LUrtiLvU7yfP/AD1mZv5mqBj3nMp59+atYTuzF41dEfaf/CQaZvdV1C03HB4uEx/Omxa7ZzElbu14+UETLg8+xr4sMSqMbBxwAOlNAVc5Dbv9k4FP6p2ZKxnkfb0epAyYHl47lWzt9AfrUhvj5bFnxj0Oa+GZGfrvdT7MRTGaTOVkkz67zS+qPqyvrl+h9ywXJyfLTarc+5PerBm3EAqc4yPzr4SMk/H76Ye4kYf1ppMmQWml3evmN/jR9V8w+tLsfdM955a4b5VORgjBNVl1JZY0xliec9RXxfpGt6vo9wJtM1K7t5F5wJSyt9VOQa6O5+KHjOeDyjrPlrjGYbeONvzC5FL6s+41i0fU9/rdlpqGXUr+3s4sk5uJQmfpmuSvvjD4M05GA1SS8k7LaQM/5EgD9a+V7yaa8uDcXs0tzO5y0szl2Y/U0xU7CtFho9WZSxb6H0JffH7R4c/2boWoXLetxKkQ/Ibq5LU/jt4kucrp+n6XYoeASjSuPxJx+leUBT0FP25PQk9a1jQguhk68n1Oj1f4g+LtWyt5r94sZ48u3IhX8kArmJjJNKXunlmkJyzSOWJ/Onsu7n14oI4zmtYxtsZubZEEHUDFKV+U854qXBPHHpQy/K278qBcx7/8D3Vfh1pYYA5aXHv+9evQwoAUhsPgkhhXn/wQby/hvpTcctN2/wCmr13qzxAswJZjzya5OXU9yKvFFi2XLMC2cjPTp7U+ANGwMagJnIANJAX+Zjk55zUyfMCgO3HbHU0OIJ22L6bdgZvm7GkdwoATJJ5461U8xYyVdgQf4QakWSLjYevSixLm2SMx3KHzwciqt/HdRwSNp9tBNLt3gTuVDH+7x0Pv0q2W24HXH6U24a4msLiKwlWC6dCsczLuCMe5Heqp6SV/xJk9NyhbQWuvaArNG6W17ECcNtkjP1HcEfpW1FCBGq79zAcnH3veszSLOTTbW2ikulkjhjEaRRoEQHqWPViScnk9+laSSZCkgqTV1bKTjB+7fQzVmrvcbJpkd5cQG4lb7NEdxtxwsjdi3qB6dPXNZ1vYXVn4fsLBLOG4mMzKyyfNHEm5myTg9sD6mtVJ8RtnjHTPNJ5zrNg5wRnfn9KqFWUUo7r/AIf/ADE4XdyPS7FbK8upIVhhgnVMW8JwqMM5b6nI6DsK0X2hs5B6/WqizoAxYZPb1pBd/KMkKR/eHSpnJzfNLcaVtEWgFDbmHOPTtRIsUs0MzxI8kRJjYjlCRgkfhxWf9sySQMZ446VHLecgZ4H8Oev1qbPoXyrqary+g9efaq7Sk7lJTb3wKyLzVIYI/Mup4rdRzmRwgH51zep/EHwzZAi41/Tgy9kmEh/Jc0coXSO9SZXX7xJHGfSopboBMB8jtjmvHNS+Nnhe3Yi3bUL0j/nhDtU/ixH8q5rUPj03I0zw+NvZrm4/9lUf1p8pLqRR9Arc4JyDx60ktxzncxPoBXy3qHxo8V3P/HsNOss/88oC5/Nia5+++IXi6/BE+v3iKeogxEP/AB0CrUbEuuj69e728MzBeucVj6n4s0XTSftmr6fb4HR7hdw/DOa+Obu9u7z5ru9urj182Zm/mariNMZ2jNNaEOt2Pqi9+LXhG2J/4nQmYdoYXf8ApisO8+OPh1Nxt4dTnbP8MCoP1avnXbxkDkdaXbjJ9Koh1Wz2u++PLYIsdClY9muLkD9Av9a5+++NniebP2a20y1HbETSEf8AfRx+leaHoc96Tg9OlO5POzq774k+Mb4HzNcniDdoEWL/ANBGa5y/1bVNQz9u1O+uc9RLOzD9TVZl4IFIRjnpRcXNcg8sA9BTJ1AQEetWsH0qC5/1Q+tS9ik9SpRRRWRqe0fsp3KWnxE1CWTAUaXJyTgD97F1Ne+az8X/AAp4fuW+0azDcSOcGKzJnI9c7eB+Jr4ksUkllMcbMAwwwBxkZHB/Sul03Synzqu3HU9DR7Hnd2RUxKpLl6n07N8dtAnWZtN0/WLpYx95oUQfnu/pWC3x8mYr9n0HIPBMlyMr+S142qYUDc3r94mlORyQGYDOStV9Vicv12bPT7v41axNEyLpVhHK4OGMjuVOQR6e9Yq/FXxM8kmY9OjjlJ+7EWIU9+TXF7crg4zwc56U2QAYyy8Gn9Wj2J+t1O50t38RPFLjYuorEMFWCRpjHscVg3PiLxDfhjc6xeTSuoVlSQqPxxiqZUcMFwAe9N5D46H2prDxQvrM2ivJG8gbMjs7HLM7bt2ew9BUAtkQjOW/HGKtOfmOc4PfHSlC8AHGfpVxpxRm6smQogjYYXB6UN2KjnuKmwM4xketBTjkcHtVpGd2QNgE8Dj0prcHpyamwPqev1prDJJPBzSsFyuwLYAHBo2jnOePXtU2B0BwO9JgDGME/wAqNx3K7LgHjPPSm7Bs+bgA5zipiCD7Z7UbRyCOM5570BcrMpBJ54phjwQKtEZ5656H1oVB6fpRYdyp5ZpGjyDxirQTJIpm0dh749KVh8xAIyUzSbPTmp3XAIPI9qULjg/Xp0oDmIFU4pdgOODU2w47HPelKepGOnNOwXIcccDPpmnbfQ1KE9Qc0oXHPbsKBXIGHA449MUm0g9sVOV+UEHpxSbQeMEY5yadguQkduSD+tKyYRvXGRnrUoXPGAO9OdT5RxwcZ9c0WFzHt/wTliHw505ZpV6ygL3H71q7lpVwuI8heOV5rzX4OpIfAlgUlKDdL0Az/rG7135Y5ZY7md34yCciuWx7yk0kaUV5KseEKAdRjkilV5ZsMzkD0X+dZP76EZM6op5+bGc0Q3kgJAlG0Hg8ZosS5Nm6qrlOoxxkjk1ZXy/LGQABz15rnGu5JHG6VmOckdqmFy20Eo557Lmgk6BrlFH7sZJ9TxSfaN2AzEA4OF4rldQ1uz05d2oajbWYHaaZU/QnNcpqXxV8MWTMF1KW8kHRbeAt+pwP1piTSPWGuUCEAhhnv60i3YQZWT8PSvnzU/jf1XS9HZx2e7lx/wCOqP61ymp/FnxZfBhFdwWSHtbQgH8zk/rRYOdI+rU1ABGZnUKP4sYA+uawNT8d+HtPZhea7YRnuBMrH8lya+Q9R1bU9UYtqWoXl0T/AM9pmYfqapbQCcDmnYTqn05qPxn8KW2RDc3l6f8Ap3tyM/i+K5nUPj1GONO0GZx2a5uAv6KD/OvCgAM4pQM8CnZEObPUdR+N/ie4+Wzg06yUjgrGZG/NiR+lcpqvj7xZqmRd69ehT/DC3lL+SYrmwO3pSqMDntTsS5MWeSS5cyXMkkrn+KRyx/WkjjABOMCngAL70oXpQQ5CBeKeFyTx0pQp65pwxx6UCuNVPlznpShM/XPSpMDAOMgCjnGQKYrjGQDGOmO9KByBjpwaeQcck0D1PNArjeQv0ppX5cjqalC5UY4J9aXjaWbtwKYEbjgLjp3NNxz3qZucAcAd6jIIznrj17UANxnI5z600j9OaeeM5+tKQD836UARgdOOnFV7wYiGc53VaZSD2z61Xvh+5X60nsVDcoUUUVkdBu+DkEmqspAP7s4z65FdoqDB29uBnjFcf4JGdWkAHPktj25Fdq3Tg+9dFP4TzMU/3hBwGyTkcc01twwSTg9yOKkIL55UngYpVUfxcZHJ9ea0OYjBGwgqNvX8ajwXbGBtqXGVzzjIGKYyhSQF5HB75osUQtgHg8H0pH+VcY5PWpsZ442jHShVGeQMDtQFytglxlev60EFjlecnpUxAOdvfqOtCgIoK9ehpAQEEEkdf0pAOpzzjNS4C4OM49TSheDtGMDnnvQO5CUOM8c9hTSOGxjsKmKjAppX5jjPvmgVyLG3OQMY60zbkLnHParAUFT/ACqMpjgnpxmk12GQlTknHtSY56ZPbFTkc5NJsHJHrwKYFYjnBGacAQCB0z2qUpyMDn0NBUDI2/hSAg2g8H9absx049qshMPkE00r1z+GaQEJ4HFN2kYwMZqwY8Ak9+OvWk2fNg9qYXIWQkcDijbj1FTlRjI6nnigJ09DzzQFyArgFj19qTaQMge9WimDlu/TimFQxHH5UWFcg244/wAml2/NwOamC45H0NNI+X3z1p7hciVQGJ/rTiPkJA7ZNOb5VAFBGQf1FAHoXwt1J4PBllEkZcq0nHbl2rtkub14AzyLaQ9SzfIPxJr5v0/xRrWn6ctlYX0ltbqSQIgFbk5+9jPU+tZ13eXV85kvLme4f+9LIWP61ypM91zTVj6Lu/E3hewYm/8AEFtJIDyIszEH/gOaxL34reGLXIsrXULxv72xY1P5nP6V4Rjj3pRVcpDkz1G/+MmpspXSdMs7QHo8mZWH8h+hrlNW8eeKdVVlu9auljPVISIl/JMVzajPSnAdscU0iHIa+52LSEs7ckk5JPvSY7+lSheKMZ4oFzDNuRyKVQBj16mnH0OcUoyO1Arjf5UfhTu3ajHPTigLiYzx+VOA+bOKUc0o6/4UE3AAYGR+FKBz2xSgelPHIwBk/WgVxAOaUAg5zzSquegzinAcZJGaCbgoyO1OVeSOlOUfLxj8KUN8v+FCEAQEGlHAyefYUL2FOIxkYIIPemA1V7eo4zQcbcZ/GnY+VfX3pMccjn0oAQ9MdPrSEZPtTyM8k8+lJjk8Z4zQITlV7Ypm3AHY0/B3HoaRcEgE4A60x3G42jgcmkwD7D1p7BeBkk9c0hHAwOKAuNPoeg6GquoACFfXP9KtH6D8araiD5Slh1brSexUNzOooorI6SWCeW3cvBK8TEYJRipx6cVN/aV9j/j8uf8Av63+NFFO4nFPdB/aN9/z+XP/AH9b/Gj+0b7/AJ/Ln/v63+NFFF2Llj2D+0b3H/H5c/8Af1v8aT+0L3r9ruM/9dW/xooouw5Y9g+33mP+Pu4x/wBdG/xo+33nX7Xcf9/G/wAaKKLsOVdg/tC8/wCfu4/7+t/jR9vvP+fu4/7+H/Giii7Dlj2E+3Xf/P1P/wB/DQL67x/x9T/9/DRRRdhyx7B9tu/+fmf/AL+Gg312f+Xqfj/poaKKLsOVdg+3XZ63U/8A38NH267PW6n/AO/hooouw5V2D7dd/wDP1P8A9/DR9uu/+fqf/v4aKKLsOVdg+3Xf/P1P/wB/DR9uu/8An6n/AO/hooouw5Y9gN7df8/M/wD38NH226z/AMfM/wD38NFFF2HLHsIL26HS5n/7+Gj7bdf8/M//AH8NFFF2HKuwfbbr/n5n/wC/hpftt3/z8z/9/DRRRdhyR7B9tu85+1T5/wCuhpPtl1j/AI+Z/wDv4aKKLsOSPYPtt1n/AI+Z8/8AXQ0fbLr/AJ+Zv+/hooouw5I9g+2XP/PxN/32aPtl1/z8zf8AfZooouw5I9iDNGT6miikUGT60ZPqaKKADcfU0u9v7x/OiigA3t/eP50b2/vH86KKYWDc394/nRvb+8fzoopBYXzH/vt+dJvf+8350UUCshd7/wB5vzo8x/77fnRRQFg8x/77Z+tHmyf32/OiigLIPNk/vt+dL5sn/PR/++jRRQFkHnS/89H/AO+jR50v/PR/++jRRTuFkHnS/wDPR/8Avo0pnlPWWQ/8CNFFFwsg8+X/AJ6v/wB9Gk8+X/nq/wD30aKKQWQefL181/8Avo0vny5/1r/99Giii4WQnnS/89H/AO+jR50v/PR/++jRRRcLIPOlP/LR/wDvo0edL/z0f/vo0UUwsg82T/no/wD30aRpHcYd2YD1OaKKQWQyiiigZ//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stimulation time thresholds in patients with cold urticaria can be determined by Temp",
"    <em>",
"     Test",
"    </em>",
"    &reg;. Stimulation time thresholds are defined as the shortest duration of skin exposure to cold that is sufficient to produce a wheal reaction. Stimulation time thresholds in the patients and test reaction sites shown are 2.5 minutes (A) and 2 minutes (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcus Maurer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5713=[""].join("\n");
var outline_f5_37_5713=null;
var title_f5_37_5714="Normal resting myocardial perfusion imaging";
var content_f5_37_5714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Normal acute rest technetium 99m sestamibi myocardial perfusion imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 209px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADRAdkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poor5n+Mfx78UeCfiLq2gaXp+izWdp5PlvcxSNI2+JHIJEijqxxx0oA+mKK+Mn/ak8bquRpXhw8Z/wCPef0/67Un/DU/jYHnS/DbDjOIZuOn/Tb3oA+zqK+NIv2ovG7orHS/DmD2EE3r/wBdqT/hqTxsRldK8OYPQ+RMfz/fCgD7Mor4tX9qnxuXUf2V4bwcdLeb/wCPVKP2pPG/GdL8NHPGBBODn/v7QB9m0V8bR/tQ+NWXJ03w2fdbebH/AKOpf+GofGu0FtK8PD2FvMcf+RaAPsiivjf/AIah8aZAGm+HM8/8u8/r/wBdqQftQ+NSwB0rw6Bg9YJs9v8AptQB9k0V8cn9p/xqACNL8Onn/nhN/wDHaT/hp/xr30vw5+EEx/8AatAH2PRXxz/w0/40/wCgZ4d/8B5v/jtIP2oPGvfS/Dg/7YT/APx2gD7Hor42P7UXjUOoOl+HMHPSCb/49TG/al8aLKynS/Dpxz/x7zcDv/y2oA+zKK+MF/am8bl8DSfDZ4z/AKicZ/OWmt+1P45Bx/ZPhsds+RNj/wBHUAfaNFfF8v7U3jmMAnSfDYz28iY/+1qj/wCGq/HH/QK8N/8AgPP/APHqAPtSiviw/tVeNgf+QV4b/wC/E/8A8epP+GqvHB/5hXhr/wAB5/8A49QB9qUV8WH9qnxwDj+yvDRPtbzn/wBrUg/ar8b99K8N/wDgPP8A/HqAPtSivi0/tU+OAAf7K8NDj/nhP/8AHqk/4aj8dAMW0nw0oHTMM3/x6gD7Oor40P7UvjQI5OleHfl/6YTDP/kakP7UnjbaCNK8OEZ5/cT8en/LX3FAH2ZRXxkf2o/HIOV0nw2y4ycQT/p+9+lDftR+OVHOl+Gzjklbefgf9/qAPs2ivis/tVeOAcf2V4a/8B5//j1PH7Uvjo4xpPho54GIJj/7WoA+0aK+Lf8Ahqfxzgn+yfDf/gPP/wDHvakb9qnxuAP+JX4aJ9ref/49QB9p0V8XR/tT+OXGRpfhrGcf8e82f/R1PP7UXjsNj+yvDWM4B8ib/wCPUAfZ1FfGFx+1N43ibjS/DWP+uE5P/o6nR/tSeNyFZtK8OFTxkW83H/kagD7Nor44H7UHjU8DTPDhI6/uJh/7Wph/ai8bB8DSvDpBBIHkTdv+21AH2VRXxmP2o/G5Cf8AEr8NhicMDbzfjj99Uq/tP+NSOdL8Ng+8E/6fvaAPseivjcftP+N8Kf7M8N9OR9nnH/tWmSftQeOU2/8AEu8L5I5HkT8f+RaAPsuivi5f2pvHBJH9meGeMH/j3n5/8i1J/wANQ+OhjOmeGBn1t5x/7WoA+zaK+K/+GqvHA/5hXhr/AMB5/wD49R/w1X44/wCgV4b/APAef/49QB9qUV8V/wDDVfjj/oFeG/8AwHn/APj1B/aq8cA4/srw1/4Dz/8Ax6gD7Uor4r/4aq8cY/5BXhr/AMB5/wD49R/w1X44/wCgV4b/APAef/49QB9qUV8Wf8NU+OP+gX4Z9f8AUTf/AB6k/wCGq/HH/QK8N/8AgPP/APHqAPtSiviv/hqvxx/0CvDf/gPP/wDHq3fAn7SnjDX/ABtoGj3um6BHa39/BaytFBMHCu4UlSZSM4PcH6UAfW9FFFABXwX+0+cfG7xGGYAH7NgEDH/HtD1r70r4L/afOfjj4hXaG/49uCf+naH/ADzQB5ZIcwjPXODu+nv3/wA96jRHJfeSSOqk5P8AP/OanlIRM4bd25x/n6VJG5YbipHb1oAIyASu4E9epP8Anmo5IWcYLdh34Bx/+qr1rZPOHaKMvKBn5R16f41FKmxyOhwOvrigDMmUrIOCh6ZySPrmrUJKx5/h4GMYOehqK42tMqgZGcd+vepxgRE8885B5NAAocJwMHOT789KfEriNVyMAc/N1wKihKlFY44PB9OPrVpMKASFb6+v0zQA1IzuIOQoyT60RjngD1x71btAoO4MAMYxnr05x+daeh6BNqU8qIFCL952IAHsOeaAMNlIAyFXODk+lSSoVSMHBJyML61b1nTJtOn8qaPYyjnnseh557/pVacqY0B5fb1J+hoAg2sqknjOR1/SmKOc5JPTHQVJkHPUlu3OfxpoGc0AQjBxubjGB79OaRYWw+WZiQc9gakXaXBwT754xxUiAM4XA+Zvf8qAIsYZQAQo4puGGSMZz90dun0+tdX4a8LzandiB4ioPyxljgE5HTHXjnjPTvUXiLw7daRkzIDFlgHCntj9OaAOVkMu0AjnIAzj5uuapN1OcZ9q05yqr178E8ev5VnSnMjHOeT9OvagBWOGOTkg5GDkZpWYh34GSTnkj8OtJhScfdPPfj88037r9+D2oAkVGEq5+8T7Hn86dv2AAkkDGDnkcemaAVYoM9eSB1JyeP8A9ddj4V8IHWyzO5t4SPvbQcjB5A3Dvjn1oA5KIPIgwQQOu7PXH1q0FbyhkjcMZPvXV+IvBVxo8RmSVZYV6kAL2PXn26VyqOm1kJBbPynI7UAMdJAGkXleO56/T6UKPlww5PUdR/8Aqqd1UISHPrj8KjVs529QeDnHP1oARoxj7oCkYwDj/PSmFSwyGyT3HQfrViUnziG5AyOuaXeqQjtkHJz/ADoAxj80h5JyeoHX8KvuvAO0ZGOeTzmtjwt4Zl12/HzGGIE7n2k46nI5Ht37/hXda/8ADlobFZLCSGURHbgyDLYPJPzYHrngHNAHkpZjI8aqD17nPcdzSEMJI1Y/eUDnPA9Kt3EJgnkSRWRwSG+bvz+FQzY8+MEEZQD73Oc0ATWy7IiuQR1HHPfig7idoB285LLx9KsW4BhlxGWOe+cj6VHPxJjAQnPCtyevFAFK8BDhTnGc45J96vWcQ8jbGoJxnrg81RvnBYKBgjn1x7V6P8LPDv8Abal2XKRlWOMdNw45Yc0AcmlvPNdMkMTZYZ6EfQnj8fxqrLEQ2R8mASOozz0/KvetQ+HtqLWYWrK8wAePzH3Kw+UFjkkjI/DjtxXk+p6ZNZylbiHaVDKVkO3yznPHzcnv3oA5BUf5MjPQYA56/wCelaNrbmQN1DckY6jHf8KqOSdgL4O7v0+nX/OK3dCto55ZkYDBQ/MB0OR0NAGeluxlzCSM9M4GD9c1WvFYOQpwcseOfTtW3LbS/a5I4x5jlsMyN97GOTz6+vGc1j6gDE5EgKsWPUdMfj7dKAK8LSKpLg7iMcH/AOvUs0jvGhCgALgDP6VqeD9GbVbuRJDj5wGOMjHHTJxn0z/+r0hPAtndxERyrHNGMZkYLyeeuff3/EUAeK3EJAyDuPueewqqc8Zz7V0XinR5tJuHV2whAK4YHI+U9ifWsCRgSuFAx78UAMBwOOD60DjBI4p8DBZQTgjpzTCpCg9jQAlOU9BgHnuabV/SbJru5AVQwGfl65wM0AMly0Y3LgDnGO3+fyqqFJGePzr0u18MWMtttkYGToW37R+RP+cfjXI+INF+wSkoHZGJIPr09PrQBgV13wi/5Kr4O/7DFpz/ANtlrka634RkD4q+Dif+gxaD/wAjLQB+k9FFFABXwf8AtOAN8bfEgPY2vTsfs0VfeFfCP7TZx8a/EmMbs23f/p2ioA8skjRoOT8p7jHtzRBGuTjcVORg+n8+1SSP5cW75c549e1Qwo6OG8xsjrzQB7F4H0iK10j7RNGzs+dwCg7lwuMHv0I96xPHmkQ3Crd6eB8o/eKvQDBPB6fh78e1rwV4gFvbPDfS7k3ArxkgnCg+/U+tM8W6xbJZxRWASK6kA3tEMFSRnp27/wCQKAPMbqMpMqupJDEEEd/TB6f/AFqlJ+XPb34ptxGHlDM+SQPr2/zmleURnO4j1I7f5NAE1jCrFlQHAByoGfft+ddCmkh442wzAxKRjA/hOVJJznpz0rLtWTyrZnl/dgHgZHO48ZyP0x1re0u9jaA5YbEUKCW6nk45PH+fTAAEt9DTzgXYEBSMDjnsfy/l3r01rD+xra2ubGBWHmbcAgOWOOd3Y5I/M8Vw5Vg0cikADcD8vJ6dD26V13hjxCLiYWmoSB40fAb73zcfLjI/PNAFbXdOTxJoouootk0ZJXcFyRxnH4genA+ledX2lyR3EcJjYvtGMrgfdBxk8f8A1q9m8Ra5ptpoS2WkSK7Tpj5Scx/jn345PTvXCSoCyCSZQxVR68Y4yRQBxkumtHG7COUAOQTjAA45H5fSsxLck5OduSDxyMV6UIoWjSN50UKzFsHPH54PQ4x6j8Me3t0EH3QxDSKhcDAG7HQfT9aAOJt4PMmGW25478Djk+3T8qns4x9uVR8wDgDIHXOOhqxpkJl1VQsik54LDGRxnI+hPHsa37LRZZrp3ysbhlbCZCjkc88AdPz9qAPQL21n03wRHfaashKFTJsG7svqe/8AnNZ9mT4hsHS9iLSZxyNp28DaT0x19x2z0rtPBWpAeGpbK/bfGOE2lcqAR03HHT2HXPvW3qsmnaaLaO0jiDzBgo2bsnAOevXv0Oc+p5APmDxBpbWEphZtzKNh3AcYP1PANc7cBfNHJx3wPc//AFq9d1jRmNoxnIA38g4zkMc45PTHX3715pqttsumjDRkI5wfXk8Y7dOlAFJV4/eJuG5gSPXAzUaxoFbcrMy5Bx/OtyGLNkGMgOXfap4x8gz/ADH5VmPEftWQ2MdQDwf88UAQR7DdhSrbd+DhuSc9a92160Om/DKC60eUvNsUzANnAKnk9ug7+teLpYM1wjJtBJI5OO+M816z4S8UiPRZtPu3iMRiwdyg9OTnnnkn88H1oAz/AAJrl5q/mWF2pljZOWZgy7djcFe36VzXjDSRp+qyopL5cMVbquexPTP+H5+kafr2naaJX00RRyPuMZBzvbYR6546enTtXKX1q2oyTXN3IjksCMqBzk4yM8j+Q6daAOR8lpLSSRFPyL824jOMH35Pf86rafEGtp5UPKOFCjIznd7+1d/eWkR013nfMZU5wmQOOQfcHHb+lYnhm3AstQ83aZo50BHcffyfTqF/KgDCu7dorqXcCBGcZbOAc8c4x/n8qN1lGbIJ7geg9P513GsafKt0VEsRQYRiV4zuz36nIxg/1rE1nR2Zi8LRfOTwRjHU4PbAAoA14pZLXwlH/Z+d6EMW25P3juwfTn9Pxrf8C69fX7JE7tKxiZS5XO0k9Dxj05wce2eeU8Ia01pPHbXO2SIKyorNu6g8DnpyePf3r1vRb3S7aJLpVSOV93ylFCvk+uTxkHjsMfgAeafE/SY7HWHMakeYwxGCMjlwc4H05rgp3AnQpkP0ZSenXkenYd/rXc+KEudU1Ce4mKmR3ZiigkAfMeGP4DH0zzg1w93bH7XHjbyAeOcc/p9PSgDU0q3+0iYonyKU3dyuSeg7+v4fnTuIxG5DFiQSC2Qc9K3/AA0JEjv0WUoPkJSMdT82OvsSOfWqGuwF70ujgI3Kjaccn3/n0/lQBzeonM6g9lwSO4r3j4bq9v8AD6aexdjdR8hDH8w4TB5Puecdu+cV4deWTNMvlspLAe3Neq/DDUTZ2i21yzbOEGMnBJHI59Wz74FAHX+CPEGpzaukMk8k8RfncQcbmHPOPX/61VfipHHbTwXSrGWZG3eXznAXGeOOO3OK3NE1bTrSSa4hVPMxh8/L3XoSe5PPBzgc+nCeKb+fVdWkmkkOzafLxuXAYememPx+mKAPMHYyug8wklh93gDmuk8NMzyTqNu3yvMJPpuUZ/X9a5uYq7qA20F8sPbIPXPeun8IIrXt4WlKobb5m2g7h5sfp/8AW6UAT3LBLvL70LDCyqpI7YB/FTwPX3JrltcnE1ySGLBslWCHqMdiSa6XVobqeWIQu2FYHKnAA4HPf16dBXPXmlTFk8uWPfNt2qOoyoxnp6igDsPh+Ft9IvprZz9tCL8qL91SfXrxweg/HtoaTqGqrqcflyzM5OAyMSx6dAc+rdjiuc8Kh7Dz4rh0DIBuO7tzkn6Zru49WtIFUxxM78/N90dsdSe3H/66AMT4j2wTTIJJWiBLcgE7mOOeTnpx1+navIZ1xhvlGeMD/P0r0Xx5qEl8gJU7Ay4GfujnHfPY+306V57cS5wqFgq524+v19qAI7ZDJMEGckEcDPY0kq7cDaR7kEZq1oqeZqKLx9xzz7ITU15EJSoRs5Y4OOAP85oAy66nwgcMRFuMmxskDOPQHn2HX/69c+lo7swBAPbdxn/CtvQVazlQkjlxuIx6jvn8KANy1ur/APtTKB/LjdR8hJCj1J6g+/XNbOuWynRnknKkl+FLLwcgZ68c5/yantr61jUny4pXwGUEkH8sjGc/yrnfFWtm/ilCSYQFdw559e5Pvz+lAHCzY8w/LsOfu+ldR8Jcf8LU8G55H9s2fX/rslco3JJyT7mur+Eqlvin4Ox21mzJ/wC/6UAfpRRRRQAV8K/tOqP+FzeIeWBb7N34wLeLivuqvH/jR4Q+HFhaX/jLxjoM99dSPFE7Q3k0ZlchY0HEioowBknAAGevUA+H2iLJ1bjBODVmytZZ3QICZG7A9Dj/ABr6XvPDfwt02y0u41zwJJY2d9fiz+0Nrkk8IUxs/mK8czB/u428HJFdBJ4J+AyaJZauYYDYXrOlu66heM0hT7+ED7vl75HHfFAHz1onhvUpLDzoFZTv27mx0JU/X8/0rldUdUZVLlyVBHzd8DA/DkV9c3Pgr4G6dcW0Ev2OGeeKO4t1Gq3W6SN87HTEnIOCcik+H/w3+D3j7w5Fq+ieHZxbsSjRT3tyskTA9GAlIz0PBPWgD4rnQmdchvmxnPJ/IU9XcrHlflP8IOD9R+f6V9jWPgf4CX0N7LbWkRSygF3Puu75CsOceaAXBKDI+YZAz1qbUfh98HopLaHT9Hs71nv7awlI1e5VY2nGVw28hmxghQcnPUUAfKFvEqaNasEAcswYbwcjccYGfbH1NPs/O3CQxghWXGWwfx5Bx78da+t9E+HPwU1vVZdN0jTorq7j3krHeXextpw219+1sE4OCa6P/hQ/w3xj/hHTj0+33P8A8coA+TIAzxjCSEgHkvuxgAgnB7jB/wD186rafPDbpcsYzE3zLiVC3GMjaDn39efy+n/+FEfDj/oXW/8AA+5/+OUp+BXw6IAPh98A5A/tC64P/fygD5AvNcihm27flTptcdOOR+tVptYKsoiVWAGFy2cDjrzz/Pn8/sYfAf4bjp4cI/7f7n/45QfgP8OCMHw6SP8Ar/uf/jlAHx3HriqcuhHzEcNgDHT8fy/So455H0KMxKBh23YI+X58jBz9BX2QPgN8Nx08OEd/+P8Auf8A45U0PwQ+H0KbIdCljXOcJqN0Of8Av5QB8T6WJ7fVUmiJZUyclthxgcnn5RyD+Fdnp0j/AGgeSimQOCA52gHcvTpnrjv+ma+o2+B3w9aTzG0GUyZzuOo3Wc/XzKswfBvwLBu8rR5gWGM/2jdEjkHgmTg8DkUAfORvdR07T2e4hMUMwO0lsbueFABzxg9T29qoT+MYRLAGQbwzHcJf4SMjPbsOfc+tfUV98JfBl/t+2aZcy7Rhd2pXXH/kSs3/AIUT8Oc5/wCEebP/AF/3X/xygD5a1rXluLeR/wByYlIPyADLZPf8T9M15pqVyst48gXarEsq7sYyc469K+8x8Dfh4EKDQZAh5K/2jdYP4eZUDfAP4asMHw2cZz/x/wB1/wDHKAPiCGZ10+MIuGErHJ4yCoBHX86qyREMTwoIyOQf6193R/Av4dRoVTw+6qTkhdQugM4x/wA9PTik/wCFE/DrGP7AlxnOP7Susf8Ao33NAHxNaNMZo1WNmHDFFbnIJ7564H15q/Ibi0eV5d6x7W25cA8jsNx719nRfBD4fRf6vQ5U/wB3Uboe/wDz19zTp/gn4BuFKz6LcSKRgh9Tuzx/39oA+I31lYAFjBbkne7HPIPuOeTWhZeIi9uxuSxfkAKflA9OvHOT+NfYP/Cgfhpuz/wjZzjGf7Quun/fypF+A3w3X7vh1h/3ELr/AOOUAfIV3r8TwSIpZCy/cjbKqecdTnj/ADmoPDF0sVvqKu21RJGxwcEkBx1J45xX2IPgP8NwxYeHWyf+n+5/+OVLF8Dvh7Fu8rQpE3Y3bdQuhnHT/lp70AfJM0h89lRWYtgb1YHuwJ74xg9ev5VFd3LW6uIYGbAY54A4wc/Tk/jx3r6/f4LeA3YF9HuWIUKCdTuzgDoP9b05oX4LeA0zt0e4GeuNTu//AI7QB8ISEx3G7cq5IYquRgEnPc9jXTz+InhtljZN5VSCpfIUk9sYz0zxgfrX2LefBH4f3rl7zRJ53P8AFLqV0x/My1CfgN8Nz18OE/W/uf8A45QB8TPrd1NE6SKCSpBcE5OQe34/yrOmnea4VtueABzyMdK+6R8BvhsM48OHn/p/uf8A45Tl+BHw4TOzw6y5GDi/uRn/AMiUAfGXhu7LTT2xDBZAsnBbGVzj/wBC7/1pL9FRwZI5PO5UuxHzgcBumeuPy65r7Xtfgv4DtYpo7fRpo45seYi6jdYfGcZHmdsn8z6mn3fwb8C3aotxosroi7FX7fcgAZJwB5nqSaAPhHUnBuA4Q4I6sxJJ5zk/jXVeHyf7NikMj5PIBHQDjH6V9er8EPh8hBXQpOP+ohdH0/6aew/KpD8F/ARgEP8AYbiIDaFF/cjj0/1lAHyNc+IJoABauzHG0N5hwuFHTk/05/CsB9akd5ImjBVlK4GFI44PU+v6V9nt8CPhwxy3h0njH/H/AHP/AMcpB8B/hwDkeHSD0yL+5/8AjlAHwpsbzBtVTg55Pbiuu8KzSSz3EbLt/wBGO5d2d4Voznr6A/lx1r69/wCFDfDfIP8Awjhz/wBf9z/8cq1D8FvAMM0ksehuskiFHb7fcnI44/1nsPyoA+RVlczSiRMICAshJG4nHA9ef5iqWqusE0LhSWwCSeQMjnbk9QR1x6Zx0r7Jf4NeBHjKPo0rITnDahcn2/56Uz/hSvgHDD+w5NrcEf2hc4P4eZQB8Z6Xc7PtEjSvgKNwYgFhj9eeBn196g1HWlRAkGRIVzuIxyCOgz06/wD16+0pfgn8P5UkR9CcpIcsv2+5AJ+nmVVPwE+GpGD4b4/6/rn/AOOUAfBU17M5k3u7O3qQQSe/+c1Xa3kOCF6jPYV98n9n34Yk5Phnn/r/ALr/AOO0q/AD4Zo+9fDRDev2+6/+OUAfCGk+bDqNu0YaNwGO5Tz905+nFX2Ro4somdpwxweM8gZH0r7kX4C/DZZBIvhwhhwD9vuf/jlSL8C/h0oAXw7gAkgfbrnAJ/7ae1AHwgiOJtoGzABOODz/APqNWrY4w7R7mPGW6cjAOc/59K+4h8B/huG3f8I5znOft1z/APHKP+FD/DjAH/COnA5A+33P/wAcoA+JL3UAIpUmDCfbwdxx0Xnn2B5+lc758kkhy5OTkHv/ADr77f4B/DV/veG8/W+uf/jlRf8ADPnww/6Fn/yfuv8A45QB8Gx2DyFQmefXHH611nwssJIPih4RL541iyOR0/1yHrX2WvwF+Gy/d8N4/wC3+54/8iVd0z4MeAdM1Kzv7HQfKu7OaOeCT7ZcNsdG3KcGQg4I6HigD0OiiigArhviJrOgXNhdaHc+LvD2kX25POh1FredSuA2ySCRhlWBB7HoQa7mvhD9po4+N3iMDr/o3/pNFQB7V4c8MeBNEvLC8i+InhlZoNYXVpYreaCG3O2JoxHHEJT5Y+bJOWzjpUqaJ4Ts2hutJ+KHhy11OK61CZZnkglj8q7ILxmMzDlcDDAj3BHFfH4kOOU5PGM9/wDIpkrKdof75x8v+eKAPt7wLF4C8H63He2Xj7QZoI9Ig0pIZL6Dd+7dmMhfzP4i33cDFXPh1qPhTwf4MHhx/iN4evLeHzEtJ47uCGSGNiSAT5jBmBY/NgDpx6/DAwwJG0qT278UrnBBwCB+eaAPrTwvoHhzQNSvtQh+LHhWfUZtIk0oTyiF2y8iv50u64PmPhSMHAOR2GDa0bw94J0bRdN0ax+Jfh86Vp2t2mtW6Sz27ShosF42cSjcHIyDtyvT5hjHx8zMHGAB069+vH8qf5hKKwwjds8fSgD7M8A2Pg/wn4ruNYHxJ8OvDLHIn2G0uoraF2dt29085kLDtsVBz07V6cPH3g5hkeLPD5HqNSh/+Kr85UY5DdSDwBxj681KkhAAZmYDpz6UAfot/wAJ54QwD/wlegYPGf7Rh/8AiqZ/wsHwZkj/AIS7w9n/ALCUP/xVfnl9oYOA3pg8kVAG/ehjnbnJ55oA/RY+PvB3/Q2eH/8AwYw//FVKnjbwq67k8TaGy+ov4iP/AEKvzvaUeVkhMgcgHPP4dq04tcKMm2JQm1UAAyePf8ff/EA+/v8AhNPC3/Qy6J/4Hxf/ABVB8aeFgMnxLomP+v8Ai/8Aiq+DE1sEDMQzxn5sfpWXeao8jzAbPLbnAPTpx79Af8mgD9AE+IHg12Cp4t8PMx4AGpQkn/x6ph428Kcf8VNofJwP9Pi5P/fXtX5x20wFwDyq4B4GRg/jXSWmoJb3UwkaSYHG1iuD2B79/wCnNAH3wnjbwq+7Z4m0NtpwcX8Rwf8Avql/4TPwvjP/AAkmi4/6/ov/AIqvhWLU0jsvNyC5Lbc8k9+2cdeB9Oa0PtqmODDAK33M4GffHX/P40Afbf8AwmXhjn/io9F9P+P6L/4qq7+P/ByMVfxZ4fVh2OpQg/8AoVfGF7rDrbSmWZlic73QcFs+o/z09q8z1e6E12zsuSTkc8eg49KAP0a/4WF4L/6G/wAO/wDgzh/+Kpp+IvgkHB8Y+GwfT+1IP/iq/OGe4X5Rghl649fSqqEtJwBk9ugoA/SgfETwSWIHjDw4SO39pwf/ABVKfiH4KUZPi/w4B6nU4P8A4qvzgBwWUsSRxkkj156/pU7yEZCk5AJAHOeKAP0Z/wCFheC/+hv8O/8Agzh/+KqWLx14SmBMXinQZAO66hCf/Zq/N+KbByVwSMZxyevGP84rpNF1M20LoyKQWyEyR2z/AEoA/QE+MPDKjJ8RaMB6m+i/+KqNfG/hRywXxPoTFeCBqERx/wCPV8PXGueZbyfv5d4G1cEA4weB7HpWBZ6m9ubptqks4wApwPbH40AfoC3jbwqgy/ibQ1HvfxD/ANmqJvHvg9Pv+K/D69+dRhHv/er4IvtWeRtqqVjIZcHgkevXsB/nNZtzMXQFtpHTkcd+mDxzmgD9BP8AhY/gf/ocvDf/AINIP/iqlXx94OYZXxZ4fI9tSh/+Kr81pW2THaCoHGDXT6fqk8NssQcnecA56AgjigD9Ah4/8HHOPFnh844P/Eyh/wDiqRviB4NU4bxb4eB99Sh/+Kr88mupGkdpHJ3PuOPfv6elVbmZ2dWIBJGAoNAH6Lr4/wDBzfd8W+Hz9NSh/wDiqT/hYXgv/ob/AA7/AODOH/4qvzuW4cH+Enrz/n8KhuJJHbKqo7k9c9fegD9FW+IvglThvGPhsH31SD/4qnp8QPBrjKeLfDzAc5GpQn/2avzavEZJCSAQe47f5xWzpl5JBbERhQhQBl/vZ9fbt60AfoafH3g4Zz4s8P8AHJ/4mUP/AMVQPH3g49PFnh89/wDkJQ//ABVfA1nqspaT96DuO8napycdBzwOn07elVDdyM0khIZWUhs5OeR0zzx/TmgD9AT8Q/BY6+L/AA6P+4nB/wDFU8ePvBxGR4s8P4/7CUP/AMVX5zSMRjCjlsHnp7davWtwREY1wNxHGTx7j8CeuaAP0K/4T/wd/wBDb4f/APBlD/8AFUjfEHwYv3vF3h0fXU4f/iq/PMySmUN0GcYx06dvyqCVvmd3IYgngdP/ANVAH6Ir8RfBLHC+MfDZPtqkH/xVKfiH4L/6G/w7/wCDOD/4qvznSQiaQIoySM55FStNK0aqjsVQHA6gc/pzQB+iJ+IvggdfGPhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FV+bzuzbgWDqRgAHvnjiq59sfhQB+lP/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VX5q0UAfpV/wsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVX5q09MhlIIHPtQB+k/8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVX5u+ZIsRjZmBUZHXjOKhbdgbs47Z/wA/SgD9KP8AhY/gf/ocvDf/AINIP/iqltPH3g68uobWz8WeH57md1jiii1GF3kdjgKqhskkkAAV+aFdX8J/+Sp+Df8AsNWX/o9KAP0pooooAK+Ef2mf+S3eJP8At2/9Joq+7q+DP2m5QPjj4kBzx9n/APSWH/GgDzGSQKM5OCOwz+vSozLuaEHqeSvT8ajmkJiXfz6Ecc46/r+lLZYduVHUdgOnv+PWgCzEoLSBRzu/M4FSFSjANgH37V0nhbQhqEsUjFQhbDKp27gACBn3yfx/Tb8W+CX02zjniBZSisVQZwScdck9vTt+QB520QDggKSBw2fb9aacAkOx6Z4yOKeRgqAO3BGOBTN27IGRgY3Hjr/LtQAqhNuTjjqW9fxpQMHPAQDPpUMb7SQzKrHoSc8fn/XvT0mLMmGUN/FjtQBMgJkUAA5POTU0ULE7iSoAyPlOT9OKXT5VS7DOMgMOAOMehGea9K8E29jPIxliTO1ScjAH3eDnk9fpz75oA83ktJxu3AkqA5HOcHv/ACqNl2kYZS5Ofl+vavaPGHhOG4szMFVSo42BOVHXGMnuf1FeP6nDLa7VeLBxwSAe/wD+ugCqilpcEhu5IJwfxqMlQGPQDnvTA4Lt8oAUcEf54pIm/fycLjuGHJ/+tQBHBIdwVuuM5AJz2/zmrsckhkIySepB5GPf8MVVKhSDtG9j1x0P8/8APatLSbiCG6kMpXfsypBHBBHseeKALUGn3lyGkhjZ0Uknb03AA46c/wCfSo5LO9to3a6jmTDbSrqVIzx6djgV1lr4ht7G3jChZI3UZI25xlT6f/W68Vuxaxaa3BKs0OyMrtCqVLA56kY+vPofc0AeTXtzIIxswqceuKyXbzHZmIBNdJ4m01dPvJY1RCucgKOepz1+n8q5pCM8nGRjPpQA6VQNoDKSBjAzTVJ3Ft2D1570sq7ZD6Z49xTo1DSkZGOfu85+lAE0PmPIxViUy2cZ/lWraaFf34zDbyMmMbkU7eAe/bv+VU7CWOEncmQo+bK47HrzXX2njI2LvHapF5W3B4B4546dOlAGBLoGp2kQlnt5lh4O7aSBkE8nHpzjrVBJSqktwMHnBGf84r1DSfGsU5htp4YfLIAYuFIAx7nr7+uKwvGWg29oiXNlLEY5OcH5SeB049c/l7UAciszZHmEkdNoOM0NOVymFw3VsHn3zVcZiblTksQueR36f54qKbKgmUKT1IHqc8en+fegCUXJMjEPvXPQZ5JP/wCv86tQx+fuCqvRuDkdjVFAJJtvysDjIyMfX9f1rc06VLV8zANGSdy5GT6fqBQBQfQb+af93A53How249smr91oWo2aq0lu6RnoSMAr61tr4oltpBE0UR29xjAx/Pv+Y/HpLbxhDcILeS2jK7GTcVUcDkEjocZIxz0oA8sYlZCr9SSBxVSaUl1Cud2RkjOPy713njLQrVImu7F4jE3JVSOOR1GO30Ga4B9wuCTtRlJPsef1oAm89SG+cqu7nAPPHf8ADimvcsJCM8ZJIx356+tR7Dg4VQSwznHHX9P8KIUBmI3L17dxg5oAfNGZJCANvJxnPPTnp0rotK0S6uV3QW0kmAMYQkYJC46dcmoJwltcbJIsOgfcuM84Pse/8q73w54kit7dT5QZ2PzZ299o46nqevT+dAHJahpN5pse67tZYo2G5T5eAenftjPX1FY07GG52hsMQO2OwPFe0R61pl6ypcQqxBDoZI1YAdQc9RnA6Vx3i3w3DBI02n/cdcrtAIJ4zgg9s/0+oB57K+5kO8bS3OeuetWDIMfIdvPJHcj+VVrlfLHlxkBieNpwKkZ1LMcDnJ49qAEF4MkrnldvTr0GP5VIS7upA3EEEDGfrVeONVuQXOM8Akj2+ldjpNpa/ZYSVTzORhBkDDDPr7enB/GgDBt9LuHOI4GKkjaUXhv5Cn3unSwxI0kbbTlSOcg+n8+nFemaBPDFcN5sYZtmQxx8uMnj3PFaeoQafdWhjZFjV138RDr8pGeCe4/OgDwKVPnYqCAD0I4B4/Cq9dt4q0NbCeRlIwpYDB54bPA6nt+VcfOu0jPBxyMAdz/hQBEaCSevNK/UcY4H8qbQAuf1q1b20u9XCsMEZ3KRwf8AJqTTrfcwZjtJ4Ga9H8P6NEt2qn5nLAdeox14HHT3x60AedSwvtA8uMkcHIIxn/8AVVOTDFcBVwB0zXuGq+FLCSxl8n7yxEpnBXgg8EDHr+f1rynW9JfTpSC0R5yvY4H+fpQBgV1fwn/5Kn4N/wCw1Zf+j0rlycrnCjGBx1NdR8J/+SpeDfX+2rL/ANHpQB+lNFFFABXwV+08MfG3xNnOCbU/h9mhyf0r71r4Q/aZTd8bvEmAOlvnjk/6NF/n8KAPJHjcIowWOcKcnp9P89KfaRu7qemcbT69sVM0QIPXJ6nNT2iIsyD5V5AycY/E/wBaAOm8Pat/Y8YaNWaVW5Q52k4HcH69q6DXfHVzqWmxwOi7gMYOcAZzj06gen8xXBxo/l741IjzwSv3iP8ADjpSwRicbY0ckjKqADz/ADx70AUbybLl1iAB5ABI5z+tQRplFAVkXBz9cj/Crd5byxsPORgWwwJGMg9x+dVoV24LDOF6D/E/yoAgWQgYwwIY5G4kn2/WpCrBUz8wxwWHOT6/rUiRpIzERls9Pk6n2qeNN4IaN84yB+WKAH6VC81xGgV9x64OSPeu/wDBV/Dp9xi7bfLgqEAyw+7+uM8fh2rjNLiHnwjLJuOQRkcnp09+9aEDym5aS3hZVUJ8pYN3XC5OcfzFAHr+veO9Oj0aKKBBKi7d0hc+g7kdcnjHb61494kvDeMX3bkzuA565GSfqf8A9VW4z/aDbDEVnXClsjDHoc8cHr0/pVHUdP8AJizuQBeTlhxj0HU/l6H2ABgIhkl4UBh0YjjqB/Wo4w4dgQMZzwePxq5ZlVnZnBIPXA9xTM+XOWCsCT0zjH+FAFQbvtCLuOCQ3ORnpkdenep4AxmIQ4GOMc9PXvTYl3uqYKkkDoO39Kt25QTFvuqF79e3+FAHRaLpsbLBczykEtlcdDj+Z4NdrbXmk6baMsIAwN4xuDAc52nHGBjvznqa88N2srv5bttwp2so9Bx0Axx+gqRpJL1wkas+eeVxjnPIGOckjJ9e1ADfFmoRajM0y5cH5BvHzHkjlv5fyFca24uSwBz3xgGul1i18tNksRhcHODIpJBJwRjntXOuyiY8KVGQNo/KgBjqVA4GD0I70yrNySXGQSSMYI6f41CoUHDhgRnv+lAE1tu8zaWbGOxPcV1FhoHnhXeZV+8vyZYg+5+grmbZ1Mg2xDIHOD7Vqx3I81mI52tgbtvUHpge/Tj0oA7bQPDthFI08t6pZAApC9OTk49eOvb8sHii/szphgErXCpu8vcemQMAHGO49uw9+Vt7tvNjLZ2KAFOVyPmJHUf41YvNPlXTQ06rGCN6q8qgnrkhTz6D8D+ABzvm7r1jsYgAj2xg9v8APSmTtt2kZABIGH4P+ferhjVrktGhcLuJA9MH/wCv9Kj2jZtaPYQ2Qvp/nigCCFSlw20FR1GDWnDGkiCR2X0IJJPO48Dn0/lUf2Uxuu4MBjIGMYHHUHirSCOKLPDqVI6AnO084z7nn2/CgB1pp8Uspaa5EYGSAsZJ457fzrq08LQJ5VympKspJ2qQ3AJ9Rye4/PmuAa4UuTjAzt4+nIH5V04ullt4trSsPMI2Eq2c56Y5Oc/qRQBoeJb+G1smtldpt7uwLA8EH278fpz7+e3MhkvFKg8sCAMHPNdFeWpaV8lVhViAWZUIIAyBljmsG9WOG8SNPuqecYI69Rjr0oAZg4OODuAOTyOT6fX+dIjf6Qxbn5sDnOOvatCNGm3EIS5b5No/oB9KaYd0o2ocjK/Mcbv5EetACXUgeQspCEltoXnA56Z5PWu98N2VotqRdyspGcZycsG9D9PavPdREa4Kpt55Bzk/5FdV4dv4WtgpQjAGdq849+cnrgcUAejx6Fpv2Z5UdgRH+7KkYXgEY564Gf6Dtj+Lbu205IoE3PIqlmXDYAO0Dk8ADA79u/fNhubd1MmWZVTJUNg9OOvb64+tVLu0W9ePE0aDaSN7qoboTgnp9c8D1oA4GdmeWHBOCfyGR/jVrypAMsoUDPJ9f8/hSanDDazLGJ43ZGB3RlWjPGeCPrgjtW9aWouxGTCygFjhEVS2PT2HHJ/AcZoA50gLMGC4YcHjH/1+1bumXiL+5Z9oLAHLH1XPUcfp06nAp8mmRNPGF8wbkA3yKRhj6jHPYd+vequoQi2T5oWUnqSgBJ4zz3HA9cZ79SAd9oVxY2bFZl37FC4IDdB09s8f4iui/teyjgHlgLsQLtJ+bAOO/XucfWvELO+aK6aQN8wxyvYgf5/Wt+11yD7PF5odcAE4HP04xjtx/wDroA1vGmpWkguEj3OCWOV3DnjGR6df89PM7uVpJmJ4BOcYxmuguZoJ/NLsiEHKk4AxwMDAx681latBawOggnEpKAgowYD2PA9KAKTgkAYYnAxzkDgUxSQVx2ORzUilZWjTZjsSvf3proVwNjA8nmgCayuDDKOuOw68132geIvKmhBBeUkFSAACSTnOD0xivOnUgKcHBHcYp0czxghDjPH8v8KAPaJPF7wx/u4w0flKcY+g9vUcemOnfgvFGtyalN5nlYOSSu455/D6ViR6ptXB3gYA4CnA46flUM1xFKxGWVT3wM+4oApO27B74xXV/CkAfFTwZg5/4nFln6+elYEqWSRoVeV3bqFIAXp/9et74U7f+Fq+Dtmdv9s2WM9f9elAH6UUUUUAFfCv7SoJ+NfiQbSc/ZsEAZH+jQ/jX3VXkXxh8KeAdNS58Y+K/DtxfvNPBDeXEN1MvlqdsayMokACjCA4GfrQB8TuQtvzHhmPX1/WooQWYbRjnHzcc5r67ufA3wbtdb16wvdBNvb6NHA11evf3HleZMMpEuJcs5GDgDuO5pr+D/gDbWFtfzCxgt7hpVjkl1K6QlosB1IaTIZdy/KeeRxQB8s6dPbWsgW5cuDySoztGMjBHOc4Ht/J0mvSIIv7Oi+y4zuOFYt6ZyPT+dfSVt4e+DGoNfx6Z4eDXFjqqaXMl1qVxCGLMq+Yh8xtwJbABwSQeB1rbuPAvwNt9Vu9OltLcXloJDOq3t2wjMaF3UsH27lVWJXOcA8UAfHE5e5uWmuSHduckc/4Utt5jMe+4cdOeePavrDU/C/wYj02O80fQP7TYahbadNCL+7heFp22qzK7A46kcc4ODW5r3ww+GejeK/DOhP4TaQ641ygm/tK5Ah8mLzSSN/OcY6igD44hjYnKEjbzxz14q/aLMbaXZAWxGQflJwMg/8AstfW2keEfgfcR6hNp0doyWELXM7i/ugFiGVMikv8yZ43LkZ70afoXwOmstSvbN7FrbTY1+1SfbrnCI5+Xq/zAnoRnJwBQB8mR7fKDTRg4O0KT147jdnjgjg81NBqNraTKCrlvLQkLhuflJ5J9v17V9h6B8NfhR4phmn0jThepbyeVL/pt2DG+AdrBnBBwQcGsGHwX8C57q7iS1jE1lC9xKGu71cRocM4y43KvcrnHWgD5bm8U6gkATTWaxLE7zEQSwz3/X86y7qS5nne4umaSd/mZ2PJPrX1zqfgX4Pwwr/Z2lWd832i1gkA1a5VUE5HlndvIJIOQvf2rSsPA3wcvtafQbCzjmvo5JIzDFeXe3eo+dd4faWAByM5HNAHxtp8T+bJmJwduc49xyfwohAaTdtwFPQcg8f56etfdcfwS+H0RJj0AqSMEi+uQcf9/KYvwO+HituXw+Q3XP2654/8iUAfCMYxNg/KAc4PH86C7RzMSMHaCMNnrX3SfgN8NjJv/wCEcO7/AK/7n/45S/8AChvhvk/8U4eev+n3PP8A5EoA+GpruOMnarl22k/L9M/1ot9e1G0jQ2c01qQ+7fA5UsD/APqFfch+Avw2JyfDhz/1/wBz/wDHKP8AhQ3w34/4pw8f9P8Ac/8AxygD4PvZZrwTTzmSWeQ/O0hyW565z9azefMYEAZyCB0r9A3+A/w3cYbw6T9b+5/+OVGfgB8M94f/AIRr5h3+33X/AMcoA+DdyiZchAAowf8AJ/zmmhfMmJMYIHU4xk9PX2r72HwE+GwYEeHGyMf8xC67f9tKR/gH8NXYFvDjEj/qIXX/AMcoA+BchJcrhiQd3PHvVkuoHB+6u7jpX3d/wz78Mc5/4Ro+n/IQuv8A47S/8KA+GfH/ABTZ46f8TC64/wDItAHwhHqd2kQSGR4h1O1sZAyf8ankurm/Yy3ksrvtADO+47QOAPavun/hQPw0/wChcb/wY3X/AMdpyfAT4bJ93w4R3/4/7r/45QB8P2UUm/aEGSkmcjnHlnP6ZployguVQ5ODgDjP1r7qh+B3w8hfdF4fZW55+33Pf/tp701PgX8OkGB4eb8b+5P85KAPjKW2eafEKlYcZQcAng44J/2evoM1WvyskASLspB3FRgckc59Oo9fcmvt6b4L+ApowkmhMVHb7dcDP1/ec1Vb4E/Dluvh5j/2/wBz/wDHKAPgG6UJJ8jjbu6KemMc4rT8+bZGu9wqHKDPQ56j0r7kP7P3wxPXw0T9dQuv/jtSj4DfDcLtHh1sehv7o/8AtSgD4QnlmuZme6d5iMqCzbuPQc+1RPk3VuqqOdqhWxjOfrx1r7yX4B/DVSSPDhH/AG/3X/xynH4C/DYyI/8AwjrbkIKkahdcEdP+WlAHxNYopSXdGHlLjtjdgn8T17Y/StBohJMZJLZvnOGRVPBw2BjI7YJ9fbpX2fD8D/h5CQY/D7D5g3/H9cnkd+ZKnHwZ8BKWI0HBOeftlxnnP/TTj7x/OgD4P8SRrJdNhTGv3sHqvA7fgOOnpU+mwW62hl8xRl8BUUFvqRnpX23P8BfhvPI0k3h13dupbUbo/wDtWnQ/Af4cQgeV4edcHIxqF1x/5EoA+N2uZpZEVYmMSkAAKc7fcA4PHb61WmuHuY4Uw7uFYku2AO+R+C19rL8D/h6pJGgyZJ3E/wBoXXJ9f9ZSf8KO+HvP/Ehl5zn/AImN1znr/wAtKAPgyfAbLKobdjGff/P5V2thZ+Wv71FQo5KhPu4wO34A888V9bt8A/hs3Xw63/gwuv8A47V2H4LeAoTlNEk6k839yev1koA+T1s/MnUQRF5GUN90ZJx/+uszWIke2feh3qByI8nGTwT6df8APFfaFv8ACrwbbszQ6Qysw2k/a5zx/wB91lXXwL+HV1K0k/h93dup/tC6GfykoA+Dtqq0pzuJ6ADAzn1x0pf+Wa5JJ+nFfdI/Z/8AhmOnhth9NQuv/jtL/wAKC+Gn/QuN/wCDC6/+O0AfBdxubKoCy55ycDtx+naq0qFAMgfNznFfff8Awz98Msg/8I0cjp/xMLrj/wAi0n/DPnww/wChZ/8AJ+6/+OUAfA8OBICzDjBwO/H5VrW1pNKD5SNI3XgA5+v6V9x/8M/fDHIP/CMnPr/aF1/8dq5b/BD4e26FIdAZAcZxf3OTj38ygD4Omt5YUQzRmNGXcOmSD3GD9azphAOVY5BztHQ/4V99XHwE+G1zJ5k/h1pHxjc2oXRP/o2ov+GfPhh/0LP/AJP3X/xygD4DbAGOMimV9/8A/DPnww/6Fn/yfuv/AI5R/wAM+fDD/oWf/J+6/wDjlAHwBXV/Cf8A5Kn4N/7DVl/6PSvtT/hnz4Yf9Cz/AOT91/8AHKt6T8Dfh1pGq2epaf4e8m9s5kuIJPtty2yRGDKcGQg4IHBGKAPSqKKKACsrxVolt4l8N6not8P9Gvrd4HIGSu4YDD3BwR7itWvhf9pKISfGzxLyd3+jAY/69YutAH0XZ/BWCL4dnw7da7cXOptqCam2qtDy0yYCboyxyoRQu3d78Vf8L/Cs6L4g0LVpNTtHl02e9uHitrAwJM1xFFHnmVyCPKySS2c44xXwxJGi24OHD5PBbI7cYxwev6VW3BwpAxxnigD7su/hVcTT6qia+qaffa9F4gEDWW545lZCyb/MGVIQAfKMe9Sn4a6rbQa3p+j+LZdP0bVJ7q7MUdkpuIpZ1bO2feDtDENjaG4xur4ShXJOFG7H65FPkjRYwQcv3w2f/wBVAH2hpXwRez+3NLr8DSXd7pt43k6cY1BtGc4wZWJL7uWJ4OTzmu88WeDo/EfiXw5qk92YotJ+1h4BHkzieAxEbsjbjOehz7da/Oz5d/q2OKmjXe21hjHHHHfHNAH2xb/BiQaTdWN54ja4VdEl0HT2FkE+zQOwJaTD/vX4UZ+UYB4yc0zx58K7i7hudT066nutRisdPtrW2hgjDebbTbhITJIqsCCcoSvT71fHdppy7Wld8gBsDuxCk4xW7ZafbtaxOy9VDEdM5A49v0/kKAPsX4M6Br+kWviK+8Vxxw6jq+pteeUu3Kr5aKMhGZQSVPAZsDHJrC0D4O6louurq8XitLnUIre6t4rm500ySsZjw8zGX94V9MKD6DnPyqdJQtHIu6LIO4bs4J7frj/9ea5tLV1vdjRyZXhgFxnOOMYPPP60AfaWj/BddH8OJoNjrzf2ZHqdpqsYls1Mgli2mQFgwyHKjHHydORWn4a+F8mi/EGbxMut7YpJJ5GsrS2a3Scy/wDPYeYUcr1BVEJOCc18VXOkxsitbLK+BhhxxyR93r/nvWiNGiIIOVB6kEZzkHj9Bnjp05oA/Q+ivzuh8PoZCMnyyCeBnoRj8cE1Un0ERR3MjOzqisUAOTwBgnj69PbrQB+jlFfmhpdh9rumjAxtBJyeB/k/5NTPpxWRgIGZVcpkZx19f0oA/SmivzYh0ppGZURmCMQSc8+3TjmtJPDiOIsrMSybm2LkLyM5P44+v5UAforRX5wzaP8AuHcIECMV75xzyTj/APX+lc9PCftKxsrFSe44474oA/T+ivzCmt0MoAJJx2yMnt/IVWWGPe2UI28459P17/lQB+o1Ffl1EpYlQhDMPvAk89PzqxLEVlIOCAD6nj06e1AH6e0V+YtvBHK4ADgAHPzkHqea0bfS82gZdxYFf3fOeQf88ZoA/Smivzrn0m4S2xhXOGb5epPoCBk/5+tU7Wwha0YyKyOsmwk5wOR1B47H0/WgD9IKK/OT+zI7hpUhWVXBQbWzz659uM/0rPvbZIIQQ4Ix0Gc9uTkDrx/nmgD9K6K/LYxbbtCF+Ut0B6dK6jSrG1uCDLEzLhj1ccDGCMdevr/9cA/SGivzcvtMRR5kVuyRgnI3MQuRxywz6/mKzpiv25fMy4yoO49egx7UAfppRX5vQW0TWoATZIHDbmxt2kgZ69ueRVB4EIO0DJ4BJ7/5zQB+mFFflzfRlZcyAkdPl4wPy/zmum8Pxx7d6Da6EE85zyMcAjgHBOfTrzwAfpBRX58WtjbSjzLiFw5AyGLAZx1PfufXoKlvNO0827C3thG4UgEMx/hUDI5z0P50AfoFRX5kTYCJwOpJx/TtXYWttFazu8YEaOQgDHHbtnnqPX+QyAfoPRX563os43dplUOy7QBjPUnIH1J5Pf61zl1bsFaUBpB0BAOByR6Dg4oA/S2ivzJtlTDtKvLdMDvg/T2+laGnwQ+dH58aLErYztwGI/DHpn2oA/SaivzU1yG3XmK3jjPOQUG4Hc3BAHHH9KwpimG3bS5B6Dp6dRmgD9SKK/LRo8sp24jKDJA9uTTJIzG5UgE4yD7UAfqdRX5XhS5yqsRjt+GatQkfdeEYOME4OCf/ANVAH6jUV+XkkQ4bCnA6bc/pmppVja2WPykVsfeCAevPr6f/AKqAP09or8rnXao65POCP616p+y62fjt4a4Az9q/D/RZqAPv2iiigAr4T/aVdf8Ahd/iVWP/AD7Zx/17RY4r7sr4P/aZ4+N/iQbsEm2I5/6doaAPMpZSIyG+6Tzjj/8AVSQQO+3ygzHGMDnv0xVq2jUo7SKcLgbF4J5HHT6/pWn4Vtlm1SFmBbGCAvf2+6fp/wDXoAy2tbhFYNE4Gccjv/kH9agLAouevv8AhxXvUOi2L2ckckMchVWX5gGJ+Ye2ARk/TGK8R1mzazuJIHCiQEqcdBwOxH1oAypXCzx7sd+vYf5FWbC5YXCPGCCuGzwcEEEf5NZ8zjfyASCcggdPTj8au2YaSfyo1LFl5wO+R7df8aANOwvCgK72ZWVg/OABjH48mty01SEqBIyRZUltg9COCMcce9cvGxUHAVsHA46/596vqrC2iZ4mjDDghSN3Tt/X3NAHZQxPPLGICGdn8sDqM5HH9KzdZ8P6haXP2gw7VO0ZTjnC+n6c9M103wxthfapbSzRmRkOWyuQ3zDrxyMY/L2r2S50C1lsxEbeNtoIO5fvY/vYHTOOefz5oA+Z471iUDW8bqdoZmXHyg4PXjr06CujguynkgbWZsMAMNnHocdOf5VgeMbT7Bq06Qo/locglskZJ9sYPWsl9Xnl2bzubPUAfljH/wCugD0jR9Rt0kMdyFwEYkHac5K9sZ6+569hWNqM8ctrcyxBRGUbBXpjB7gDP/1jXPaJfvLdzkqzgRliFHXLrngDrSahdsolj8qRhJuG5wPmAwOPl68D6cd6AK2iSgajvbkA846Drz9K73QtFuNZMkaoj/vAAuMgjPGfTgH9Pw8ys7gQTCUAhuo9vwx64r6A+AMcWpyzzXUbKp2hXPXPIOOMc8f/AKuaAJr/AMBXdtoLSRLFLId2NsYyfmx8pxk+vXvXLXQL6taRxxRD9wylFwAThsjj3yPz+tfTE0Vvc3TW0oTI3N/CCSQD06n6+w6185/FExaJ4nCgRCFkBBVQRklwT04yQenqDQBUe1+02c3mNbB0fcSoVRj5uhAHU+v9a8t1psa4WZgQrYO1+wx7fh/jXUXWvQxW7Lu3gFgNq46+pxz/APXrgdQunuNQ3ElzknJ4zxQBrXwRZDJmKRWyRt5C8+ntgdD3rDdn8xlOVRuAffpV25lMuwHIweuOv/1uKpGdAzbh8wwf/wBR/wA9aAOh8L6JLql46Qq5YRsSeGHQ+vHf9Py7zXvh3cvJM8cjtMULbZEII5OPcAAGtT9m/TrTU7q6kvISyRDdvVScYDd8fXgda7DXL0XXjOa0s4kaNdwGNzHhjn8xyQfX16gHzhJBcaff+RNEwcEqQ3HfGefoa7Dw9GZbPDxhm3qRuwmMqPX1z1rofjp4fh0q6tLyCJlSclnwmBuJbvj2IwfSvPtF1VbKPypSdpJPXgZHsM/X60Aema3ZwrZqfOt1nw7JgjB5Jz6ngYA9xzXK6aiNbyKUZQr4HmIFLdDn69Krza/BcXDKFMiurkiVhkHDcHj2/HIrLs72O3gYOCjMwJ2LuIAPGc5HsMf/AKwDavS5mj2hRuZcMqc5zjBwOnPqO9OTSHv5baDyxvYkORwMkDJP44P5/SsO+1SIk/JvJIb5sZXoSAMfhk56V6z8B7S11zUrm4uY1IhUvh/m2884yD247fSgDgLz4dXwvSgIWUEN86YUnjv179ME/wA6rizu9PnukaNYkRWOWPPTg4/I8j16V2vjfxOI/iQLSJY2td0ajOGK5xnPBzxg9ulafxK0WI+GLLU0UEfMrvtGOmOSFzkZGPb2oA8qtmtWt4g4Tc0oZicKVHHboV68cf1rEuIit1vRsldrZHUZxx3/AM/lUYufJJBJAHJ3dMk9M1AbrN9Eg3bd6rgHB25HFAHYQSwxW8EbPmRGG75fu/PyenAzjqenPtXNXJk+0439BygI5GBj2z7fnVqOT93E4DB1Icknjrweg6VUmaOOYOWUDvz09+nvmgCN4Gmu0hjUO7EIASOTwAPzr1/w54Gv5dKjmOFjAJAUY3gsMHgE9D15x79K5v4QaRB4j8VRwXEW8hXZVC8jAQ9AOBycHjvXrmteK7XRdfTR7eEtDFxujIVQMqMHI46nntQB5HrNneWOpRxygRAYUh1APPdSeuRyMccd6iS8UELLLEqnJXJKknoeD7g9/wCteq/EvR7fVfD/APaVjGFuI1Lb06tkdDjuDzz0PpXgd3I0V0yyqjEA/OehBHUZHOR3/H3oArXELGcbQNpUYK8jp/8AXrptHiRIDK2UY5JLegyMZx6gn8s1x1xOoUMGTbjgA9efp/KuhtbjyplXbIu1mJwx4x1BwvTA5B70AWdbWSZowjFjjKRqhDHg55/L/wCt3oiDF40BIeNT5Zx1b5z0z9en/wBeo7+5Elwxk4dV2nIwScnrwOeg/Cus+GVpDr3iK2t5RvYOoO4jLlnPqPc/UdaAJNB8EXF1p7zrCrIuSV3EsDgdccDnPXtiuf8AFdk2myqrqsUpb7uw4I6DB6Ecdv68fRmpSxaHeDTLa1TCgq/HXg4OeMj/ABxxiuN+Kvhe3uNJ+2W6R8lSMEnH3jxweP6ZoA8F81hE4MikMDn5c46/49e1Zt8pd9yrwAAAPqafceZHNNGDlc4Djp25HHSq0029dg6Due9AAiqYW+Zc5HXPofakkc+UEbk5znjHeo8ZGRgn0ApX5bgg9zjP9aAHQRs7AcAHjJH4d67LSfC9zfKsioNp5wVOcZ5OBXPeG4luNUgjkKhdw6rndyODge1fXnhfw7p9hpUDXEe+Y4JOM7BzwVwOcHP4mgD5Q1e0m05pILgMGVcnAwOnv34rNe4CquSW7ZY89/619AfG/wAEx29gb+AR+UW3lwo+Yk5I6DgenrjPQV87XWElIQY4HQ/0oAfMPMBYqcZ4HTHrn/PFemfsvD/i+/hrHA/0ruD/AMu0teVl2IIJ4PNepfsuf8l28M/9vX/pLLQB9/0UUUAFfCP7TYJ+NviE4XA+z4OOf+PaGvu6vhr9peI/8Lo19tpGTb8kH/n3h+b0x2/CgDy2MKwU4OQeflGMdOPfpXQ+DSYtSR2+VFQY2dcZHT35rmLhyGyFJX0UdPpVzRb4QywvNvGCGGCOmP5f40Ae4Wd6DaiR0ZFkJAXAIJLZ47549s/pXkni+SBrpZYed2cjHsPYHIzjp1B9K07HXjNCkTtJjPIGBu5HIAA7jp16da4y/nZi5jBJOTnHuO1AGbMrebtwNze3vWv4btlkmu22hzFbmQDs2JEBx68E/kTWMufvEHGO3t6Guw8ATmPULqTB3m0Kpng5EkZ4J6HAPPFAGTdqolOzj/ZJyf8AD8qRvmjRRtJAP3fw68fhVnU4Al1JFGjApIV+cbTnjgj1rNlaRUARAQBkE9/6mgD174RR+XqMDEEIwXCNwQdwBOffA7en1r2y1ufOt2kDMABgoUwfXIHvx39K+W/D+tNbeQHbaysFXAUBOmD0x+vrXdeE/FoIaK5YoPlXnPQdB0wfu5/AnnjIBh/E9Io9emWMO2WClgoPAA9unPUdfyrg2RRMN33D39PUdK1PFdy1xqjuckvhs5P4g5HB9hWOVwispBU8AD6D/GgDX8LQx3Go3SSAkm2bAHu6Dj3qvrD4u2V0ZHOcgkjOcHOCB6Z/w6VZ8HQyT3uqMqiRoLIyAMvAPnRAHt3IGfxqtrQMlxKyowHbCgEDHbHGMYwaAMwM5kAIAGOf84r2H4LagunwXDM4JJ+T5sEHnPBHOBngHv2rxdCzSEKM8ZyRgj9PWtbStUNhHJGCDnnG7G07TyP07dqAPr3RNbE95J+8Z5SCS6gZ2jHcnJ69eM8+9eGfHKVR4gjKMcLGFB4PJZyepz13f5FUvCniXy5C8jSCXICDzOwyRwOuMY9uvtXPfEDVX1LUGxGixqoRNoBIxu74znPYmgDmbm6eQlpG2k9z0J/OqFuym+3MrY5JUdehqSUoBtbj+ItjODk//XqOwz9tjGDuGeAO+KAJ75toZSuSDydvH+fpVAnLEnvWlrSEOh2kZBYsE2rnJ4GOPSsugD1v4Oa3FpVtdFmKZRui9WII6+v5frx0Wmanb3/jCa5Rw08gZXIILcc+nTgdO/pyK8T0+Z4UdF4JIJ9v0rp/D+obJz5Stu2livHzkD6ZAx29aAPT/jzdrNounPGQ0IkIDkdMhs46Ht79O3fwhZcRDcwIx/AOvWvSPiLqwv8AT7UK4Ug5MeMAHL47YJwR+f4V5tFG+Pm6YABIwQMGgCa3lkF5DyQSSD+OR1+lT30zpPKxcEh8k8YJz/j3qugxcxEhWJcjgDHeptUi224EiOszHf8AN3HbHH1oAoyyNIx2kdAQMd+Pb/P416z8FdaGlxXTOSsbrtByR2GR0weM4z/+vyCEblYb9uSBjGc1p6ZeXFrGRG7JnIIXgHj+maAOi1K9F94za6V2IeVcfNkkYxgHFeveLrwnwK6xOWCh2UheMYXtjrzweo/l8/6fOfti+SvmPuBUKuSORj8cmvTNa1yNfB0EeCZW2qCyAgDgnr+Ix+HuQDyeVmQMVYn5gW+XH6/lUETg3UbEZ+YEg96WX/WkNgLk4xx7elJED9ojz8xLA45oA0JZSqqOfL3fdA75qC6lEsYc/wB7kjHX6d6tyAvA+cFxjOAOee36VmwKCwLKDhscDrwaAO8+Fmspo+rPNKBja21goBBwueSOBwepA61u61qv23xVLcKrHccq44xyuTkdOOcYB/OvKhObeYtExAz0H0Haup0u9RVRiu5BnbknGflzk98cdqAPoi7uVm8CM8Ssx8v5cR53c9MEfT8a+ZNbnP8AacilWAz3Tk8dTx36/jXtM+tww+D2jjjeW5lQLhc84GMdMA5Gc9eR614heMZrqWWTlmOck5yOwz9KAMqZw2CgKqOcEDH+etbsys0rhQSU3fKV6YzntWNMjYA2ts7DAz+GK3rldqZO1RsY7im4scc8gemBigDODqWIKsXI6jr1+ma6b4ZaiNN8RRysg2+YGDMSOOc9s++PauWaPbcOSGDKNuCc9zSWpMExf5gdwIC9QM0AfQviTWZLzWYbgpIVcsCCpJ68Yzjnrn059cV0mvXTXHgYpJzsQsMdiFYfyB/T2rw/TdcEtuquzKpYkBsYXJ7c+g/T1xXba/rBs/DUDpKMsnPQAjbzjjjrjFAHimvMy31wMDJlbLH6n8OayDwcYII61t6k4uLq4deGLsRz0PP+NY83D4wcgAc96AHSJkLtAJwOB16elRCraojFFLEMQMjv92qdAFzSZWh1CF0xuB4OM4r6f8P+L2utNtFGCBkcggYxwPr3x1x+Jr5UrufBniD7KsaOyo6Nkscndx1OOfQfnQB9F/Eq9TUfCGyV1Ma9MkncOuAPqAPx/CvkbUcicqQvHTAxivYvF3iGC68PlY0cMwGCeQ3B4H4d/evHLn99NiPLEcA5znv1oAq16r+y5/yXbwz/ANvX/pLLXlZBBwa9W/ZbUn46eGiOg+05/wDAWagD79ooooAK+KP2jsSfGDXU4AVoGcsRgZt4eecAdPXr+Ffa9fInx28JeI9S+K+uXeneH9ZvLK4MKiW2s3dGAggyQwBHVSPqvXtQB893m4FiPvdzkZHrUMTnhXC7sDj/AOtj/Oa7m6+HXjP5SvhPXiSBkDTpT+Z29fpVP/hXfjQsobwj4hGcEldMn6+v3e1AHORTOoOw4H+e1MlXdGRgcjgGuqg+HPjIMP8AikfEIQHJB02b/wCJpX+HnjTGP+ES8QD3GmTen+5QBxpGPnKnOS3I6cj8uBXU+ASV1OeSPK7LXeoU8Z86LqO/WnSfDfxmcD/hEPEJAz8v9mz4/wDQa3/CXgTxZZX7vL4V8RQgQkI39mzD5t6ED7nsT/k0Ac3ftE19OsaII+VIRQo6EemepP1IznpWJNkBMAY7n/gI/wDrV6Dc+APFV1dySt4Q1yMHG8DT5MEgHkYQZ6fiT15qofh54veJVl8J66SoLbRpkuPu9PunPpj+vFAHGRRkyQgusYZuHYHA6cnAJx9AatWV+9vN8hzjIUkZA9wPX/AV1EfgDxcxRm8Ja8dpHDaZOAORnouccVXT4eeL/MUjwl4ixkqQ2mzDjHX7lAHL3ruxOQd2OS2T3HPv9aY4cRoxDAj9OldfN8P/ABi5VB4T8R7hk7zp82OnH8HrVs/DnxSbZTJ4Y8RGQ/cC6dL8vTqdmfy9KAMP4eqi6lqk7rGUisC7Bs7SPOiHb6/pVK9jPlufKC8ZOM4X/ZPfOc/ka6/w34F8Y2t1eoPDOvRLNBtZm02ZQ+JI2252eqA/QfnJcfDnxVFMfJ8N63hw3P8AZ8pAGOh+U9s0AeZMMSYK9D34xz19M/rTWG0bfK3DP3dvTr6/5/Ku4g+Hni6a5HmeEvEQU5zu06YDqeOU469agk+HvjJmcjwj4jHJP/INm55/3KAObtLl4GYRu6E45VsVHM5dic57ZPpXUj4e+M3k+bwl4gHOP+QZNjH/AHxUrfD3xhtU/wDCJ+Ij9dNlJ7n+560AcTKo8seYuxOxI/T9Kg04L9ui3bthznHU8HOK7t/h34xKuT4T8Rbs5406YjP/AHzVa1+HXjIalGT4R8QpGARubTJ9o4OOi+tAHO6vKWZNsZTqW7gDP8sY9elYleiXnw88aPI6yeE9ec5ILJpc2D9Pkqifhx4wUj/ij/EjcjJOlzn/ANkoA4vAGO+RV3T7xoHPCH5SBkV0v/Ct/GrEbvCXiTO0EFdMnAz+K/4U7/hW/jJ32/8ACI+JAm3/AKBU4z1/2OKAMW9vTdqhfOATjJ757/iTUOCE+6eMcLXRxfDvxkkwx4M8RYHrpc2OD/u1cg+HvjIx8+EfEAwRtU6ZMPb+57UActbqY7tGjJ3q+8Z7HOafeSyzI7MqrIGGQFAAGcdh9a7Ob4d+KoniC+EdfOHy2NPlYNgnoNnH41I3gHxf/ZJA8Ka755kHJ0yXdjqP4enTn6/iAeatARLu2rt44Jxz+VWI4wI8FcgnnI6mvQLr4ceKlmPk+GNeZdud39mTAk5/3fx/TrVSX4beLdgYeEvEBfJ/5h8vPQ4xs4+v+FAHn9pKILkOwG3PJx29hWveXz3EcMZjVQpILDqR2z/L/IrSf4deN/tSn/hDfEQAI+7pc2P/AECtL/hXvjKMr/xSPiM47jTpvQf7NAHCRo+07wwDHBP4jrmpogftUTOuBuXcD3wfUe3pXXr8O/GaIP8AikfERHYDTJs49Pufz9asr8OPGKajAG8J68EJjDGPTpiAOM5JX3yfSgDnp4s2oxCd6kNhgDtyEA7Z9fzFZUqsZgrDaemM8/XpxXqH/CBeK100svhbXixAj2DTJFO0Hgn5c54BP1/EZEnw98Vtcqx8H+I8Fv8AoHTdPQnZ/wDWoA8+vgFlwMkdjjrwPzra0K4a2VJBGzHjHPA6DPT0z+daup/DvxobgmLwf4iZd3H/ABK5jwAMZ+Sta28CeLjCkcvg7xAGT+L+zJeRwSMlOue+O/tyAZl7qb3UBRAyKVwV7nOeOR/nPftgrEfOCkZPXn6D1Hsa9GXwR4tF15lr4R1aLJwoOmygDgA/wZA9OnTpmkPgDxRtDjwnrjOsI4bTpMZI7fLyc44Pv7UAeZOPkUmNienI6g/h9a3U/dFCIY5AYvugYbBQHrggY5P+Arbm+Hviv7Mv/FIeIHfjJXTZuBgcYKc9f0rfg+H3icQIf+EZ1p5PLZR5mnyLgEdOFz+vc0AeX3u43jiZRkAjAG3HtjGPSmyRsibmDKpBIYjHfFeiS/DjxP8AapSfDGuMvlkqf7OkIBzj+5+OB+FZ9/8ADnxZG6iPwn4hI5I/4lsj/wARPZfp+tAHI2F5LCkjCPoeAWxzggH69cVr6lrM09rHHH5mZE+bgcZ6ge3OPp+t2PwF4zRHj/4RDxCQef8AkFTHJwQOqe9PPgXxoBGV8H+IQyrtz/Zcx7Y/uUAcdKSGIwe/IHT/AD6Vn3BO87uT2P5/1ruT8PvGruSfCPiHJ/6hkwz/AOO1Xufh3403Ejwb4jfj/oFzfh/D70AcwM7YhgEsACeh6cc/TIqi5yc8ZPXGa7aT4eeNFggSPwf4kBwCT/Zcxwe+fk96p/8ACuPG4J/4o3xIfppc/wD8RQBygBJ4qW3kaNiwLYHJA6H6/jiulHw48b9/BviX/wAFc/8A8RSn4c+N8kL4N8S7c8Z0ufP/AKDQBnX2s3Eto0LSMVYbSCc575zj6VlAFGAztGCfm55xXVN8OvG21Sng3xECBzjS58/qlIvw58bHdv8AB3iTlT/zCp85/wC+KAOSYliTzjP1xXrP7Lsjf8Lw8OKTgH7QcHqf9FlrkG+HPjcMwXwd4l254/4lc/8A8TXpn7OfgzxTpPxn8O3mqeGdbsLGL7R5lxc2EsUa5tpVBZmUAZJA69TQB9uUUUUAFcP8a/FF/wCC/hlrOv6OIGvrTyfLE6Fk+eaNDkAjsx713FZXinw9pfirQrrRtetftem3O3zYfMaPdtYOvzKQRhlB4PagDyo/GeSDxL4lFzpN/Fpen2dq9taXNm1rdyzzSCMKRIRhSSOcdMnmtuf4si1g8m58PXp1pNZi0SXT4Z42IlkiaRGWQlVKkDvtwTziur1XwP4c1a91W71LTI7mfVLdLW7LyORJGh3INucKQcEMADkA5qG0+H/hm0tbSCHTTstdQXVY2e4leQ3SqVEruWLOcEj5iR7cCgDmV+IV9aXXjGW6024c6KtlJcWU1xbxLZrLbCV8S5w+DweTk/d4qvP8X5orCCb/AIRPUVuRpL67d2008cb21krlQ/P3mO0kJwcDkiur174d+F9ebVTqumvMdUmgnvNt1NH5rwpsjPyuMbR2GAepyeahvvhl4Tv7a1hvtOnuVt0eJHlvrh5GjZtzRu5k3SITzsclfagDmfEPxmg0xtVms/D97qGl6VBZXV5eJPHGI4bldyMEY7mPPQehyR3dp3xN1VW8czavo1pFZaDfG1t5TdpCJPuBUcsx+Y792QPRQC3B7DUvAXhrUo9bjvNMV49aighvlWaRBKkP+qUBWGwL/s4z3zUOo/DrwtqM+rzXell21Yq14BcyqsjKVKuFDAK4KL86gNx1oA4XSvixd+JNf8L21haSaYsusz6bqFvMA+8JbGVSrFQQOQegNbnjvx5N4S8dxx3kjHQodCudSnhjjUu8kciKu0nn+IjGcc81u6T8OPC2k3dvdWOmutzBdtfJLJdzSN57R+Wzks53Erxzkd+vNaereFdF1fUjf6nYR3NybOSwJkZipgkILoVztIOByRn3oA4e5+Lo0/T9VbVfDt3b6np7WZNlHcRyeal022NlfgZzkEHGPU9abH8XJWuX0p/DF2niUaoNMTTjdRlSTH5vmGUfKFCcngntz26W2+GvhO20u50+LSiba5mhnm33MzyO0JBizIzl8LgYXOB0xyaz/G3wy07X4bmTTTBp+pXN9HfzXcqTSkyJGYwV2TRshxjlWA45BzQBqeEvGcPiLwZP4h+yNZxwNcLJDNMo2mFmVsucKBlTyeB3rktB+MQ1a115k8PXBuNKs01AxwXAdbi3JIZo2KqCQATjoccE11ngnwPYeGfAi+F5XOo2jrMty0yYE/msxcFecKdxGMnjuetU7X4U+DrW0vLaHS5/Ju7dLScPqFy5eFG3LGSZCdoPGOmOOnFAGNZ/E1NcvPC11pkN7BpGrahcWts5RCbxIo2JcqRuRdykDGGJHIx1u/DT4nQ+OdVvbKLTTp728ZlMU90puFw4XEkOAyHntkDpnkZ27b4e+FrW6huLbSkhaG6kvYkSaRY45pE2OyxhtoypwQBjvjPNTeGvA/h/w1fy3ukWLx3kkItzNPcy3DrEDu8tTIzFUzztXAzQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal acute myocardial perfusion scan was obtained on a 44-year-old female admitted with typical chest pain and nonspecific ECG abnormalities. Serial enzymes were negative for myocardial infarction and cardiac catheterization revealed normal coronary arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Heller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5714=[""].join("\n");
var outline_f5_37_5714=null;
var title_f5_37_5715="Color Doppler endometrial polyp";
var content_f5_37_5715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Color Doppler sonogram of an endometrial polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Saline infusion reveals a polypoid lesion emanating from the fundus. Color flow Doppler clearly identifies a central feeder vessel. Presence of such a feeder vessel can be used to make the diagnosis of polyp even in the absence of saline infusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5715=[""].join("\n");
var outline_f5_37_5715=null;
var title_f5_37_5716="Focal tracheal stenosis CT";
var content_f5_37_5716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal tracheal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shaded surface display reconstruction of a high resolution chest computed tomographic data set reveals a focal area of tracheal stenosis (red arrows) just above the thoracic inlet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5716=[""].join("\n");
var outline_f5_37_5716=null;
var title_f5_37_5717="Ultrasound of sixth extensor compartment wrist";
var content_f5_37_5717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    Ultrasound of the sixth extensor compartment of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These ultrasound images show the sixth extensor compartment of the wrist. The superior image, marked by the red box, was obtained with the ultrasound probe positioned where the red mark appears on the wrist in the photograph. The image below was obtained where the yellow mark appears on the wrist.",
"    <div class=\"footnotes\">",
"     ECU: extensor carpi ulnaris tendon.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5717=[""].join("\n");
var outline_f5_37_5717=null;
var title_f5_37_5718="Valganciclovir: Drug information";
var content_f5_37_5718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Valganciclovir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/29/19925?source=see_link\">",
"    see \"Valganciclovir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/18/21798?source=see_link\">",
"    see \"Valganciclovir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Valcyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Valcyte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F232963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F232945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CMV retinitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction (active retinitis):",
"     </i>",
"     900 mg twice daily for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     Following induction treatment, or for patients with inactive CMV retinitis who require maintenance therapy: 900 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of CMV disease following transplantation:",
"     </b>",
"     900 mg once daily beginning within 10 days of transplantation; continue therapy until 100 days (heart or kidney-pancreas transplant) or 200 days (kidney transplant) post-transplantation",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9515067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/18/21798?source=see_link\">",
"      see \"Valganciclovir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of CMV disease following kidney or heart transplantation:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 4 months to 16 years: Dose (mg) = 7 x body surface area x creatinine clearance* once daily beginning within 10 days of transplantation; continue therapy until 100 days post-transplantation. Doses should be rounded to the nearest 25 mg increment; maximum dose: 900 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     *Cl",
"     <sub>",
"      cr",
"     </sub>",
"     (mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) = [k x Height (cm)]  divided by serum creatinine (mg/dL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If the calculated Cl",
"     <sub>",
"      cr",
"     </sub>",
"     is &gt;150 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     , then a maximum value of 150 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     should be used to calculate the dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Calculated using",
"     <i>",
"      modified",
"     </i>",
"     Schwartz formula where k is as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients &lt;2 years: k = 0.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Girls 2-16 years: k = 0.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Boys 2 to &lt;13 years: k = 0.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Boys 13-16 years: k = 0.7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F232946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F232947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 4 months to 16 years: No additional dosage adjustments required; calculation for all patients adjusts for renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: 450 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-39 mL/minute: 450 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-24 mL/minute: 450 mg every 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: 450 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-39 mL/minute: 450 mg every 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-24 mL/minute: 450 mg twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Valganciclovir is not recommended in patients receiving hemodialysis. For patients on hemodialysis (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute), it is recommended that ganciclovir be used (dose adjusted as specified for ganciclovir).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10818242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valcyte&reg;: 50 mg/mL (100 mL) [contains sodium benzoate; tutti frutti flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valcyte&reg;: 450 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F232919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Valganciclovir should be taken with meals. The preferred dosage form for pediatric patients is the oral solution; however, valganciclovir tablets may used so long as the calculated dose is within 10% of the available tablet strength (450 mg).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to the carcinogenic and mutagenic potential, avoid direct contact with broken or crushed tablets, powder for oral solution, and oral solution. Consideration should be given to handling and disposal according to guidelines issued for antineoplastic drugs. However, there is no consensus on the need for these precautions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS); prevention of CMV disease in high-risk patients (donor CMV positive/recipient CMV negative) undergoing kidney, heart, or kidney/pancreas transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F232970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Valcyte&reg; may be confused with Valium&reg;, Valtrex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ValGANciclovir may be confused with valACYclovir",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F232961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (12% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (9% to 31%), headache (6% to 22%), insomnia (6% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (16% to 41%), nausea (8% to 30%), vomiting (3% to 21%), abdominal pain (15%), constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (&le;31%), thrombocytopenia (&le;22%), neutropenia (3% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (12% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retinal detachment (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.5-2.5 mg/dL: 12% to 50%; S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;2.5: 3% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%: Central nervous system: Peripheral neuropathy (9%), paresthesia (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, depression, dizziness, fatigue, hallucination, pain, psychosis, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, dermatitis, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, hyperglycemia, hyper-/hypokalemia, hypocalcemia, hypomagnesemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention/pain, appetite (decreased), dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Aplastic anemia, bleeding (potentially life-threatening due to thrombocytopenia), bone marrow depression, pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Ascites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, muscle cramps, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine clearance (decreased), dysuria, renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasopharyngitis, pharyngitis, pleural effusion, rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, local and systemic infection (including sepsis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Valganciclovir is expected to share the toxicities which may occur at a low incidence or due to idiosyncratic reactions which have been associated with ganciclovir",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F232922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to valganciclovir, ganciclovir, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F232907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute renal failure: Acute renal failure may occur; ensure adequate hydration and use with caution in patients receiving concomitant nephrotoxic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias:",
"     <b>",
"      [U.S. Boxed Warning]: May cause dose- or therapy-limiting granulocytopenia, anemia, and/or thrombocytopenia;",
"     </b>",
"     do not use in patients with an absolute neutrophil count &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or hemoglobin &lt;8 g/dL.  Use with caution in patients with pre-existing bone marrow suppression, cytopenias, or in those receiving myelosuppressive drugs/irradiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinogenic/teratogenic:",
"     <b>",
"      [U.S. Boxed Warning]: Ganciclovir may be teratogenic, carcinogenic, and cause aspermatogenesis.",
"     </b>",
"     Due to its teratogenic potential, contraceptive precautions for female and male patients need to be followed during and for at least 90 days after therapy with the drug. Fertility may be temporarily or permanently impaired in males and females.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with impaired renal function; dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Acute renal failure may occur in elderly patients with or without pre-existing renal impairment; use with caution and adjust dose as needed based on renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Liver transplant recipients: Not indicated for use in liver transplant patients (higher incidence of tissue-invasive CMV relative to oral ganciclovir was observed in trials).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: The preferred dosage form for pediatric patients is the oral solution; however, valganciclovir tablets may used so long as the calculated dose is within 10% of the available tablet strength (450 mg). Use of valganciclovir for the treatment of congenital CMV disease has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product bioavailability variation: Due to differences in bioavailability, valganciclovir tablets cannot be substituted for ganciclovir capsules on a one-to-one basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F232911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imipenem: Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Imipenem. May increase risk of seizures.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Ganciclovir-Valganciclovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Nucleoside): Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Stavudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F232937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Coadministration with a high-fat meal increased AUC by 30%. Management: Valganciclovir should be taken with meals.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F232925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Valganciclovir is converted to ganciclovir and shares its reproductive toxicity.",
"     <b>",
"      [U.S. Boxed Warning]: Ganciclovir may be teratogenic and cause aspermatogenesis.",
"     </b>",
"     Based on animal data, temporary or permanent impairment of fertility may occur in males and females. Ganciclovir is also teratogenic in animals. Females should use effective contraception during treatment and for 30 days after; males should use barrier contraception during treatment and for 90 days after.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F232951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F232926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HIV-infected mothers are discouraged from breast-feeding to decrease the potential transmission of HIV.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F232927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F232924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Valcyte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (88 mL): $825.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Valcyte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     450 mg (60): $4090.27",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F232915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Retinal exam (at least every 4-6 weeks), CBC, platelet counts, serum creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F232928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Rovalcyte (FR);",
"     </li>",
"     <li>",
"      Valcyte (AT, AU, BE, BG, BR, CH, CL, CZ, DE, DK, EE, ES, FI, GB, GR, HK, HN, ID, IE, IL, IT, KP, MX, MY, NL, NO, NZ, PH, PL, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Valixa (AR, CN, CO, EC, PE, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F232906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Valganciclovir is rapidly converted to ganciclovir in the body. The bioavailability of ganciclovir from valganciclovir is increased 10-fold compared to oral ganciclovir. A dose of 900 mg achieved systemic exposure of ganciclovir comparable to that achieved with the recommended doses of intravenous ganciclovir of 5 mg/kg. Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F232921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; high-fat meal increases AUC by 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Ganciclovir: 0.7 L/kg; widely to all tissue including CSF and ocular tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Ganciclovir: 1% to 2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted to ganciclovir by intestinal mucosal cells and hepatocytes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: With food: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Ganciclovir: 4.08 hours; prolonged with renal impairment; Severe renal impairment: Up to 68 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Ganciclovir: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as ganciclovir)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ljungman P, de La Camara R, Milpied N, et al, &ldquo;Randomized Study of Valacyclovir as Prophylaxis Against Cytomegalovirus Reactivation in Recipients of Allogeneic Bone Marrow Transplants,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(8):3050-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/37/5718/abstract-text/11929799/pubmed\" id=\"11929799\" target=\"_blank\">",
"        11929799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pescovitz MD, Rabkin J, Merion RM, et al, &ldquo;Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2000, 44(10):2811-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/37/5718/abstract-text/10991864/pubmed\" id=\"10991864\" target=\"_blank\">",
"        10991864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10058 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-02B1BD5894-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5718=[""].join("\n");
var outline_f5_37_5718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708869\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232941\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232942\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232963\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232945\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9515067\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232946\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232947\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10818242\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232917\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232903\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232919\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232918\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232970\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232961\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232922\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232907\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300203\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232911\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232937\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232913\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232925\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232951\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232926\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232927\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232924\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232915\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232928\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232906\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232921\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10058\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10058|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/29/19925?source=related_link\">",
"      Valganciclovir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/18/21798?source=related_link\">",
"      Valganciclovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_37_5719="Overview of peripheral nerve blocks";
var content_f5_37_5719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of peripheral nerve blocks",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/37/5719/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5719/contributors\">",
"     Christina L Jeng, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5719/contributors\">",
"     Meg A Rosenblatt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/37/5719/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5719/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/37/5719/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5719/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/37/5719/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerve blocks are safe and effective regional anesthesia techniques used for a variety of surgical procedures. Enlisting the operating surgeon to introduce the concept of peripheral nerve blocks during preoperative preparation will improve patient acceptance.",
"   </p>",
"   <p>",
"    Peripheral nerve blocks offer distinct benefits over general and neuraxial anesthesia. These benefits are of particular value in the ambulatory surgery setting. Use of peripheral nerve blocks allows bypass of the phase I anesthetic recovery room, and mitigates issues known to prolong post-anesthesia care unit (PACU) stay, thereby decreasing overall cost. Peripheral nerve blocks also provide analgesia postoperatively, both in the immediate postoperative period, and post discharge with indwelling perineural catheters.",
"   </p>",
"   <p>",
"    This topic will provide an overview of peripheral nerve blocks. Specific techniques are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link\">",
"     \"Peripheral nerve block: Techniques\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific guidelines for peripheral nerve blocks. Peripheral nerve blocks can be particularly useful for patients in whom neuraxial anesthesia or general anesthesia are contraindicated. For example, a peripheral block is advantageous in patients at high risk for respiratory depression (eg, sleep apnea, morbid obesity, advanced age) and the American Society of Anesthesiologists&rsquo; (ASA) statement regarding obstructive sleep apnea (OSA) suggests regional anesthesia as an alternative to general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/1\">",
"     1",
"    </a>",
"    ]. Peripheral nerve blocks can also be performed to avoid some of the known side effects and complications of general and neuraxial anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of peripheral nerve blocks over general anesthesia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No airway manipulation and therefore no airway complications",
"     </li>",
"     <li>",
"      No mechanical ventilation, therefore decreased perioperative respiratory complications",
"     </li>",
"     <li>",
"      Decreased risk for postoperative delirium",
"     </li>",
"     <li>",
"      Decreased postoperative nausea and vomiting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with neuraxial anesthesia, peripheral nerve blocks have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No hypotension (ie, no central inhibition of sympathetic nerves)",
"     </li>",
"     <li>",
"      No respiratory depression",
"     </li>",
"     <li>",
"      No risk of post-procedural headache",
"     </li>",
"     <li>",
"      No urinary retention",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disadvantages of peripheral nerve block are few but include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placing and allowing peripheral nerve blocks to develop their full effect takes time. Logistical planning is needed to minimize operative turnover time (ie, block placement in the holding area before the surgery).",
"     </li>",
"     <li>",
"      Incomplete or failed block may require supplemental rescue or more selective distal block",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mild sedation or conversion to general anesthesia.",
"     </li>",
"     <li>",
"      Peripheral nerve blocks are associated with a higher incidence of seizures compared the neuraxial blocks due to the greater volume of local anesthetic administered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few contraindications to the use of peripheral nerve blocks. Absolute contraindications include infection at the site of injection, patient refusal or inability to cooperate, and allergy to local anesthetics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34792?source=see_link\">",
"     \"Allergic reactions to local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medical anticoagulation or coagulopathy are relative contraindications to the placement of deeper peripheral nerve blocks (eg, lumbar plexus, sciatic).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NERVE IDENTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetic is administered into the space directly adjacent the target nerve. Placement of peripheral nerve blocks and indwelling perineural catheters rely on anatomic landmarks for needle placement in conjunction with one or more of the following nerve identification techniques: elicitation of paresthesia, elicitation of motor response or direct visualization with ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Elicitation of paresthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placement of some peripheral nerve blocks requires only the elicitation of paresthesia for correct needle position prior to local anesthetic administration. Paresthesias can be obtained during manipulation of the needle. As the needle approaches the target nerve, tingling sensations in the correct sensory distribution are signs the needle is positioned correctly. Paresthesias may also be elicited with the use of a peripheral nerve stimulator; however, these devices are used more often to elicit motor responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Elicitation of motor responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral nerve stimulator delivers electrical current (&lt;1.0 mA for a duration of 0.3 seconds at a frequency of 2 Hz) to the tip of a hollow, insulated needle (eg, Stimuplex&reg;, ProBloc&reg;) to elicit sensory (ie, paresthesias) or motor (ie, twitching) responses.",
"   </p>",
"   <p>",
"    For most blocks, 1 mA of electrical current is initially used to achieve peripheral nerve stimulation. The current is decreased progressively as the needle is manipulated. Stimulation at 0.4 mA is adequate for most blocks; discomfort is minimal. If stimulation persists at currents below 0.4 mA, the needle may be too close to the nerve with a risk of intraneural injection. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'General complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ultrasound guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound imaging permits direct visualization of needle location relative to target nerves, blood vessels, and related structures, as well as distribution of the local anesthetic during and after injection. Use of ultrasound decreases the time to perform most blocks, and time to onset of anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The quality of ultrasound guided blocks is equal to or better than blocks performed with nerve stimulator techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound also facilitates the placement of blocks in patients with challenging anatomy (ie, scarring from previous surgeries, obese patients), and in those for whom peripheral nerve block has relative contraindications (ie, anticoagulation). Ultrasound is also used to rescue a block when the initial block is inadequate or incomplete; this is an advantage over the use of nerve stimulation, which does not allow for redirection of the needle: once the local anesthetic is injected, the nerve no longer responds to nerve stimulation.",
"   </p>",
"   <p>",
"    Portable ultrasound machines provide imaging of adequate quality for the placement of peripheral nerve blocks. A variety of ultrasound transducers are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27592?source=see_link&amp;anchor=H8#H8\">",
"     \"Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology\", section on 'Transducers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The high frequency (10 to 15 MHz) probe is used to identify more superficial nerves (eg, upper extremity blocks), whereas low frequency (5 to 7 MHz) probes provide greater tissue penetration for identification of deeper nerves (eg, sciatic nerve blocks).",
"   </p>",
"   <p>",
"    Two techniques for ultrasound-guided needle placement can be used: in-plane and out-of-plane. With the in-plane technique, the needle is placed parallel to the transducer at the midpoint of the short axis. The needle tip is visualized as it punctures the skin and the advancement of the shaft of the needle can be followed into the tissue. In contrast, when performing an out-of-plane technique, the needle is placed perpendicular to the transducer at the midpoint of the long axis. The needle tip appears as a hyperechoic dot but the shaft of the needle is not visualized completely. The out-of-plane needle approach is more useful for deeper targets.",
"   </p>",
"   <p>",
"    Mastery of ultrasound guided peripheral nerve blocks requires specialized training. Additional skills include: use of ultrasound equipment (management of the machine, choice of probe, medical record documentation); scanning techniques (sonoanatomy, performance of the exam, recognizing artifacts); and sonographic needle guidance (understanding",
"    <span class=\"nowrap\">",
"     needle/probe",
"    </span>",
"    orientation, optimization of needle visualization) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TYPES OF NERVE BLOCKS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Single shot",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single shot nerve block refers to one time injection of local anesthetic to the target nerve for perioperative analgesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Continuous perineural blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous peripheral nerve blockade refers to the percutaneous insertion of a catheter directly adjacent to the target peripheral nerve(s). Its purpose is to provide prolonged nerve block by continuous infusion of local anesthetic for longer procedures, as well as postoperative analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Continuous blockade is primarily used for inpatient procedures but can also be used in outpatients.",
"   </p>",
"   <p>",
"    Electrical nerve stimulation catheters are available and are similar to stimulation needles. As with single shot peripheral nerve blocks, use of ultrasound decreases the time from needle insertion to catheter placement and with less pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When peripheral nerve block is chosen, continuous perineural catheters should be used for any procedure expected to have significant postoperative pain. For example, continuous anesthetic infusion is especially useful following joint contracture release surgery because pain control in order maintain postoperative joint mobility is essential. Overall, continuous blockade improves patient satisfaction by decreasing pain, opioid use and side effects, and incidence of sleep disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of continuous perineural catheters in the outpatient setting has been somewhat limited. Many physicians are unfamiliar with their use or may have undue catheter-related concerns. Establishment of an outpatient protocol will promote the successful utilization of continuous perineural catheters. The protocol should include: extensive preoperative oral and written instructions, contact with the patient on the first postoperative day, 24 hour anesthesiologist availability to manage questions or complications, and examination by a physician (often the operating surgeon) within the first week following discharge. Under these conditions, the majority of patients are able to manage and remove their catheters at home [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LOCAL ANESTHETICS AND ADJUVANTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Local anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different local anesthetic agents have different onset to action, duration of action and degree of motor blockade. For example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    (0.75 percent) compared to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/55/40821?source=see_link\">",
"     mepivacaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    provides significantly longer postoperative analgesia with the same or shorter onset times for femoral, sciatic and interscalene blocks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The concentration of local anesthetic determines the rate of diffusion into the nerve with higher concentrations of providing more rapid onset of nerve block. Inadvertent administration of a large volume of a higher concentration local anesthetic can, however, result in toxicity.",
"   </p>",
"   <p>",
"    Alternatively, different local anesthetics can be combined to decrease onset time while providing longer a duration of analgesia. Mixing local anesthetics can lead to unpredictable blockade characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adjuvants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of adjuvant agents provides minimal, if any, additional benefit when used for peripheral nerve blockade.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasoconstrictors - Epinephrine causes vasoconstriction which decreases the absorption of the local anesthetic. It is added to local anesthetics to prolong the effects of the block. Side effects include tachycardia and a potential risk of nerve ischemia due to a decrease in peripheral nerve blood flow.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      - The pKa of a local anesthetic is the pH at which the concentrations of the uncharged and charged forms of the anesthetic agent are equal. The uncharged, basic form of local anesthetic traverses the nerve membrane to exert its action. The addition of sodium bicarbonate increases the proportion of the basic form, thereby decreasing onset time of the local anesthetic effect.",
"      <br/>",
"      <br/>",
"      For peripheral nerve blocks, adding sodium bicarbonate to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or to 0.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      has no benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/20\">",
"       20",
"      </a>",
"      ]. However, addition of sodium bicarbonate to 1.25 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/55/40821?source=see_link\">",
"       mepivacaine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/21\">",
"       21",
"      </a>",
"      ] for axillary block and to 2 percent mepivacaine for femoral and sciatic block [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/22\">",
"       22",
"      </a>",
"      ] has improved onset and quality of analgesia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       Fentanyl",
"      </a>",
"      - Time to onset is not improved with the addition of either fentanyl or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      for axillary block [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Fentanyl, however, improves the degree of sensory blockade achieved with axillary block using 1.5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , but a decrease in pH also occurs, which delays the onset of analgesia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      - Clonidine, an alpha2-agonist, prolongs the duration of sensory and motor blockade, particularly when added to local anesthetics of intermediate duration. In a trial of 56 patients undergoing axillary block for carpal tunnel release, a significant reduction in block onset time was demonstrated with the addition of clonidine to 1%",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      compared to lidocaine alone. However, 50 percent of patients experienced sedation with doses as small as 30 mcg which may be an issue for some patients (eg, elderly, sleep apnea) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GENERAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general complications which can occur with any peripheral nerve block though uncommon include: block failure, perineural hematoma, infection, unanticipated allergy to the local anesthetic, inadvertent intravascular injection, and excessively dense block. Specific complications for individual peripheral nerve blocks depend on regional anatomy, which are discussed in the topic on peripheral nerve block techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link\">",
"     \"Peripheral nerve block: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Block failure - If the block is unsuccessful at achieving the desired effect, options include redosing the block, or using supplemental local anesthesia at the surgical site. The amount of local anesthetic which can be administered depends upon how much was initially used. Conversion to general anesthesia is sometimes necessary.",
"     </li>",
"     <li>",
"      Perineural hematoma - Inadvertent puncture of adjacent vascular structures can lead to perineural hematoma and is more likely to occur in patients who are anticoagulated. The vast majority resolve with direct pressure to the block injection site. Rarely, surgical decompression is required.",
"     </li>",
"     <li>",
"      Infection - Infection risk for single shot peripheral nerve block is negligible. Risk of infection for peripheral nerve catheters is minimized if the catheter is discontinued within the first 72 hours of placement [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/28-31\">",
"       28-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nerve injury - Neurologic injuries after single shot peripheral nerve blocks are uncommon with rates on the order of 1 in 10,000 blocks [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/32\">",
"       32",
"      </a>",
"      ]. The reported incidence of nerve injury associated with peripheral nerve catheters is low, ranging from zero to 0.21 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/30,31,33\">",
"       30,31,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unanticipated allergic reaction to local anesthetic - Most idiosyncratic reactions to local anesthetics are nonallergic. However, these agents have been implicated in rare cases of urticaria and anaphylaxis (type I hypersensitivity). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34792?source=see_link\">",
"       \"Allergic reactions to local anesthetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravascular injection - Inadvertent intravascular injection of local anesthetic may lead to local anesthetic toxicity depending upon the volume injected. Local anesthetic toxicity may be more common with the placement of cervical plexus blocks due to the vascularity of the neck but likely occurs because of inadvertent injection into the vessel rather than absorption.",
"      <br/>",
"      <br/>",
"      When epinephrine is added to local anesthetics, intravascular injection results in tachycardia and hypertension which are useful signs that inadvertent intravascular injection has occurred. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link&amp;anchor=H2694354#H2694354\">",
"       \"Infiltration of local anesthetics\", section on 'Catecholamine sensitivity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excessively dense block - Care must be taken not to produce an insensate extremity, especially in a patient who may not have much post-operative discomfort. Such a patient may be at risk for injury, while at home or on the inpatient floors, due to the loss of protective reflexes to pain, or place the patient at risk for falling secondary to a loss of proprioception.",
"     </li>",
"     <li>",
"      Intraneural injection - Intraneural injections are categorized as extra fascicular or intra-fascicular. Extra fascicular injections, as seen on ultrasound, are characterized by diffuse local anesthetic spread within the epineurium, with fluid escape into the extraneural space. These injections do not necessarily result in nerve injury [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/34-38\">",
"       34-38",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Intra-fascicular injection, on the other hand, may cause neurologic symptoms resulting in persistent paresthesias that typically resolve within six months. If symptoms persist, the patient should be referred to a specialist. Intra-fascicular injection is avoided by halting injection of anesthetic if the patient feels a shooting pain, or if the pressure required for injection is unduly excessive. Also, appropriate spread of the anesthetic should be observed on ultrasound [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5719/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ultrasound guidance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=see_link\">",
"       \"Patient information: Anesthesia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many safe and effective regional anesthetic techniques are available to provide both anesthesia and analgesia for a variety of surgical procedures.",
"     </li>",
"     <li>",
"      Peripheral nerve blocks are especially useful for patients in whom neuraxial anesthesia or general anesthesia are contraindicated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral nerve block can be achieved with a one-time administration of local anesthetic, or a perineural catheter may be placed to provide prolonged nerve block by continuous infusion of local anesthetic for longer procedures, as well as postoperative analgesia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Types of nerve blocks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral nerve blocks and placement of indwelling perineural catheters use techniques which rely on anatomic landmarks, and nerve identification by elicitation of paresthesia, motor responses with the use of a nerve stimulator, or direct ultrasound guidance. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nerve identification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications can occur with placement of peripheral nerve blocks and include: block failure, perineural hematoma, infection, unanticipated allergy to the local anesthetic, inadvertent intravascular injection, excessively dense block and nerve injury from intraneural injection. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'General complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/1\">",
"      Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology 2006; 104:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/2\">",
"      Williams SR, Chouinard P, Arcand G, et al. Ultrasound guidance speeds execution and improves the quality of supraclavicular block. Anesth Analg 2003; 97:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/3\">",
"      Marhofer P, Schr&ouml;gendorfer K, Koinig H, et al. Ultrasonographic guidance improves sensory block and onset time of three-in-one blocks. Anesth Analg 1997; 85:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/4\">",
"      Walker KJ, McGrattan K, Aas-Eng K, Smith AF. Ultrasound guidance for peripheral nerve blockade. Cochrane Database Syst Rev 2009; :CD006459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/5\">",
"      Smith HM, Kopp SL, Jacob AK, et al. Designing and implementing a comprehensive learner-centered regional anesthesia curriculum. Reg Anesth Pain Med 2009; 34:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/6\">",
"      Tran de QH, Mu&ntilde;oz L, Russo G, Finlayson RJ. Ultrasonography and stimulating perineural catheters for nerve blocks: a review of the evidence. Can J Anaesth 2008; 55:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/7\">",
"      Casati A, Fanelli G, Koscielniak-Nielsen Z, et al. Using stimulating catheters for continuous sciatic nerve block shortens onset time of surgical block and minimizes postoperative consumption of pain medication after halux valgus repair as compared with conventional nonstimulating catheters. Anesth Analg 2005; 101:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/8\">",
"      Salinas FV, Neal JM, Sueda LA, et al. Prospective comparison of continuous femoral nerve block with nonstimulating catheter placement versus stimulating catheter-guided perineural placement in volunteers. Reg Anesth Pain Med 2004; 29:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/9\">",
"      Dauri M, Sidiropoulou T, Fabbi E, et al. Efficacy of continuous femoral nerve block with stimulating catheters versus nonstimulating catheters for anterior cruciate ligament reconstruction. Reg Anesth Pain Med 2007; 32:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/10\">",
"      Mariano ER, Afra R, Loland VJ, et al. Continuous interscalene brachial plexus block via an ultrasound-guided posterior approach: a randomized, triple-masked, placebo-controlled study. Anesth Analg 2009; 108:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/11\">",
"      Fredrickson MJ, Ball CM, Dalgleish AJ, et al. A prospective randomized comparison of ultrasound and neurostimulation as needle end points for interscalene catheter placement. Anesth Analg 2009; 108:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/12\">",
"      Ilfeld BM, Morey TE, Wang RD, Enneking FK. Continuous popliteal sciatic nerve block for postoperative pain control at home: a randomized, double-blinded, placebo-controlled study. Anesthesiology 2002; 97:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/13\">",
"      Ilfeld BM, Morey TE, Enneking FK. Continuous infraclavicular brachial plexus block for postoperative pain control at home: a randomized, double-blinded, placebo-controlled study. Anesthesiology 2002; 96:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/14\">",
"      Ilfeld BM, Morey TE, Wright TW, et al. Continuous interscalene brachial plexus block for postoperative pain control at home: a randomized, double-blinded, placebo-controlled study. Anesth Analg 2003; 96:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/15\">",
"      Swenson JD, Bay N, Loose E, et al. Outpatient management of continuous peripheral nerve catheters placed using ultrasound guidance: an experience in 620 patients. Anesth Analg 2006; 103:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/16\">",
"      Ludot H, Berger J, Pichenot V, et al. Continuous peripheral nerve block for postoperative pain control at home: a prospective feasibility study in children. Reg Anesth Pain Med 2008; 33:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/17\">",
"      Casati A, Fanelli G, Aldegheri G, et al. Interscalene brachial plexus anaesthesia with 0.5%, 0.75% or 1% ropivacaine: a double-blind comparison with 2% mepivacaine. Br J Anaesth 1999; 83:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/18\">",
"      Fanelli G, Casati A, Beccaria P, et al. A double-blind comparison of ropivacaine, bupivacaine, and mepivacaine during sciatic and femoral nerve blockade. Anesth Analg 1998; 87:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/19\">",
"      Galindo A, Witcher T. Mixtures of local anesthetics: bupivacaine-chloroprocaine. Anesth Analg 1980; 59:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/20\">",
"      Bedder MD, Kozody R, Craig DB. Comparison of bupivacaine and alkalinized bupivacaine in brachial plexus anesthesia. Anesth Analg 1988; 67:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/21\">",
"      Quinlan JJ, Oleksey K, Murphy FL. Alkalinization of mepivacaine for axillary block. Anesth Analg 1992; 74:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/22\">",
"      Capogna G, Celleno D, Laudano D, Giunta F. Alkalinization of local anesthetics. Which block, which local anesthetic? Reg Anesth 1995; 20:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/23\">",
"      Fletcher D, Kuhlman G, Samii K. Addition of fentanyl to 1.5% lidocaine does not increase the success of axillary plexus block. Reg Anesth 1994; 19:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/24\">",
"      Racz H, Gunning K, Della Santa D, Forster A. Evaluation of the effect of perineuronal morphine on the quality of postoperative analgesia after axillary plexus block: a randomized double-blind study. Anesth Analg 1991; 72:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/25\">",
"      Nishikawa K, Kanaya N, Nakayama M, et al. Fentanyl improves analgesia but prolongs the onset of axillary brachial plexus block by peripheral mechanism. Anesth Analg 2000; 91:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/26\">",
"      Bernard JM, Macaire P. Dose-range effects of clonidine added to lidocaine for brachial plexus block. Anesthesiology 1997; 87:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/27\">",
"      P&ouml;pping DM, Elia N, Marret E, et al. Clonidine as an adjuvant to local anesthetics for peripheral nerve and plexus blocks: a meta-analysis of randomized trials. Anesthesiology 2009; 111:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/28\">",
"      Neuburger M, B&uuml;ttner J, Blumenthal S, et al. Inflammation and infection complications of 2285 perineural catheters: a prospective study. Acta Anaesthesiol Scand 2007; 51:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/29\">",
"      Cuvillon P, Ripart J, Lalourcey L, et al. The continuous femoral nerve block catheter for postoperative analgesia: bacterial colonization, infectious rate and adverse effects. Anesth Analg 2001; 93:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/30\">",
"      Capdevila X, Pirat P, Bringuier S, et al. Continuous peripheral nerve blocks in hospital wards after orthopedic surgery: a multicenter prospective analysis of the quality of postoperative analgesia and complications in 1,416 patients. Anesthesiology 2005; 103:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/31\">",
"      Borgeat A, Blumenthal S, Lambert M, et al. The feasibility and complications of the continuous popliteal nerve block: a 1001-case survey. Anesth Analg 2006; 103:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/32\">",
"      Auroy Y, Benhamou D, Bargues L, et al. Major complications of regional anesthesia in France: The SOS Regional Anesthesia Hotline Service. Anesthesiology 2002; 97:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/33\">",
"      Comp&egrave;re V, Legrand JF, Guitard PG, et al. Bacterial colonization after tunneling in 402 perineural catheters: a prospective study. Anesth Analg 2009; 108:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/34\">",
"      Bigeleisen PE. Nerve puncture and apparent intraneural injection during ultrasound-guided axillary block does not invariably result in neurologic injury. Anesthesiology 2006; 105:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/35\">",
"      Kapur E, Vuckovic I, Dilberovic F, et al. Neurologic and histologic outcome after intraneural injections of lidocaine in canine sciatic nerves. Acta Anaesthesiol Scand 2007; 51:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/36\">",
"      Sala-Blanch X, Pom&eacute;s J, Matute P, et al. Intraneural injection during anterior approach for sciatic nerve block. Anesthesiology 2004; 101:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/37\">",
"      Mackinnon SE, Hudson AR, Llamas F, et al. Peripheral nerve injury by chymopapain injection. J Neurosurg 1984; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5719/abstract/38\">",
"      Schafhalter-Zoppoth I, Zeitz ID, Gray AT. Inadvertent femoral nerve impalement and intraneural injection visualized by ultrasound. Anesth Analg 2004; 99:627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 397 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5DB5CB92DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5719=[""].join("\n");
var outline_f5_37_5719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NERVE IDENTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Elicitation of paresthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Elicitation of motor responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ultrasound guidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TYPES OF NERVE BLOCKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Single shot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Continuous perineural blockade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LOCAL ANESTHETICS AND ADJUVANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adjuvants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GENERAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34792?source=related_link\">",
"      Allergic reactions to local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27592?source=related_link\">",
"      Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=related_link\">",
"      Patient information: Anesthesia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_37_5720="Pathology of internal carotid artery dissection";
var content_f5_37_5720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Pathology of internal carotid artery dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Elastica van Gieson stain of specimens from a 61-year-old man with internal carotid artery dissection and fibromuscular dysplasia.",
"    <br>",
"     (A) Postmortem exposition of intramural hematoma of the right internal carotid artery above the bifurcation (arrow).",
"     <br>",
"      (B) Cross-section of the dissected artery shows subintimal and intramedial hematoma (small arrows).",
"      <br>",
"       (C) Longitudinal section with zipper-like separation within the arterial wall (large arrow) corresponding to the false lumen and myxoid degeneration of the media (small arrows).",
"       <div class=\"footnotes\">",
"        Asterisk: true lumen; Scale bar: 0.25 mm.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Besselmann M, Vennemann B, Lowens S, et al. Internal carotid artery dissection. Neurology 2000; 54:442. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5720=[""].join("\n");
var outline_f5_37_5720=null;
var title_f5_37_5721="Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis";
var content_f5_37_5721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/37/5721/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5721/contributors\">",
"     David M Gershenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/37/5721/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5721/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5721/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5721/contributors\">",
"     Rochelle L Garcia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/37/5721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5721/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/37/5721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian germ cell neoplasms are derived from primordial germ cells of the ovary (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ). They may be benign or malignant. These neoplasms comprise approximately 20 to 25 percent of ovarian neoplasms overall, but account for only about 5 percent of all malignant ovarian neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Ovarian germ cell neoplasms arise primarily in young women between 10 and 30 years of age and represent 70 percent of ovarian neoplasms in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathology, clinical manifestations, and diagnosis of ovarian germ cell neoplasms are reviewed here. Treatment of malignant germ cell neoplasms of the ovary as well epithelial ovarian carcinoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF OVARIAN GERM CELL TUMORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Histopathology overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histological types of ovarian germ cell neoplasms (OGCNs) that arise from the ovary are similar to those developing in the testes of men (",
"    <a class=\"graphic graphic_table graphicRef76682 \" href=\"UTD.htm?15/55/16251\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"     \"Anatomy and pathology of testicular tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ovarian germ cell neoplasms can be broadly divided into those that differentiate towards embryo-like neoplasms (teratomas and their subtypes and dysgerminomas) and those that differentiate primarily toward extraembryonic fetal-derived (placenta-like) cell populations or a mixture of both. Categories include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Teratomas",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Benign cystic mature teratomas (dermoid cysts) are the most common OGCNs. Some malignant OGCNs develop when components of dermoid cysts develop into a somatic malignant neoplasm (termed mature cystic teratoma with malignant degeneration).",
"     </li>",
"     <li>",
"      Immature teratomas",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysgerminomas &mdash; These are the female version of the male seminoma and are essentially comprised of immature germ cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"       \"Anatomy and pathology of testicular tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endodermal sinus (yolk sac) tumors &mdash; These are carcinomas (epithelial neoplasms) that differentiate toward yolk",
"      <span class=\"nowrap\">",
"       sac/primitive",
"      </span>",
"      placenta forms.",
"     </li>",
"     <li>",
"      Mixed germ cell tumors &mdash; These are typically combinations of a teratoma with yolk sac, dysgerminoma,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      embryonal carcinoma.",
"     </li>",
"     <li>",
"      Rare OGCNs &mdash; pure embryonal carcinomas, nongestational choriocarcinomas, and pure polyembryoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among malignant OGCNs, dysgerminoma, immature teratoma, yolk sac tumors, and mixed germ cell neoplasms account for 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Pure embryonal carcinomas and nongestational choriocarcinomas are rare, and pure polyembryomas are very rare.",
"   </p>",
"   <p>",
"    A study of findings from a United States national cancer database from 1973 to 2002 reported 1262 malignant OCGNs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/6\">",
"     6",
"    </a>",
"    ]. Incidence by histology was: pure dysgerminomas (39 percent); teratomas, immature plus mature with malignant transformation (39 percent); and nondysgerminoma or mixed cell types (29 percent) (",
"    <a class=\"graphic graphic_table graphicRef72483 \" href=\"UTD.htm?15/13/15579\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    OGCNs grow rapidly, unlike the more common epithelial ovarian neoplasms, yet most patients present with stage IA disease (limited to one ovary). Evidence of bilateral ovarian involvement suggests the presence of a tumor with a propensity for involvement of the contralateral ovary, including benign cystic teratoma, dysgerminoma, or a tumor with components of dysgerminoma (mixed germ cell tumor). These conditions are bilateral in 10 to 12 percent of cases, while the majority of other histologies present as unilateral ovarian masses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;OGCNs arise primarily in young women between 10 and 30 years of age; they represent 70 percent of ovarian neoplasms in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/4\">",
"     4",
"    </a>",
"    ]. For unclear reasons, malignant OGCNs occur more frequently among",
"    <span class=\"nowrap\">",
"     Asian/Pacific",
"    </span>",
"    Islander and Hispanic women than Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;OGCNs often produce hormones, particularly the beta subunit of human chorionic gonadotropin (hCG). Patients typically present with one or more of the following signs and symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal enlargement &mdash; from the mass itself, ascites, or both",
"     </li>",
"     <li>",
"      Abdominal pain &mdash; from rupture or torsion",
"     </li>",
"     <li>",
"      Precocious puberty, abnormal vaginal bleeding &mdash; presumably from hCG production",
"     </li>",
"     <li>",
"      Symptoms of pregnancy &mdash; from hCG production",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eighty-five percent of women with an OGCN have both abdominal pain and an abdominal mass; fever or vaginal bleeding occurs in 10 percent. OGCNs tend to be large (median size 16 cm). Ascites, rupture (pre- or intraoperative), and torsion are reported in 20, 20, and 5 percent of cases, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made by histology at time of surgical excision. The diagnosis is strongly suggested preoperatively by the presence of an adnexal mass on pelvic imaging and an elevated level of an associated tumor marker (eg, hCG, alpha fetoprotein [AFP]).",
"   </p>",
"   <p>",
"    For benign cystic mature teratomas, the diagnosis be made with reasonable confidence using pelvic ultrasonography; however, removal of the cyst is still advised (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Mature cystic teratoma (dermoid cyst)'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;OGCNs are often associated with hormonal or enzymatic activity. Some of these proteins can be measured in the serum, providing a highly sensitive and variably specific marker for the presence of certain histologic components (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 3",
"    </a>",
"    ). Some tumor markers are present in some, but not all tumors of a specific histology. Tumor markers produced by tumors types are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      hCG &mdash;embryonal cell carcinomas, and ovarian choriocarcinomas, mixed germ cell tumors, and some dysgerminomas",
"     </li>",
"     <li>",
"      AFP &mdash; endodermal sinus tumors, embryonal cell carcinomas and polyembryoma carcinomas, mixed germ cell tumors, and some immature teratomas [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]; most dysgerminomas are associated with a normal AFP.",
"     </li>",
"     <li>",
"      Lactate dehydrogenase (LDH) &mdash; dysgerminomas",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Staging and surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant germ cell neoplasms are staged according to the International Federation of Gynecology and Obstetrics (FIGO) staging system for epithelial ovarian cancer (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/10\">",
"     10",
"    </a>",
"    ]. In brief, stage I disease is confined to the ovaries; stage II includes extension into other pelvic tissues; stage III refers to disease that has spread beyond the pelvis or to retroperitoneal lymph nodes but remains in the abdomen; and stage IV refers to the presence of distant metastasis or involvement of liver parenchyma.",
"   </p>",
"   <p>",
"    In virtually all cases, surgery is required for definitive histological diagnosis, treatment, and staging (if malignant) of OGCNs. Oophorectomy, ovarian cystectomy, or resection of the ovarian mass can be performed, depending on the clinical situation, and tissue sent for frozen section. Confirmation of the diagnosis should be obtained prior to definitive surgical treatment.",
"   </p>",
"   <p>",
"    The following sections review the pathology and clinical manifestations of the individual types of OGCNs. Treatment of benign OGCNs is also described below, while management of malignant OGCNs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TERATOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teratomas are the most common type of germ cell neoplasm. Most, but not all, teratomas are benign. The designation teratoma refers to a neoplasm that differentiates toward somatic-type cell populations (typically including cell populations that would normally derive from ectoderm, endoderm, and mesoderm) that can be typical of either adult or embryonic development. The component tissues in a teratoma range from immature to well differentiated, and are foreign to the anatomic site in which they are found.",
"   </p>",
"   <p>",
"    Teratomas are divided into four categories: mature (cystic or solid, benign), immature (malignant), malignant due to a component of another somatic malignant neoplasm, and monodermal or highly specialized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mature cystic teratoma (dermoid cyst)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most teratomas are cystic and composed of mature differentiated (adult); they are better known as dermoid cysts. The mature cystic teratoma accounts for more than 95 percent of all ovarian teratomas and is almost invariably benign [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/11\">",
"     11",
"    </a>",
"    ]. Dermoid cysts are the most common ovarian tumor in women in the second and third decade of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mature cystic teratomas contain mature tissue of ectodermal (eg, skin, hair follicles, sebaceous glands), mesodermal (eg, muscle, urinary), and endodermal origin (eg, lung, gastrointestinal) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/12\">",
"     12",
"    </a>",
"    ]. The mechanism by which these cysts develop is possibly by failure of meiosis II or from a premeiotic cell in which meiosis I has failed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/13\">",
"     13",
"    </a>",
"    ]. They are bilateral in 10 to 17 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristic macroscopic appearance of benign cystic teratomas is a multicystic mass that contains hair, teeth,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin that is mixed into sebaceous, thick, sticky, and often foul-smelling material (",
"    <a class=\"graphic graphic_picture graphicRef70608 \" href=\"UTD.htm?21/22/21858\">",
"     picture 1",
"    </a>",
"    ). A solid prominence (Rokitansky's protuberance) is located at the junction between the teratoma and normal ovarian tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/2\">",
"     2",
"    </a>",
"    ]. The greatest cellular variety is found in the area of this junction, which should therefore be examined carefully by the pathologist to exclude",
"    <span class=\"nowrap\">",
"     immature/malignant",
"    </span>",
"    components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with dermoid cysts are asymptomatic. If present, symptoms depend upon the size of the mass. Torsion is not uncommon. Rupture of dermoid cysts with spillage of sebaceous material into the abdominal cavity can occur, but is uncommon. Shock and hemorrhage are the immediate sequelae of rupture; a marked granulomatous reaction (chemical peritonitis) may subsequently develop and lead to formation of dense adhesions.",
"   </p>",
"   <p>",
"    A rare condition associated with either mature or immature teratomas is Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link&amp;anchor=H3370789#H3370789\">",
"     \"Paraneoplastic and autoimmune encephalitis\", section on 'Anti-NMDA receptor encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;These tumors have a characteristic ultrasound appearance, which allows reasonably accurate noninvasive diagnosis in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/16\">",
"     16",
"    </a>",
"    ]. The reported specificity is 98 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Definitive diagnosis is made at the time of surgical excision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cystectomy is suggested in order to make a definitive diagnosis, preserve ovarian tissue, and avoid potential problems such as torsion, rupture, or development of malignant components. For women who have completed childbearing, salpingo-oophorectomy is also acceptable treatment. Benign cystic teratomas do not recur if surgically resected.",
"   </p>",
"   <p>",
"    Dermoid cysts may be removed via either laparoscopy or laparotomy. With either approach, the abdomen should be copiously irrigated to avoid a chemical peritonitis from spillage of the sebaceous cyst fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link&amp;anchor=H23#H23\">",
"     \"Oophorectomy and ovarian cystectomy\", section on 'Laparoscopic cystectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Malignant transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant transformation occurs in 0.2 to 2 percent of mature cystic teratomas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Mature teratomas with malignant transformation comprise 2.9 percent of all malignant OGCNs (",
"    <a class=\"graphic graphic_table graphicRef72483 \" href=\"UTD.htm?15/13/15579\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/6\">",
"     6",
"    </a>",
"    ]. Although any of the components of a mature cystic teratoma may undergo malignant degeneration, squamous cell carcinoma arising from the ectoderm is the most common secondary neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/14,21\">",
"     14,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for malignant neoplasm in a mature cystic teratoma include age over 45 years (mean age 50 years versus 33 years for benign teratomas), tumor diameter greater than 10 cm, rapid growth, and findings on imaging (eg, low resistance intra-tumor flow on Doppler) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/14,21\">",
"     14,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possible malignant neoplasms include (but are not limited to) basal cell carcinoma, melanoma, adenocarcinoma, sarcoma, and thyroid carcinoma. When malignant transformation has occurred within a teratoma, treatment must be tailored to the transformed histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Monodermal highly specialized teratomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specialized or monodermal teratomas are a rare and remarkable subset of teratomas that consist of a predominant mature histologic cell type, the most common of which are struma ovarii and carcinoid, a well-differentiated neuroendocrine neoplasm. They are usually unilateral, although a contralateral teratoma may be present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Struma ovarii &mdash; Struma ovarii is a benign teratoma predominantly composed of mature thyroid tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/12\">",
"       12",
"      </a>",
"      ]. The secretion of thyroid hormones results in clinical hyperthyroidism in 25 to 35 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13799?source=see_link\">",
"       \"Struma ovarii\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carcinoid neoplasms &mdash; Ovarian carcinoid neoplasms are rare [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/22\">",
"       22",
"      </a>",
"      ]. Primary ovarian carcinoid neoplasms are usually unilateral, localized to the ovary, and indistinguishable histologically from metastasis. They have similar appearances to those that arise in any other site (eg, gastrointestinal or respiratory). They are comprised of nests and cords of relatively bland cells with endocrine features and a fine vascular network. Some carcinoid neoplasms secrete bioactive polypeptides and amines, producing a constellation of symptoms, predominantly flushing and diarrhea (",
"      <a class=\"graphic graphic_table graphicRef63079 \" href=\"UTD.htm?37/54/38763\">",
"       table 5",
"      </a>",
"      ). Carcinoid syndrome develops in about one-third of cases, and it can develop without hepatic metastases due to direct venous drainage from the ovary into the systemic circulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical characteristics of carcinoid tumors\", section on 'Ovary'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical features of the carcinoid syndrome\", section on 'Clinical features'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      5-hydroxyindoleacetic acid, a metabolite of serotonin (",
"      <a class=\"graphic graphic_figure graphicRef51368 \" href=\"UTD.htm?12/15/12542\">",
"       figure 2",
"      </a>",
"      ), is excreted in the urine and can be used to confirm the diagnosis of carcinoid syndrome, and as a marker of disease activity in patients with advanced disease or the carcinoid syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Biochemical testing for the carcinoid syndrome'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Carcinoid tumors metastatic to the ovary are even more rare; they tend to be bilateral and arise from primary ileal carcinoid tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/23\">",
"       23",
"      </a>",
"      ]. In such cases, disseminated abdominal disease is common.",
"     </li>",
"     <li>",
"      Mixed struma ovarii and carcinoid &mdash; The presence of a mixed struma ovarii and carcinoid is even more rare. These lesions usually follow a benign course.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mature solid teratoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare instances, a teratoma is solid but is composed entirely of benign-appearing heterogeneous collections of tissue and organized structures derived from all three cell layers. Most mature solid teratomas are unilateral and benign, although peritoneal implants have been described. Grossly, it may be",
"    <span class=\"nowrap\">",
"     difficult/impossible",
"    </span>",
"    to differentiate these neoplasms from malignant solid immature teratomas, which are almost always solid and they therefore require liberal sampling (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Immature teratoma'",
"    </a>",
"    below). Management is as described above for mature cystic teratomas (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Immature teratoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immature teratomas are also called malignant teratoma, teratoblastoma, or embryonal teratoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/12\">",
"     12",
"    </a>",
"    ]. They comprise less than 1 percent of ovarian teratomas and are most common in the first two decades of life. They comprise 35.6 percent of all malignant OGCNs (",
"    <a class=\"graphic graphic_table graphicRef72483 \" href=\"UTD.htm?15/13/15579\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;These neoplasms are typically composed of tissue from the three germ cell layers: ectoderm, mesoderm, and endoderm, arranged in a haphazard manner. Histologically, there are varying amounts of immature tissue, most frequently with neural differentiation, although immature stromal elements can also be present.",
"   </p>",
"   <p>",
"    Immature teratomas are the only OGCN that are histologically graded. The grade of differentiation (ranging from I [well differentiated] to III [poorly differentiated]) is based upon the proportion of tissue in histologic sections containing immature neural elements [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/24\">",
"     24",
"    </a>",
"    ]. Grade is an important indicator of the risk for extraovarian spread. The presence of foci of yolk sac tumor in immature teratomas generally reflects more aggressive behavior and a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation is similar to that of other OGCNs (incidentally discovered adnexal mass, abdominal enlargement or pain). In some cases, AFP or LDH may be elevated.",
"   </p>",
"   <p>",
"    A rare condition associated with either mature or immature teratomas is anti-N-methyl-D-aspartate (NMDA) receptor encephalitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link&amp;anchor=H3370789#H3370789\">",
"     \"Paraneoplastic and autoimmune encephalitis\", section on 'Anti-NMDA receptor encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DYSGERMINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although dysgerminomas are relatively uncommon among all ovarian neoplasms (accounting for only about 2 percent), they account for 32.8 percent of malignant OGCNs (",
"    <a class=\"graphic graphic_table graphicRef72483 \" href=\"UTD.htm?15/13/15579\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/6\">",
"     6",
"    </a>",
"    ]. The majority of cases (75 percent) arise in adolescents and young adults, in whom they account for about one-third of all ovarian malignant neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/26\">",
"     26",
"    </a>",
"    ]. Because of their predilection for young women, they are one of the more common ovarian malignant neoplasms detected during pregnancy. Nevertheless, dysgerminoma can occur at any age; case reports have described patients with dysgerminoma between 7 months and 70 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although dysgerminomas are considered to be malignant, the degree of histologic atypia is variable, and only about one-third behave aggressively. The neoplasm is composed of undifferentiated germ cells, large vesicular cells with clear cytoplasm, well-defined cell boundaries, and centrally placed regular nuclei; the overall appearance is sometimes described as resembling \"fried eggs\" (",
"    <a class=\"graphic graphic_picture graphicRef79890 \" href=\"UTD.htm?12/14/12519\">",
"     picture 2",
"    </a>",
"    ). The stroma is infiltrated by clusters of small lymphocytes and frequently contains granulomas. Dysgerminoma is the ovarian counterpart of testicular seminoma; histologically it has a similar appearance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"     \"Anatomy and pathology of testicular tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Grossly, dysgerminoma appears as a lobulated mass that is firm and cream colored or pale tan (",
"    <a class=\"graphic graphic_picture graphicRef73177 \" href=\"UTD.htm?7/13/7380\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dysgerminomas may develop within a gonadoblastoma (a benign or in situ germ cell ovarian neoplasm composed of germ cells and sex cord stroma) in phenotypic females who have a Y chromosome. Included in this group are patients with pure gonadal dysgenesis 46XY, mixed gonadal dysgenesis",
"    <span class=\"nowrap\">",
"     45X/46XY,",
"    </span>",
"    or complete androgen insensitivity (formerly called testicular feminization) 46XY. Occasional patients may have stigmata of Turner syndrome. These latter patients may have a 45X,",
"    <span class=\"nowrap\">",
"     45X/46XX,",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     45X/46XY",
"    </span>",
"    karyotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Risk of malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first two patients with unique gonadal tumors were described in 1953, at which time the term gonadoblastoma was introduced [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/27\">",
"     27",
"    </a>",
"    ]. These tumors may produce either testosterone or estrogens. Clinical presentation may include developmental abnormalities of the genitalia, primary amenorrhea, or virilization. Although gonadoblastoma may be overgrown by dysgerminoma, as occurs in approximately 50 percent of cases, other malignant germ cell components may predominate, including yolk sac tumor, immature teratoma, embryonal carcinoma, or choriocarcinoma. Thus, karyotyping is recommended for all patients with the operative finding of gonadoblastoma, with or without a coexistent malignant germ cell tumor, or young patients who present with an ovarian mass or masses and either primary amenorrhea or abnormalities of the genitalia.",
"   </p>",
"   <p>",
"    It is important to determine whether a gonadoblastoma is present, since oophorectomy should be performed in these patients to prevent the development of gonadal neoplasia, although the age at which the procedure is performed depends upon the underlying etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Women at risk for having dysgenetic gonads ideally should be identified preoperatively; frozen section is not reliable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The growth of dysgerminomas is usually rapid; as a result, patients often present with abdominal enlargement and pain due to rupture with hemoperitoneum or torsion. Menstrual abnormalities may occur if the tumor is hormonally active.",
"   </p>",
"   <p>",
"    Dysgerminomas can contain syncytiotrophoblastic giant cells that produce placental alkaline phosphatase, and lactate dehydrogenase (LDH) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Serial measurements of these markers can be useful for monitoring disease (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 3",
"    </a>",
"    ). In addition, 3 to 5 percent of dysgerminomas produce human chorionic gonadotropin (hCG). In general, dysgerminomas do not produce alpha-fetoprotein (AFP), although borderline elevations (&lt;16",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    are described in case series, but most often in the setting of mixed germ cell tumors that contain a yolk sac element.",
"   </p>",
"   <p>",
"    Seventy-five percent of women with dysgerminomas present with stage I disease (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 4",
"    </a>",
"    ); the contralateral ovary is involved in 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Bilateral ovarian disease is more common with dysgerminoma than with any other malignant OGCN.",
"   </p>",
"   <p>",
"    Surgery is performed for definitive diagnosis, staging, and initial treatment. For a unilateral neoplasm confined to the ovary without capsular involvement or rupture (stage IC), simple salpingo-oophorectomy is curative in over 95 percent. Treatment is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ENDODERMAL SINUS (YOLK SAC) TUMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endodermal sinus tumors (also called yolk sac tumors) make up 14 to 20 percent of all malignant OGCNs (",
"    <a class=\"graphic graphic_table graphicRef72483 \" href=\"UTD.htm?15/13/15579\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/6,34\">",
"     6,34",
"    </a>",
"    ]. The name was chosen because the tumor structure is similar to that of the endodermal sinuses of the rat yolk sac and is derived from the primitive yolk sac. These neoplasms usually occur in young girls and women; the median age at presentation is 23 years and one-third of patients are premenarchal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, these epithelial neoplasms consist of tubules or spaces lined by single layers of flattened cuboidal cells, reticular stroma, and scattered globules (",
"    <a class=\"graphic graphic_picture graphicRef83636 \" href=\"UTD.htm?9/50/10026\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/37\">",
"     37",
"    </a>",
"    ]. Invaginated papillary structures with a central vessel (Schiller-Duval bodies) are found within some of the spaces (",
"    <a class=\"graphic graphic_picture graphicRef58480 \" href=\"UTD.htm?43/11/44215\">",
"     picture 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with endodermal sinus tumors often present with abdominal pain and a pelvic mass, similar to dysgerminomas. The pain may be acute and is commonly misdiagnosed as appendicitis.",
"   </p>",
"   <p>",
"    Tumor growth can be very rapid and aggressive with extensive intraperitoneal dissemination. Serum AFP levels are elevated in a significant number of patients and, if elevated, are useful for monitoring the response to treatment and for post-treatment surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Serum LDH may also be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of endodermal sinus tumors is discussed in detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     EMBRYONAL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryonal carcinoma accounts for 4 percent of malignant OGCNs (",
"    <a class=\"graphic graphic_table graphicRef72483 \" href=\"UTD.htm?15/13/15579\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/6,41\">",
"     6,41",
"    </a>",
"    ]. It resembles the more common embryonal carcinoma of the testis and is one of the most aggressive ovarian malignant neoplasms. The average age at diagnosis is 15 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"     \"Anatomy and pathology of testicular tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, this neoplasm is epithelial and therefore forms nests and may form papillary or gland-like structures. Many atypical mitotic figures are usually present, reflecting the high proliferative activity of the neoplastic cells. Multinucleated giant cells resembling syncytial cells may be present; these are the cells that produce hCG [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with embryonal carcinoma usually present with an abdominal or pelvic mass and abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/42\">",
"     42",
"    </a>",
"    ]. Most of these neoplasms produce hCG, while some also make AFP (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     MIXED GERM CELL NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed germ cell neoplasms consist of two or more admixed types of ovarian germ cell neoplasms. They account for 5.3 percent of all malignant OGCNs (",
"    <a class=\"graphic graphic_table graphicRef72483 \" href=\"UTD.htm?15/13/15579\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/6\">",
"     6",
"    </a>",
"    ]. Components of dysgerminoma mixed with an endodermal sinus tumor are found most commonly. In cases in which a dysgerminoma component is present, the contralateral ovary is involved 10 percent of the time. The neoplasms may secrete tumor markers, such as LDH, AFP, or hCG, depending upon the type of tissue present.",
"   </p>",
"   <p>",
"    Treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     POLYEMBRYOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyembryoma is composed of embryoid bodies that morphologically resemble normal embryos [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/2\">",
"     2",
"    </a>",
"    ]. This malignant germ cell neoplasms is very rare and, in most instances, is associated with other germ cell elements such as immature teratoma. It usually occurs in young girls and may present with signs of pseudopuberty.",
"   </p>",
"   <p>",
"    Polyembryoma is a very aggressive tumor with extensive local infiltration and distant metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/43\">",
"     43",
"    </a>",
"    ]. Serum hCG and AFP concentrations may be elevated.",
"   </p>",
"   <p>",
"    Treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     CHORIOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-gestational choriocarcinoma is a rare and highly malignant type of OGCN [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/44\">",
"     44",
"    </a>",
"    ]. Choriocarcinomas are more commonly of placental than ovarian origin; the estimated incidence of a primary ovarian choriocarcinoma is 1 in 369,000,000. They comprise 2.1 percent of all malignant OGCNs (",
"    <a class=\"graphic graphic_table graphicRef72483 \" href=\"UTD.htm?15/13/15579\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/6\">",
"     6",
"    </a>",
"    ]. A choriocarcinoma of ovarian origin derives from an extraembryonic differentiation of malignant germ cells. This highly malignant germ cell epithelial neoplasm differentiates towards trophoblastic structures and often contains other malignant germ cell elements.",
"   </p>",
"   <p>",
"    Non-gestational ovarian choriocarcinoma is histologically identical to primary gestational choriocarcinoma associated with pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The two entities can be distinguished by DNA analysis; the presence of paternal DNA within the tumor indicates a gestational (placental) origin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5721/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=see_link&amp;anchor=H25#H25\">",
"     \"Gestational trophoblastic disease: Pathology\", section on 'Choriocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All choriocarcinomas produce hCG, which may cause isosexual precocity in young girls and irregular vaginal bleeding of uterine origin. Serum levels of hCG are useful for monitoring response to treatment.",
"   </p>",
"   <p>",
"    Like gestational choriocarcinomas, those arising in the ovary tend to develop early hematogenous metastasis to several different sites, including lung, liver, brain, bone, vagina, and other viscera. In contrast to gestational choriocarcinomas, those arising in the ovary are relatively chemoresistant.",
"   </p>",
"   <p>",
"    Treatment is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian germ cell neoplasms are derived from primordial germ cells of the ovary (",
"      <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"       figure 1",
"      </a>",
"      ). They may be benign or malignant. These neoplasms comprise approximately 20 to 25 percent of ovarian neoplasms overall, but account for only about 5 percent of all malignant ovarian neoplasms. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ovarian germ cell neoplasms arise primarily in young women between 10 and 30 years of age; they represent 70 percent of ovarian neoplasms in this age group. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ovarian germ cell neoplasms often produce tumor markers (",
"      <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Tumor markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common ovarian germ cell neoplasm is the benign mature cystic teratoma (dermoid cyst), which can be bilateral. Approximately 1 percent contain a secondary malignancy arising from one of the components, usually a squamous cell cancer. Ovarian cystectomy or oophorectomy provides definitive diagnosis and treatment (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Mature cystic teratoma (dermoid cyst)'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Dysgerminoma is the most common malignant ovarian germ cell neoplasm. Bilateral ovarian disease is more common than with any other ovarian germ cell neoplasm. These neoplasms are less likely to produce tumor markers than other malignant germ cell neoplasms (",
"      <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"       table 3",
"      </a>",
"      ), but lactic dehydrogenase is often elevated (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Dysgerminoma'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/1\">",
"      Sagae S, Kudo R. Surgery for germ cell tumors. Semin Surg Oncol 2000; 19:76.",
"     </a>",
"    </li>",
"    <li>",
"     Talerman A. Germ cell tumours of the ovary. In: Blaustein's Pathology of the Female Genital Tract, Kurman RJ (Ed), Springer Verlag, New York 1994. p.849.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/3\">",
"      Tewari K, Cappuccini F, Disaia PJ, et al. Malignant germ cell tumors of the ovary. Obstet Gynecol 2000; 95:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/4\">",
"      Zalel Y, Piura B, Elchalal U, et al. Diagnosis and management of malignant germ cell ovarian tumors in young females. Int J Gynaecol Obstet 1996; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     Serov SF, Scully RE, Sobin LJ. Histological typing of ovarian tumors. In: International Histological Classification of Tumors, World Health Organization, Geneva 1973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/6\">",
"      Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006; 107:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/7\">",
"      Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev 2008; 34:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/8\">",
"      Ihara T, Ohama K, Satoh H, et al. Histologic grade and karyotype of immature teratoma of the ovary. Cancer 1984; 54:2988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/9\">",
"      Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18:3809.",
"     </a>",
"    </li>",
"    <li>",
"     Berek JS. Epithelial ovarian cancer. In: Practical Gynecologic Oncology, 4th, Berek JS, Hacker NF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.443.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/11\">",
"      Ayhan A, Bukulmez O, Genc C, et al. Mature cystic teratomas of the ovary: case series from one institution over 34 years. Eur J Obstet Gynecol Reprod Biol 2000; 88:153.",
"     </a>",
"    </li>",
"    <li>",
"     DiSaia PJ, Creasman WT. Germ cell, stromal and other ovarian tumors. In: Clinical Gynecologic Oncology, 7th, Mosby-Elsevier, 2007. p.381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/13\">",
"      Caspi B, Lerner-Geva L, Dahan M, et al. A possible genetic factor in the pathogenesis of ovarian dermoid cysts. Gynecol Obstet Invest 2003; 56:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/14\">",
"      Hackethal A, Brueggmann D, Bohlmann MK, et al. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncol 2008; 9:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/15\">",
"      Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/16\">",
"      Patel MD, Feldstein VA, Lipson SD, et al. Cystic teratomas of the ovary: diagnostic value of sonography. AJR Am J Roentgenol 1998; 171:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/17\">",
"      Tongsong T, Luewan S, Phadungkiatwattana P, et al. Pattern recognition using transabdominal ultrasound to diagnose ovarian mature cystic teratoma. Int J Gynaecol Obstet 2008; 103:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/18\">",
"      Westhoff C, Pike M, Vessey M. Benign ovarian teratomas: a population-based case-control study. Br J Cancer 1988; 58:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/19\">",
"      Comerci JT Jr, Licciardi F, Bergh PA, et al. Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature. Obstet Gynecol 1994; 84:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/20\">",
"      Singh P, Yordan EL, Wilbanks GD, et al. Malignancy associated with benign cystic teratomas (dermoid cysts) of the ovary. Singapore Med J 1988; 29:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/21\">",
"      Dos Santos L, Mok E, Iasonos A, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol 2007; 105:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/22\">",
"      Davis KP, Hartmann LK, Keeney GL, Shapiro H. Primary ovarian carcinoid tumors. Gynecol Oncol 1996; 61:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/23\">",
"      Strosberg J, Nasir A, Cragun J, et al. Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. Gynecol Oncol 2007; 106:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/24\">",
"      Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 1976; 37:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/25\">",
"      Woodruff JD, Protos P, Peterson WF. Ovarian teratomas. Relationship of histologic and ontogenic factors to prognosis. Am J Obstet Gynecol 1968; 102:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/26\">",
"      La Vecchia C, Morris HB, Draper GJ. Malignant ovarian tumours in childhood in Britain, 1962-78. Br J Cancer 1983; 48:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/27\">",
"      SCULLY RE. Gonadoblastoma; a gonadal tumor related to the dysgerminoma (seminoma) and capable of sex-hormone production. Cancer 1953; 6:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/28\">",
"      Krasna IH, Lee ML, Smilow P, et al. Risk of malignancy in bilateral streak gonads: the role of the Y chromosome. J Pediatr Surg 1992; 27:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/29\">",
"      De Arce MA, Costigan C, Gosden JR, et al. Further evidence consistent with Yqh as an indicator of risk of gonadal blastoma in Y-bearing mosaic Turner syndrome. Clin Genet 1992; 41:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/30\">",
"      Levato F, Martinello R, Campobasso C, Porto S. LDH and LDH isoenzymes in ovarian dysgerminoma. Eur J Gynaecol Oncol 1995; 16:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/31\">",
"      Schwartz PE, Morris JM. Serum lactic dehydrogenase: a tumor marker for dysgerminoma. Obstet Gynecol 1988; 72:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/32\">",
"      Gordon A, Lipton D, Woodruff JD. Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol 1981; 58:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/33\">",
"      Boran N, Tulunay G, Caliskan E, et al. Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas. Arch Gynecol Obstet 2005; 271:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/34\">",
"      Fujita M, Inoue M, Tanizawa O, et al. Retrospective review of 41 patients with endodermal sinus tumor of the ovary. Int J Gynecol Cancer 1993; 3:329.",
"     </a>",
"    </li>",
"    <li>",
"     Berek JS, Hacker NF. Nonepithelial ovarian and fallopian tube cancers. In: Practical Gynecologic Oncology, 4th, Berek JS, Hacker NF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.511.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/36\">",
"      Shah JP, Kumar S, Bryant CS, et al. A population-based analysis of 788 cases of yolk sac tumors: A comparison of males and females. Int J Cancer 2008; 123:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/37\">",
"      Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer 1976; 38:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/38\">",
"      Talerman A, Haije WG, Baggerman L. Serum alphafetoprotein (AFP) in diagnosis and management of endodermal sinus (yolk sac) tumor and mixed germ cell tumor of the ovary. Cancer 1978; 41:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/39\">",
"      Gershenson DM, Del Junco G, Herson J, Rutledge FN. Endodermal sinus tumor of the ovary: the M. D. Anderson experience. Obstet Gynecol 1983; 61:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/40\">",
"      Kawai M, Kano T, Kikkawa F, et al. Seven tumor markers in benign and malignant germ cell tumors of the ovary. Gynecol Oncol 1992; 45:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/41\">",
"      Abu-Rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin Oncol 1998; 25:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/42\">",
"      Ueda G, Abe Y, Yoshida M, Fujiwara T. Embryonal carcinoma of the ovary: a six-year survival. Int J Gynaecol Obstet 1990; 31:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/43\">",
"      Chapman DC, Grover R, Schwartz PE. Conservative management of an ovarian polyembryoma. Obstet Gynecol 1994; 83:879.",
"     </a>",
"    </li>",
"    <li>",
"     DiSaia PJ, Creasman WT. Germ cell, stromal and other ovarian tumors. In: Clinical Gynecologic Oncology, 7th, Mosby-Elsevier, 2007. p.379.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/45\">",
"      Wheeler CA, Davis S, Degefu S, et al. Ovarian choriocarcinoma: a difficult diagnosis of an unusual tumor and a review of the hook effect. Obstet Gynecol 1990; 75:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/46\">",
"      Steigrad SJ, Cheung AP, Osborn RA. Choriocarcinoma co-existent with an intact pregnancy: case report and review of the literature. J Obstet Gynaecol Res 1999; 25:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/47\">",
"      Cunanan RG Jr, Lippes J, Tancinco PA. Choriocarcinoma of the ovary with coexisting normal pregnancy. Obstet Gynecol 1980; 55:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5721/abstract/48\">",
"      Fisher RA, Newlands ES, Jeffreys AJ, et al. Gestational and nongestational trophoblastic tumors distinguished by DNA analysis. Cancer 1992; 69:839.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3236 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5721=[""].join("\n");
var outline_f5_37_5721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF OVARIAN GERM CELL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Histopathology overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TERATOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mature cystic teratoma (dermoid cyst)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Monodermal highly specialized teratomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mature solid teratoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Immature teratoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DYSGERMINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ENDODERMAL SINUS (YOLK SAC) TUMOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      EMBRYONAL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      MIXED GERM CELL NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      POLYEMBRYOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      CHORIOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3236\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3236|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44307\" title=\"figure 1\">",
"      Origins ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/15/12542\" title=\"figure 2\">",
"      Tryptophan and serotonin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3236|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/22/21858\" title=\"picture 1\">",
"      Mature teratoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/14/12519\" title=\"picture 2\">",
"      Dysgerminoma histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/13/7380\" title=\"picture 3\">",
"      Dysgerminoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/50/10026\" title=\"picture 4\">",
"      Endodermal sinus tumor histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/11/44215\" title=\"picture 5\">",
"      Schiller-Duval body",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3236|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/55/16251\" title=\"table 1\">",
"      Types of germ cell neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/13/15579\" title=\"table 2\">",
"      Frequency malignant OGCNs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/4/24653\" title=\"table 3\">",
"      Ovarian tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 4\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/54/38763\" title=\"table 5\">",
"      Carcinoid symptoms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=related_link\">",
"      Gestational trophoblastic disease: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13799?source=related_link\">",
"      Struma ovarii",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=related_link\">",
"      Treatment of malignant germ cell tumors of the ovary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_37_5722="Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age";
var content_f5_37_5722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/37/5722/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5722/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/37/5722/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5722/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5722/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/37/5722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/37/5722/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/37/5722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood and adolescent immunizations are one of the most effective means of preventing serious illness. Diphtheria, tetanus, and pertussis immunization in infants and children zero through six years of age will be discussed here. Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age and other childhood immunizations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria is an acute respiratory or cutaneous illness caused by",
"    <em>",
"     Corynebacterium diphtheriae",
"    </em>",
"    . Respiratory diphtheria has a case fatality rate of 5 to 10 percent; mortality is increased (up to 20 percent) among children younger than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11046?source=see_link\">",
"     \"Diagnosis and treatment of diphtheria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tetanus is a nervous system disorder characterized by muscle spasms. It is caused by",
"    <em>",
"     Clostridium tetani",
"    </em>",
"    , a toxin-producing anaerobe. Mortality is increased among unvaccinated persons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pertussis, or \"whooping cough\", is an acute respiratory illness caused by",
"    <em>",
"     Bordetella pertussis",
"    </em>",
"    . The case fatality rate for pertussis is approximately 0.2 percent; mortality is increased among infants younger than three months of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines for diphtheria, tetanus, and pertussis were introduced into the routine childhood immunization schedule in the United States during the 1940s, with dramatic effects on disease incidence (",
"    <a class=\"graphic graphic_figure graphicRef72244 graphicRef53397 graphicRef62288 \" href=\"UTD.htm?4/29/4566\">",
"     figure 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vaccine components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria, tetanus, and pertussis immunizations for infants and children (zero through six years) include diphtheria toxoid, tetanus toxoid, and acellular or whole-cell pertussis vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Whole-cell pertussis-containing vaccines are no longer available in the United States, but are used elsewhere in the world.",
"   </p>",
"   <p>",
"    The pertussis antigens that are included in acellular pertussis vaccines and the amount of diphtheria and tetanus toxoids vary depending upon the vaccine product (",
"    <a class=\"graphic graphic_table graphicRef73107 \" href=\"UTD.htm?33/15/34045\">",
"     table 1",
"    </a>",
"    ). Vaccines for children younger than seven years contain more diphtheria toxoid and pertussis antigens and may contain more tetanus toxoid than vaccines for children older than seven years and adults.",
"   </p>",
"   <p>",
"    Conjugate vaccines that contain diphtheria toxoid or CRM197, a nontoxic variant of diphtheria toxin (eg, pneumococcal conjugate vaccine, meningococcal conjugate vaccine), are not substitutes for diphtheria toxoid immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/5\">",
"     5",
"    </a>",
"    ]. The conjugate",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    vaccines that contain tetanus toxoid (PRP-T [ActHIB, Hiberix]) are not a substitute for tetanus toxoid immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vaccine preparations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diphtheria-tetanus-pertussis &ndash; Two federally licensed combined diphtheria-tetanus-acellular pertussis (DTaP) vaccines are available in the United States for the first five doses: Daptacel and Infanrix [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"       4",
"      </a>",
"      ]. DTaP also is available in combination with other vaccines (eg, inactivated polio vaccine,",
"      <em>",
"       H. influenzae",
"      </em>",
"      type b, hepatitis B) (",
"      <a class=\"graphic graphic_table graphicRef73107 \" href=\"UTD.htm?33/15/34045\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Some preparations of DTaP may contain latex.",
"      <br/>",
"      <br/>",
"      Diphtheria-tetanus-whole cell pertussis vaccines (DTwP) are no longer available in the United States, but are used elsewhere in the world.",
"      <br/>",
"      <br/>",
"      Care must be taken to distinguish DTaP from the tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine (Tdap), which is used for a single booster dose during adolescence or adulthood (",
"      <a class=\"graphic graphic_table graphicRef73107 \" href=\"UTD.htm?33/15/34045\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link&amp;anchor=H4#H4\">",
"       \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\", section on 'Vaccine preparations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diphtheria and tetanus toxoids &ndash; A vaccine that includes diphtheria and tetanus toxoids, but not pertussis (DT, pediatric DT) is available for children younger than seven years in whom it is desirable to avoid pertussis vaccine. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Contraindications'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22\">",
"       'Precautions'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Care must be taken to distinguish DT from the reduced diphtheria toxoid and tetanus toxoid vaccine (dT, Td, adult dT, adult Td) which is the vaccine typically used for booster doses in adolescents and adults (",
"      <a class=\"graphic graphic_table graphicRef73107 \" href=\"UTD.htm?33/15/34045\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link&amp;anchor=H4#H4\">",
"       \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\", section on 'Vaccine preparations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choice of vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;DTaP is the vaccine of choice for children six weeks through six years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/9\">",
"     9",
"    </a>",
"    ]. The risk of adverse reactions is lower with acellular than whole-cell pertussis vaccines. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Adverse reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When it is feasible, the same brand of DTaP vaccine should be used for all DTaP doses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ]. However, an opportunity to administer a dose of DTaP to an eligible child should not be missed because the brand used for earlier doses is not available (or not known). Limited data suggest that using different brands to complete the primary series does not adversely affect vaccine safety or immunogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/3,9\">",
"     3,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dose and route",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of diphtheria toxoid, tetanus toxoid, and pertussis vaccines is 0.5 mL. The vaccines are administered intramuscularly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/9\">",
"     9",
"    </a>",
"    ]. The anterolateral thigh is the preferred site for children younger than three years and the deltoid the preferred site for children older than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In observational studies, local reactions requiring medical attention are uncommon following DTaP, occurring in &lt;1 percent of children &lt;3 years and approximately 1.5 percent of children three to six years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/12\">",
"     12",
"    </a>",
"    ]. Administration in the anterolateral thigh is associated with fewer such reactions than administration in the deltoid [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Adverse reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Storage and handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria toxoid-, tetanus toxoid-, and acellular pertussis-containing vaccines should be stored continuously at 35&ordm; to 46&ordm;F (2&ordm; to 8&ordm;C) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/11\">",
"     11",
"    </a>",
"    ]. During transport, the vaccine may be out of refrigeration for as long as four days, but it should be refrigerated immediately upon arrival. Freezing reduces the potency of the tetanus component; vaccine exposed to freezing temperature should not be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EFFICACY AND EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and effectiveness of diphtheria, tetanus, and pertussis immunization vary depending upon the definition used for efficacy (ie, levels of antibody correlated with protection or protection from disease) and the number of doses received. Vaccine effectiveness is a measure of how well a vaccine works to protect against an infection when the vaccine is used in routine circumstances in the community.",
"   </p>",
"   <p>",
"    After a series of four appropriately spaced doses of diphtheria-tetanus toxoid-containing vaccines, approximately 95 percent of infants and children achieve levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/15/21745?source=see_link\">",
"     diphtheria antitoxin",
"    </a>",
"    correlated with protection (&gt;0.1 international unit of",
"    <span class=\"nowrap\">",
"     antitoxin/mL)",
"    </span>",
"    and virtually all infants and children achieve levels of tetanus antitoxin correlated with protection (&gt;0.1 international unit of",
"    <span class=\"nowrap\">",
"     antitoxin/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated efficacy of diphtheria toxoid in the prevention of diphtheria disease is 97 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical efficacy of tetanus toxoid has not been studied in vaccine trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review, the efficacy of acellular pertussis vaccines containing &ge;3 pertussis antigens (",
"    <a class=\"graphic graphic_table graphicRef73107 \" href=\"UTD.htm?33/15/34045\">",
"     table 1",
"    </a>",
"    ) was approximately 85 percent in preventing typical pertussis (&ge;21 days of cough with laboratory confirmation of pertussis in the vaccinee or household contact) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/14\">",
"     14",
"    </a>",
"    ]. The efficacy of acellular pertussis vaccines containing &lt;3 pertussis antigens ranged from 59 to 75 percent. When compared with DTwP, DTaP was as effective or more effective, with fewer adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/9,14-18\">",
"     9,14-18",
"    </a>",
"    ]. However, DTwP may provide more durable protection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of diphtheria, tetanus, and pertussis immunization is demonstrated by the decline of these diseases in the United States after the immunizations were added to the routine immunization schedule in the 1940s (",
"    <a class=\"graphic graphic_figure graphicRef72244 graphicRef53397 graphicRef62288 \" href=\"UTD.htm?4/29/4566\">",
"     figure 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1-3,23\">",
"     1-3,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protection provided by acellular pertussis vaccine decreases with time. A large pertussis outbreak in California in 2010 provided the opportunity to evaluate the effectiveness of acellular pertussis vaccines in several case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/20,21,24,25\">",
"     20,21,24,25",
"    </a>",
"    ]. In the largest study (682 cases), receipt of five doses of DTaP was associated with decreased risk of pertussis (odds ratio [OR] 0.11, 95% CI 0.06-0.21); the estimated vaccine effectiveness was 89 percent (95% CI 79-94 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/25\">",
"     25",
"    </a>",
"    ]. However, vaccine effectiveness decreased with increasing duration of time since the last dose of DTaP (from 98 percent in the first 12 months to 71 percent by &ge;60 months). These findings are consistent with those of other observational studies and national surveillance (",
"    <a class=\"graphic graphic_figure graphicRef86449 \" href=\"UTD.htm?6/61/7135\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/20,21,26-30\">",
"     20,21,26-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite waning immunity, vaccination continues to be the most effective strategy to reduce pertussis morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]. Further study of the safety and effectiveness of earlier",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    additional booster doses of acellular pertussis vaccine is necessary before changes to the routine immunization schedule are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/20,32\">",
"     20,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Waning immunity after Tdap is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link&amp;anchor=H117307237#H117307237\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\", section on 'Tdap'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AFP) recommend routine immunization with diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine for infants and children aged six weeks through six years (",
"    <a class=\"graphic graphic_figure graphicRef82617 \" href=\"UTD.htm?24/55/25463\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who are unimmunized or underimmunized should undergo catch-up immunization, as discussed below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Catch-up schedule'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Catch-up immunization is particularly important for the following children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Close contact of individual with pertussis disease (should complete the primary series with minimal intervals (",
"      <a class=\"graphic graphic_table graphicRef58271 \" href=\"UTD.htm?21/54/22383\">",
"       table 2",
"      </a>",
"      )) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Vaccination'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diphtheria disease or close contact of individual with diphtheria disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11046?source=see_link\">",
"       \"Diagnosis and treatment of diphtheria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tetanus disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     VACCINE SCHEDULE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Routine schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, five doses of diphtheria, tetanus, and pertussis vaccines are recommended between six weeks and seven years of age; a booster dose is recommended beginning at age 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/33\">",
"     33",
"    </a>",
"    ]. For children who have an absolute contraindication to pertussis vaccine, diphtheria-tetanus toxoid (DT) is an acceptable alternative. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Contraindications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5\">",
"     'Vaccine preparations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Administration of DTaP vaccine is typically recommended at 2 months, 4 months, 6 months, 15 through 18 months, and 4 to 6 years of age (",
"    <a class=\"graphic graphic_figure graphicRef82617 \" href=\"UTD.htm?24/55/25463\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The minimum age for administration of the first dose is six weeks (",
"      <a class=\"graphic graphic_table graphicRef58271 \" href=\"UTD.htm?21/54/22383\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The second and third doses should be given at minimum intervals of four weeks.",
"     </li>",
"     <li>",
"      The minimum interval between the third and fourth doses is six months. Although a six-month interval is preferred, if the fourth dose is accidentally given at least four months after the third dose, it should be counted as valid [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/34\">",
"       34",
"      </a>",
"      ]. The fourth dose may be given as early as 12 months of age if this interval is met and the child is considered unlikely to return for a visit at the recommended age of 15 to 18 months.",
"     </li>",
"     <li>",
"      The minimum age for the fifth dose is four years (",
"      <a class=\"graphic graphic_figure graphicRef82617 \" href=\"UTD.htm?24/55/25463\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58271 \" href=\"UTD.htm?21/54/22383\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/33\">",
"       33",
"      </a>",
"      ]. The minimum interval between the fourth and fifth doses is six months. If the fourth dose is delayed until after the patient is four years old, the fifth dose is not necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"       4",
"      </a>",
"      ], but may be given to increase pertussis antibody levels and decrease the risk of transmission to younger siblings who are not fully vaccinated [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diphtheria-, tetanus-, and pertussis-containing vaccines can be administered at the same visit as other recommended vaccines (",
"      <a class=\"graphic graphic_figure graphicRef82617 \" href=\"UTD.htm?24/55/25463\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/9,35\">",
"       9,35",
"      </a>",
"      ]. DTaP vaccine should not be mixed in the same syringe with another vaccine unless the specific combination is licensed by the FDA (eg, Pentacel) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4,36\">",
"       4,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Catch-up schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catch-up schedule for children with lapsed or incomplete diphtheria, tetanus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pertussis immunization is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef58271 \" href=\"UTD.htm?21/54/22383\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When catching up with diphtheria, tetanus, and pertussis immunizations, immunization should proceed with the next dose in the sequence, provided the minimum interval between doses has been met (",
"      <a class=\"graphic graphic_table graphicRef58271 \" href=\"UTD.htm?21/54/22383\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DTaP should be used to complete the immunization series for children younger than seven years with incomplete immunizations who received DTwP as part of the primary immunization series [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Maximum number of doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;No more than six doses of diphtheria-tetanus toxoid should be given before the seventh birthday (eg, in children who received one or more DT vaccines as part of the primary series) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Special circumstances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     History of pertussis disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural infection with diphtheria and tetanus disease does not induce immunity. Individuals with diphtheria or tetanus disease should receive diphtheria-tetanus toxoid during their convalescence (even if they were completely immunized before their illness) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11046?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis and treatment of diphtheria\", section on 'Follow up'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link&amp;anchor=H27#H27\">",
"     \"Tetanus\", section on 'Active immunization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Well-documented pertussis disease (eg, positive culture or epidemiologic linkage to a culture-proven case) confers short-term immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the duration of protection is unknown. DTaP should be used to complete the primary series (if the child is younger than seven years) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the administration of diphtheria and tetanus toxoids may be deferred until age 12 months for children in whom the decision is made to temporarily defer pertussis immunization (ie, during evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    observation of neurologic conditions) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"     4",
"    </a>",
"    ]. The risk of developing diphtheria or tetanus in such children is remote. However, at or near the first birthday, when the child becomes ambulatory, the risk of a tetanus-prone wound increases, and the decision to administer DT or DTaP must be made. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Neurologic condition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Use of DT vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of doses of DT vaccine needed to complete the primary series depends upon the child's age at the time of the first dose [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the first dose is administered at &lt;12 months of age, four doses (total) are necessary to complete the primary series.",
"     </li>",
"     <li>",
"      If the first dose is administered at &ge;12 months of age, three doses (total) are necessary to complete the primary series.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vaccine mix-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not inadvertent administration of Tdap (rather than DTaP) to a child younger than seven years should be counted as a valid dose depends upon which dose was inadvertently administered [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If Tdap is administered for the first, second, or third dose, it should not be counted as a valid dose. DTaP should be administered on the same day or as soon as possible to keep the child on schedule. The interval between the replacement dose of DTaP and the subsequent dose should be at least four weeks.",
"     </li>",
"     <li>",
"      If Tdap is administered as the fourth or fifth dose to a child &lt;7 years, it should be counted as valid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccine administration errors should be reported to the",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     Vaccine Adverse Event Reporting System",
"    </a>",
"    (telephone number: 1-800-822-7967).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications, precautions, and conditions that are neither contraindications nor precautions (and therefore should not be used to defer immunization) for diphtheria toxoid-, tetanus toxoid-,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acellular pertussis-containing vaccines are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef63855 \" href=\"UTD.htm?20/61/21469\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute contraindications to diphtheria-, tetanus-,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pertussis-containing immunizations include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4,7,9,11\">",
"     4,7,9,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylactic reaction to the diphtheria-, tetanus-,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pertussis-containing vaccine or vaccine constituent (contraindication to subsequent doses of all components) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"       \"Allergic reactions to vaccines\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Encephalopathy within seven days of the administration of a previous dose of the vaccine without another identifiable cause (contraindication to subsequent doses of pertussis vaccine)",
"     </li>",
"     <li>",
"      Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy (administration of pertussis-containing vaccines should be deferred until the neurologic status is clarified and stabilized) (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Neurologic disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Some DTaP vaccines contain latex and are contraindicated in patients with anaphylactic reaction to latex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children younger than seven years who have a contraindication to pertussis immunization should not receive subsequent doses of pertussis-containing vaccine, but they may receive DT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Vaccine preparations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precautions are conditions that might increase the risk for a serious reaction to immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/11\">",
"     11",
"    </a>",
"    ]. Precautions to immunization with pertussis-containing vaccines include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderate or severe illness with or without fever (immunization should be administered upon recovery)",
"     </li>",
"     <li>",
"      Certain adverse reactions to previous doses (discussed below)",
"     </li>",
"     <li>",
"      Certain neurologic conditions, or awaiting further characterization of neurologic conditions (discussed below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Previous reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of any of the following conditions (without another identifiable cause) after administration of a pertussis-containing vaccine is considered a precaution to administration of subsequent doses of DTaP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4,11,38-40\">",
"     4,11,38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Temperature &ge;105&ordm;F (40.5&ordm;C) within 48 hours of vaccine",
"     </li>",
"     <li>",
"      Hypotonic-hyporesponsive episode (collapse or shock-like state) within 48 hours of vaccine",
"     </li>",
"     <li>",
"      Seizure (with or without fever) within three days of vaccine",
"     </li>",
"     <li>",
"      Persistent, inconsolable crying for &ge;3 hours within 48 hours of vaccine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of a subsequent similar reaction is unknown. The possibility of such a reaction may justify discontinuing administration of pertussis vaccine. However, in certain circumstances (eg, an outbreak of pertussis) the benefits of pertussis immunization may outweigh the risks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/3\">",
"     3",
"    </a>",
"    ]. Several reports describe uneventful vaccination with acellular pertussis vaccine in children who had a hypotonic-hyporesponsive episode after immunization with whole-cell pertussis vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. Although the number of patients is small, vaccination of such patients with acellular pertussis vaccine appears to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previous adverse reactions to diphtheria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tetanus toxoids that constitute precautions to subsequent doses of diphtheria-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tetanus-containing vaccines include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guillain-Barr&eacute; syndrome (GBS) within six weeks of tetanus or diphtheria toxoid-containing vaccine. Although there have been case reports of GBS following tetanus or diphtheria toxoid-containing vaccines in adolescents and adults, an increased risk of GBS following diphtheria, tetanus, pertussis immunization has not been observed in children [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      History of Arthus-type reaction (a specific type III, immune complex mediated hypersensitivity reaction) following diphtheria or tetanus toxoid-containing vaccine, characterized by severe pain, swelling, induration, edema, hemorrhage, and occasionally necrosis at the injection site [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Neurologic condition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary or indefinite deferral of pertussis immunization may be warranted for infants and children with certain neurologic conditions (described below) or children who are undergoing evaluation for these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4,9,11\">",
"     4,9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decisions regarding pertussis immunization in such children should be made on a case-by-case basis, after weighing the risks and benefits of immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"     4",
"    </a>",
"    ]. The decision should be reassessed at subsequent immunization visits.",
"   </p>",
"   <p>",
"    Neurologic conditions that are considered precautions to administration of pertussis-containing vaccines include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conditions that predispose to seizures or neurologic deterioration &ndash; To avoid confusion about causation, children with unstable or evolving neurologic conditions that predispose to seizures or neurologic deterioration (eg, tuberous sclerosis complex, inherited metabolic or degenerative conditions) should not receive pertussis vaccine until the diagnosis and prognosis of the neurologic disorder are ascertained. Administration of pertussis-containing vaccine should be reconsidered at each visit. Pertussis immunization may be administered to children whose condition is resolved, corrected, or controlled.",
"     </li>",
"     <li>",
"      History of seizures &ndash; Children with a history of seizures have an increased risk of seizures after pertussis vaccine. However, there is no evidence that vaccine-associated seizures induce permanent brain damage, cause epilepsy, or aggravate or affect the prognosis of the underlying neurologic disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We suggest that pertussis immunization be deferred in children with a history of seizures until a progressive neurologic condition is excluded [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/48\">",
"       48",
"      </a>",
"      ]. We suggest that pertussis vaccination be administered to infants and children with well-controlled seizures or those in whom seizures are unlikely to recur.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      or other antipyretic may be administered before the immunization and at appropriate intervals during the ensuing 24 hours. The potential benefits and risks of administration of prophylactic acetaminophen are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H7#H7\">",
"       \"Standard immunizations for children and adolescents\", section on 'Prophylactic acetaminophen'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Not contraindications or precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that are NOT considered contraindications or precautions to diphtheria-, tetanus-,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pertussis-containing immunization and should NOT be used to defer immunization include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild acute illness with or without fever",
"     </li>",
"     <li>",
"      Family history of seizure or sudden infant death syndrome",
"     </li>",
"     <li>",
"      Stable or resolved neurologic condition (eg, controlled idiopathic epilepsy, cerebral palsy, developmental delay)",
"     </li>",
"     <li>",
"      Immunosuppression (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H15#H15\">",
"       \"Medical management of immune deficiency\", section on 'Vaccination'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extensive local reaction after the fourth dose of DTaP",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acellular pertussis-containing vaccines produce fewer local reactions, fever, and systemic symptoms than whole-cell pertussis-containing vaccines (",
"    <a class=\"graphic graphic_table graphicRef52093 \" href=\"UTD.htm?13/0/13324\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/9,14,49,50\">",
"     9,14,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse reactions to diphtheria-tetanus-pertussis vaccines may include, (from most to least frequent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/1-4,51\">",
"     1-4,51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild local and systemic reactions",
"     </li>",
"     <li>",
"      Entire limb swelling",
"     </li>",
"     <li>",
"      Persistent, inconsolable crying (&ge;3 hours)",
"     </li>",
"     <li>",
"      Hypotonic-hyporesponsive episode (collapse or shock-like state)",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Fever &ge;105&ordm;F (40.5&ordm;C)",
"     </li>",
"     <li>",
"      Anaphylaxis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"       \"Allergic reactions to vaccines\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild local and systemic reactions are the most common adverse reactions to DTaP. These reactions include fever (1 in 4 children); redness and tenderness at the injection site (1 in 4 children); drowsiness or poor appetite (1 in 10 children); fussiness (1 in 3 children); and vomiting (1 in 50 children) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4,51\">",
"     4,51",
"    </a>",
"    ]. These reactions occur within several hours of vaccination and resolve spontaneously without sequelae. Higher rates of low-grade fever have been reported among infants who receive the DTaP-HepB-IPV combination vaccine than among children who receive the vaccines separately [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extensive local reactions (&gt;46 mm) of erythema or swelling are more common among children who receive four or five consecutive doses of DTaP than those who receive a mixture of DTaP and DTwP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Extensive local reaction after the fourth DTaP is not predictive of a similar reaction after the fifth dose [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/57\">",
"     57",
"    </a>",
"    ]. In a retrospective review, local reactions to the fifth dose of DTaP serious enough to require medical attention were uncommon (43.5 per 10,000 injections) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/13\">",
"     13",
"    </a>",
"    ]. However, they occurred more frequently after administration in the arm than in the thigh (47.4 versus 32.1 per 10,000 injections). Administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    before and 6 to 12 hours after the fifth dose does not appear to prevent extensive local reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/58\">",
"     58",
"    </a>",
"    ]. The potential benefits and risks of administration of prophylactic acetaminophen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H7#H7\">",
"     \"Standard immunizations for children and adolescents\", section on 'Prophylactic acetaminophen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Swelling of the entire limb has been reported in 2 to 3 percent of children after receipt of the fourth or fifth dose of DTaP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4,59\">",
"     4,59",
"    </a>",
"    ]. Limb swelling may be accompanied by erythema, pain, and fever. It may interfere with walking, but most children have no limitation of activity.",
"   </p>",
"   <p>",
"    Prolonged crying and hypotonic-hyporesponsive episodes have been associated with other vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4,41\">",
"     4,41",
"    </a>",
"    ]. Neither of these reactions is known to be associated with long-term sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4,40,41\">",
"     4,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures following pertussis-containing vaccines are usually febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=see_link\">",
"     \"Febrile seizures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=see_link\">",
"     \"Patient information: Febrile seizures (Beyond the Basics)\"",
"    </a>",
"    .) The risk of seizures depends upon the vaccine preparation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort of more than 430,000 children who received DTaP at ages 6 through 23 months, the risk of seizures was not increased within zero to three days after vaccination (incidence rate ratio 0.87, 95% CI 0.72-1.05) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of 378,834 Danish children who received combination DTaP-inactivated polio-",
"      <em>",
"       H. influenzae",
"      </em>",
"      type b (DTaP-IPV-Hib) vaccine at 3, 5, and 12 months, the risk of febrile seizure was increased on the day of the first (hazard ratio [HR] 6.02, 95% CI 2.86-12.65) and second (HR 3.94, 95% CI 2.18-7.10) dose compared with a reference cohort [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/61\">",
"       61",
"      </a>",
"      ]. However, the absolute risk was small (&lt;4 per 100,000 vaccinations). Vaccination with DTaP-IPV-Hib was not associated with an increased risk of epilepsy.",
"     </li>",
"     <li>",
"      In a cohort of almost 680,000 children who received DTwP, the risk of febrile seizures was increased on the day of vaccination (adjusted RR 5.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/62\">",
"       62",
"      </a>",
"      ]. Vaccine-associated febrile seizures were not associated with an increased risk of afebrile seizures or neurodevelopmental disability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccine associated seizures may be the initial presentation of severe myoclonic epilepsy of infancy (Dravet syndrome), which should be considered before attributing the seizures to DTaP [",
"    <a class=\"abstract\" href=\"UTD.htm?5/37/5722/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H6#H6\">",
"     \"Epilepsy syndromes in children\", section on 'Severe myoclonic epilepsy of infancy (Dravet syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources related to immunization in children zero through six years of age include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines\">",
"       Centers for Disease Control and Prevention",
"      </a>",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www2.aap.org/immunization/\">",
"       American Academy of Pediatrics",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/vis/default.htm\">",
"       Vaccine information statement for DTaP",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.immunize.org/\">",
"       Immunization Action Coalition",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=see_link\">",
"       \"Patient information: Whooping cough (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31266?source=see_link\">",
"       \"Patient information: Tetanus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In accordance with the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, and the American Academy of Family Physicians, we recommend immunization with diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine (DTaP) (",
"      <a class=\"graphic graphic_table graphicRef73107 \" href=\"UTD.htm?33/15/34045\">",
"       table 1",
"      </a>",
"      ) for infants and children aged six weeks through six years (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunization is also indicated for unimmunized or underimmunized children with diphtheria or tetanus disease and unimmunized or underimmunized contacts of patients with diphtheria, tetanus, or pertussis disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, DTaP vaccine is typically administered at 2 months, 4 months, 6 months, 15 through 18 months, and 4 to 6 years of age (",
"      <a class=\"graphic graphic_figure graphicRef82617 \" href=\"UTD.htm?24/55/25463\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Routine schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The catch-up schedule for children with lapsed or incomplete diphtheria, tetanus,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pertussis immunization is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef58271 \" href=\"UTD.htm?21/54/22383\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Catch-up schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternate schedule may be necessary for infants and children who develop natural tetanus, diphtheria, or pertussis disease and children with certain neurologic conditions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Special circumstances'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absolute contraindications, precautions, and conditions that are neither contraindications nor precautions to administration of DTaP are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef63855 \" href=\"UTD.htm?20/61/21469\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild local and systemic reactions are the most common adverse events after DTaP. Swelling of the entire limb occurs in 2 to 3 percent of recipients. More severe reactions are rare (",
"      <a class=\"graphic graphic_table graphicRef52093 \" href=\"UTD.htm?13/0/13324\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Adverse reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. Diphtheria. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink book, 12th ed. Atkinson W, Wolfe S, Hamborsky J (Eds). Public Health Foundation, Washington, DC 2011. file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Tetanus. In:  Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed. Washington DC: Public Health Foundation, 2011. file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Pertussis. In:  Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed. Washington DC: Public Health Foundation, 2011. file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.553.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Diphtheria. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.307.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Tetanus (lockjaw). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.707.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep 2008; 57:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep 2008; 57:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/9\">",
"      Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/10\">",
"      Langley JM, Halperin SA, Rubin E, et al. Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial. Pediatr Infect Dis J 2012; 31:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/11\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/12\">",
"      Jackson LA, Peterson D, Nelson JC, et al. Vaccination site and risk of local reactions in children 1 through 6 years of age. Pediatrics 2013; 131:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/13\">",
"      Jackson LA, Yu O, Nelson JC, et al. Injection site and risk of medically attended local reactions to acellular pertussis vaccine. Pediatrics 2011; 127:e581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/14\">",
"      Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 2012; 3:CD001478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/15\">",
"      Bettinger JA, Halperin SA, De Serres G, et al. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J 2007; 26:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/16\">",
"      Guiso N, Njamkepo E, Vi&eacute; le Sage F, et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007; 25:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/17\">",
"      Bisgard KM, Rhodes P, Connelly BL, et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 2005; 116:e285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/18\">",
"      Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002; 161:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/19\">",
"      Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/20\">",
"      Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/21\">",
"      Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012; 54:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/22\">",
"      Witt MA, Arias L, Katz PH, et al. Reduced Risk of Pertussis Among Persons Ever Vaccinated With Whole Cell Pertussis Vaccine Compared to Recipients of Acellular Pertussis Vaccines in a Large US Cohort. Clin Infect Dis 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/23\">",
"      Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007; 298:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/24\">",
"      Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. J Pediatr 2012; 161:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/25\">",
"      Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/26\">",
"      Khan FN, Lin M, Hinkle CJ, et al. Case-control study of vaccination history in relation to pertussis risk during an outbreak among school students. Pediatr Infect Dis J 2006; 25:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/27\">",
"      Moore DM, Mathias RG. Patterns of susceptibility in an outbreak of Bordetella pertussis: evidence from a community-based study. Can J Infect Dis 2002; 13:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Pertussis epidemic--Washington, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/29\">",
"      Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 2013; 368:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/30\">",
"      Tartof SY, Lewis M, Kenyon C, et al. Waning Immunity to Pertussis Following 5 Doses of DTaP. Pediatrics 2013; 131:e1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/31\">",
"      Cherry JD. Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease. N Engl J Med 2012; 367:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/32\">",
"      DeMaria A Jr. Editorial commentary: Accounting for pertussis. Clin Infect Dis 2012; 54:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/33\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     Immunization Action Coalition Vaccination. Ask the experts Diptheria, tetanus, pertussis. file://www.immunize.org/askexperts/experts_per.asp (Accessed on August 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/35\">",
"      Trofa AF, Klein NP, Paul IM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age. Pediatr Infect Dis J 2011; 30:e164.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Haemophilus influenzae infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.345.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/37\">",
"      Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     BOOSTRIX (tetanus toxoid, reduced diptheria toxoid and acellular pertussis vaccine, adsorbed) prescribing information, 2011. file://us.gsk.com/products/assets/us_boostrix.pdf (Accessed on August 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/39\">",
"      Goodwin H, Nash M, Gold M, et al. Vaccination of children following a previous hypotonic-hyporesponsive episode. J Paediatr Child Health 1999; 35:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/40\">",
"      Gold MS. Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern? Drug Saf 2002; 25:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/41\">",
"      DuVernoy TS, Braun MM. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998. Pediatrics 2000; 106:E52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/42\">",
"      Baraff LJ, Shields WD, Beckwith L, et al. Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: follow-up evaluation. Pediatrics 1988; 81:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/43\">",
"      Vermeer-de Bondt PE, Labadie J, R&uuml;mke HC. Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study. BMJ 1998; 316:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/44\">",
"      Gold M, Goodwin H, Botham S, et al. Re-vaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service. Arch Dis Child 2000; 83:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/45\">",
"      Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/46\">",
"      Rantala H, Cherry JD, Shields WD, Uhari M. Epidemiology of Guillain-Barr&eacute; syndrome in children: relationship of oral polio vaccine administration to occurrence. J Pediatr 1994; 124:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/47\">",
"      McIntosh AM, McMahon J, Dibbens LM, et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. Lancet Neurol 2010; 9:592.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Children with a personal or family history of seizures. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.90.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/49\">",
"      Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/50\">",
"      Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med 1996; 150:457.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Vaccine Information Statement DTaP (5/17/07). www.cdc.gov/vaccines/pubs/vis/downloads/vis-dtap.pdf (Accessed on August 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/52\">",
"      Partridge S, Alvey J, Bernstein H, et al. Safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated polio vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. Vaccine 2007; 25:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/53\">",
"      Zepp F, Schuind A, Meyer C, et al. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Pediatrics 2002; 109:e58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/54\">",
"      Skowronski DM, Remple VP, Macnabb J, et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics 2003; 112:e453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/55\">",
"      Rowe J, Yerkovich ST, Richmond P, et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect Immun 2005; 73:8130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/56\">",
"      Liese JG, Stojanov S, Zink TH, et al. Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group. Pediatr Infect Dis J 2001; 20:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/57\">",
"      Rennels MB, Black S, Woo EJ, et al. Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose. Pediatr Infect Dis J 2008; 27:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/58\">",
"      Jackson LA, Dunstan M, Starkovich P, et al. Prophylaxis with acetaminophen or ibuprofen for prevention of local reactions to the fifth diphtheria-tetanus toxoids-acellular pertussis vaccination: a randomized, controlled trial. Pediatrics 2006; 117:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/59\">",
"      Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000; 105:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/60\">",
"      Huang WT, Gargiullo PM, Broder KR, et al. Lack of association between acellular pertussis vaccine and seizures in early childhood. Pediatrics 2010; 126:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/61\">",
"      Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. JAMA 2012; 307:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/62\">",
"      Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/37/5722/abstract/63\">",
"      Reyes IS, Hsieh DT, Laux LC, Wilfong AA. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics 2011; 128:e699.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2844 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5722=[""].join("\n");
var outline_f5_37_5722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vaccine components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vaccine preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choice of vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dose and route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Storage and handling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EFFICACY AND EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VACCINE SCHEDULE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Routine schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Catch-up schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Maximum number of doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - History of pertussis disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Use of DT vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vaccine mix-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Previous reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Neurologic condition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Not contraindications or precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2844\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2844|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/7/23679\" title=\"figure 1A\">",
"      Diphtheria epidemiology US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/5/2143\" title=\"figure 1B\">",
"      Tetanus epidemiology US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/32/29199\" title=\"figure 1C\">",
"      Pertussis epidemiology US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/61/7135\" title=\"figure 2\">",
"      US pertussis cases by age 2012",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/55/25463\" title=\"figure 3\">",
"      Childhood immunization schedule 0 to 6 yrs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2844|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/15/34045\" title=\"table 1\">",
"      DTaP DT TdaP Td vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/54/22383\" title=\"table 2\">",
"      Catch-up immunization schedule age 4 months through 6 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/61/21469\" title=\"table 3\">",
"      DT DTaP contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/0/13324\" title=\"table 4\">",
"      DTP adverse reaction rates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11046?source=related_link\">",
"      Diagnosis and treatment of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=related_link\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=related_link\">",
"      Patient information: Febrile seizures (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31266?source=related_link\">",
"      Patient information: Tetanus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=related_link\">",
"      Patient information: Whooping cough (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_37_5723="Manual defibrillation performance bundle";
var content_f5_37_5723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Manual defibrillation performance bundle",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          Attach and charge the defibrillator while continuing excellent chest compressions.",
"         </li>",
"         <li>",
"          Stop compressions and assess rhythm (should take no more than 5 seconds).",
"         </li>",
"         <li>",
"          If VF or VT is present, deliver shock; if non-shockable rhythm is present, resume excellent CPR.",
"         </li>",
"         <li>",
"          Resume excellent chest compressions and CPR",
"          <strong>",
"           immediately",
"          </strong>",
"          after the shock is delivered.",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Critical point: Interruptions in excellent chest compressions must be kept to a minimum: Do",
"        <strong>",
"         NOT",
"        </strong>",
"        stop compressions while defibrillator is charged.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5723=[""].join("\n");
var outline_f5_37_5723=null;
var title_f5_37_5724="Medication interactions travel and transplant";
var content_f5_37_5724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interactions between common travel and transplant medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calcineurin inhibitors (CNI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trimethoprim/sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetazolamide (Diamox)",
"       </td>",
"       <td>",
"        May increase levels",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artemether/lumefantrine (Coartem)",
"       </td>",
"       <td>",
"        May enhance the QT-prolonging effect",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atovaquone/proguanil (Malarone)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        May increase risk of bone marrow toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin (Zithromax)",
"       </td>",
"       <td>",
"        May increase levels",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloroquine (Aralen)",
"       </td>",
"       <td>",
"        May increase levels; may enhance the QT-prolonging effect",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline",
"       </td>",
"       <td>",
"        May increase levels",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mefloquine (Lariam)",
"       </td>",
"       <td>",
"        May increase levels; may enhance the QT-prolonging effect",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primaquine",
"       </td>",
"       <td>",
"        May increase levels",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfadoxine/pyrimethamine (Fansidar)",
"       </td>",
"       <td>",
"        May decrease levels",
"       </td>",
"       <td>",
"        May increase risk of bone marrow toxicity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Significant interactions of azathioprine, mycophenolate mofetil, and corticosteroids with travel medicines and have not been reported.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: MicroMedex DrugReax Interactive Drug Interactions and Lexicomp Online Interaction Analysis.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5724=[""].join("\n");
var outline_f5_37_5724=null;
var title_f5_37_5725="Cariogenic potential beverages";
var content_f5_37_5725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative decay potential of beverages",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative decay potential",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Standards",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Water",
"       </td>",
"       <td>",
"        0.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10% sucrose solution",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Human breast milk (HBM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HBM alone",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HBM with 10% sucrose",
"       </td>",
"       <td>",
"        1.30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Formula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ProSobee",
"       </td>",
"       <td>",
"        1.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bonamil",
"       </td>",
"       <td>",
"        0.89",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gerber-Fe",
"       </td>",
"       <td>",
"        0.80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isomil",
"       </td>",
"       <td>",
"        0.79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enfamil-Low Fe",
"       </td>",
"       <td>",
"        0.74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lactofree",
"       </td>",
"       <td>",
"        0.68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carnation Follow-Up",
"       </td>",
"       <td>",
"        0.62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SMA-Fe",
"       </td>",
"       <td>",
"        0.62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enfamil-Fe",
"       </td>",
"       <td>",
"        0.62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Next Step",
"       </td>",
"       <td>",
"        0.51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Similac-Fe",
"       </td>",
"       <td>",
"        0.51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SMA-Low Fe",
"       </td>",
"       <td>",
"        0.51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gerber-Low Fe",
"       </td>",
"       <td>",
"        0.45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gerber-Soy",
"       </td>",
"       <td>",
"        0.45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Similac-Low Fe",
"       </td>",
"       <td>",
"        0.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carnation Good Start",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nursoy",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alsoy",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other Beverages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yo-J",
"       </td>",
"       <td>",
"        0.32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple Juice",
"       </td>",
"       <td>",
"        0.80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Orange Juice",
"       </td>",
"       <td>",
"        0.85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grape Juice",
"       </td>",
"       <td>",
"        0.74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fruit Drinks",
"       </td>",
"       <td>",
"        0.93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soda",
"       </td>",
"       <td>",
"        1.05",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Erickson PR, personal communication; Erickson PR, Mazhari E. Pediatr Dent 1999; 21:86; and Erickson PR, McClintock KL, Green N, LaFleur J. Pediatr Dent 1998; 20:395.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5725=[""].join("\n");
var outline_f5_37_5725=null;
var title_f5_37_5726="Contents: Mental and medical disorders";
var content_f5_37_5726=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Mental and medical disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Mental and medical disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/13/12504\">",
"           Depression, mania, and schizophrenia in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31080\">",
"           Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/43/5816\">",
"           Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/38/7781\">",
"           Eating disorders in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/1/27673\">",
"           Management of psychiatric and psychologic disorders in patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/46/38631\">",
"           Neuropsychiatric manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/62/24551\">",
"           Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/40/1674\">",
"           Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/44/5831\">",
"           Overview of the neuropsychiatric aspects of HIV infection and AIDS",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36517\">",
"           Psychiatric aspects of organ transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/3/11322\">",
"           Psychiatric illness in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/52/22343\">",
"           Psychological stress and infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/55/16250\">",
"           Psychosocial and other social factors in acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/19/41273\">",
"           Psychosocial factors and rheumatic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/59/25528\">",
"           Psychosocial factors in coronary and cerebral vascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/15/23800\">",
"           Psychosocial factors in sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/31/2551\">",
"           Substance abuse and addiction in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-B97B55B8F9-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_37_5726=[""].join("\n");
var outline_f5_37_5726=null;
var title_f5_37_5727="Pharyngocele lateral Ba swallow";
var content_f5_37_5727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pharyngocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of the pharynx during a barium swallow shows two small anterior pharyngoceles (arrow) which have developed from the hypopharynx (HP).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_37_5727=[""].join("\n");
var outline_f5_37_5727=null;
